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SUMMARY
The hypothesis of Davies (1984) that antibodies to cows’ milk are elevated in 
myocardial infarction (Ml) patients was initially investigated. An ELISA for antibodies to 
bovine milk fat globule (BMFGM) showed no significant differences in IgG, IgA or IgM 
anti-(BMFGM) antibody titres between Ml patients and controls.
In order to define, more precisely, the target(s) of human anti-BMFGM antibodies, lipid 
extracts of BMFGM were tested in competitive ELISA and shown not to be antigenic. 
However, immunoblots from SDS-PAGE patterns of BMFGM proteins identified the enzyme, 
xanthine oxidase (XO), as a major antigenic target. Xanthine oxidase was, accordingly, 
prepared from milk and used in competitive ELISA to confirm this identification.
An ELISA for anti-(bovine XO) antibodies was developed and used to compare levels in 
male Ml patients and controls. In three seperate studies, IgM anti-(bovine XO) antibody 
levels were found to be significantly ( p < 0.001 ) higher in Ml patients. No significant 
differences were shown for IgG or IgA antibodies. Total IgM levels were not raised in Ml 
patients, compared to controls, nor did total IgM correlate with IgM anti-(bovine XO) levels, 
indicating that elevation of the latter in Ml patients did not simply reflect raised total IgM. 
Serial assays of anti-(bovine XO) antibodies, for periods up to six months following Ml, 
showed no consistent patterns, suggesting that their elevation was not a consequence of Ml 
itself.
In attempt to define the origin of the human anti-(bovine XO) antibodies, human XO was 
prepared from human liver. Although enzymatically active, the human enzyme showed 
evidence of proteolytic degradation, with bands on SDS-gels, of 90 KD, 70 KD, 55 KD, and 
35 KD. This is to be compared with the bovine XO preparation, which showed a major band
(150 KD) with a minor band (140 KD). The human XO was much less effective than bovine 
XO in competitive ELISA of human anti-XO antibodies, but this could be attributed to the lack 
of a 150 KD subunit in the human enzyme preparation.
Attempts to generate viable mouse-human heterohybridoma clones, producing 
monoclonal antibodies were unsuccessful, but fifteen viable clones were raised by 
Epstein-Barr Virus transformation of human peripheral blood lymphocytes. The 
coresponding monoclonal antibodies, of both IgG and IgM types, showed immunoblot 
interactions with the 150 KD band of bovine XO and also with several polypeptide 
degradation products. In contrast, no interaction was detected with human XO SDS-PAGE 
patterns.
Although the evidence favours the identification of bovine XO as the immunogen for 
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Pathological disorders in the circulatory system made up 49 % of the total number of 
deaths recorded in England and Wales in 1985 (Fig. 1). Conditions specifically relating to 
heart represented 67 % of the total deaths within this group and, in fact, one death in every 
three in England and Wales is attributable to heart disease.
1- Coronary Heart Disease (CHD): Importance and Statistics
Arterial disease has been described in Egyptian mummies of the second century B.C. 
(Ruffer.,1911) and anatomical descriptions of CHD were made in the eighteenth and 
nineteenth centuries. The real clinical features did not, however, become manifest until the 
beginning of this century.
By the beginning of the 1980s, CHD seemed destined to become the world’s " disease 
of the decade". Recent surveys (Vemura and Piza.,1985) reveal that countries of the United 
Kingdom are becoming increasingly isolated at the top of the international league table for 
CHD (Fig. 2), which is certainly the major cause of premature male death. CHD was the 
cause of 163.104 deaths in 1985 in England and Wales (OPCS, 1986). The magnitude of 
the problem is reflected in the research effort aimed in clarifying the pathogenesis of CHD 
and discovering more effective treatments. Between 1980 and 1986, the spend, in the 
United Kingdom, was 536 million pounds (OPCS, 1986). Considerable epidemiological 
surveys (eg. Dawber, 1980; Keys, 1980; Sharper et al..1981: Marmot, 1985). have linked 
hypertention, lipid cholesterol, relative body weight, cigarette smoking, diabetes and 
evidence of left-ventricular hypertrophy as major risk factors but uncertainty remains about 
the precise relationship between most CHD associated factors and the cellular development 
of atherosclerosis (Ross, 1986). The mortality from CHD in all the " developed countries ",
(some which are represented in Fig. 2) is much higher than that in the " Third World " (Heller 
et a l..1987) although there are, in fact, few rigorous statistical surveys for the M Third world 
countries
During the middle decades of life, CHD is far more common in men than in women 
(Barrett-Connor and Khaw.,1988), a difference which disappears with increasing age (Fig. 
3). One possible explanation is that endogenous oestrogen production may prevent 
development of the disease (Kennel et al..1976). In contrast the incidence of venous 
thrombosis in younger women is higher than men from the same age group (OPCS, 1986) 
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Fig. 2 : Coronary heart disease mortality 1968-1981 in selected countries, men aged 35-74 
years. Age adjusted rates/100.000 ( From Wells, 1986).
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Fig, 3 : Deaths from CHD as percentage of all deaths at selected ages, England and Wales 
1985. ( From Wells, 1986).
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2- Anatomy of the circulatory system
2-1 The heart
The blood is circulated through! the body by means of electrically-stimulated 
contractions of heart muscle, the myocardium, which makes up the principal heart wall and is 
dependent on a continuous flow of blood. Blood reaches the myocardium ( before any other 
part of the body ) via the left and right coronary arteries which are situated at the base of the 
aorta (Fig. 4) and then distributed throughout the myocardium by a complex network of 
progressively smaller vessels.
a r c h  o f  a o r t a
l e f t  co mmon c a r o t i d  a r t e r y  
► v .  /  l e f t  s u b c l a v i a n  a r t e r y
b r a c h i o c e p h a l i c  a r t e r y
s u p e r i o r  v e n a  c a v a
p u l m o n a r y  t r u n k
r i g h t  p u l m o n a r y  a r t e r y
l e f t  a u r i c l e  
- l e f t  c o r o n a r y  a r t e r y
— - g r e a t  c a r d i a c  v e i n
a s c e n d i n g  a o r t a
r i g h t  a u r i c l e
l e f t  v e n t r i c l er i g h t  c o r o n a r y  a r t e r y
r i g h t  a t r i u m
a n t e r i o r  i n t e r v e n t r i c u \ a  
a r t e r y
a n t e r i o r  c a r d i a c  v e i n
a t r i o v e n t r i c u l a r  g r o o v e -
a p e x
m a r g i n a l  a r t e r y r i g h t  v e n t r i c l e
i n t e r v e n t r i c u l a r  g r o o v e
Fig. 4 : Anterior view of the heart and great vessels. 
( From Snell, 1981 ).
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2-2 Structure of the arterial wall
Normal arterial-wall Is mainly composed of three morphologically distinct layers (Fig. 
5). Although, in the smallest vessels, the three layers are simplified, blood vessels have a 
number of structural features in common and are structurally adapted according to 
physiological requirements ( Junqueira et al..1986). Thus, systemic arteries (high- pressure 
system) such as the carotid artery have a thicker wall than pulmonary (low-pressure system) 
arteries. The structure of the arterial wall depends on its size, function and its propensity to 
disease in the different parts of the body.
The three layers of arterial wall comprise :
a- The intima or inner layer, which consists of layers of endothelial cells lying within a 
well-marked, undulating, fenestrated elastic membrane (the internal elastic lamina) and 
separated from it by connective tissue fibres.
b- The media which makes up the middle layer of arterial wall. It extends from the 
abluminal aspect of the internal elastic lamina to the most peripheral layer of smooth 
muscle-cells or, in the case of a large elastic artery like the aorta, to the outermost lamina.
c- The adventitia which consists of a loose arrangement of collagen, elastic fibres, 
connective tissue cells of various kinds, vascular channels and nerves.
3- Pathology of coronary heart disease
Heart disease most commonly involves lesions of coronary arteries and so is generally 
referred to as Coronary Heart Disease (CHD) (Friedberg.,1966). Obstructions occur in the 
arteries as a result of a number of processes including those which lead to thickening of the 
intima layer and consequential narrowing of the lumen. Lesions are commonly patches of 
atheromatous plaques containing lipids and cellular deposits (Ross.,1986). Clinical
indications of CHD include the development of an acute myocardial infarction (AMI), arising 
from sudden interruption in the coronary blood supply and death of the heart muscle cells. It 
is indisputable that atherosclerosis can lead to severe occlusion of the coronary arteries 
(Goldin et al..1986) leading to the principal manifestations of CHD below.
3-1 The three principal manifestations of CHD
3-1-1 Angina pectoris
This is a gripping pain experienced in the chest and often extending to the neck and 
left arm. It occurs when an additional workload is placed upon the heart during, for example, 
physical exertion or profound emotional stress. The pain is caused by an inadequate supply 
of oxygen reaching the heart muscle and inability of regional blood to increase and meet the 
higher metabolic needs of the myocardium. It recedes once the supply returns to 
equilibrium. The transient reduction of blood in unstable angina was thought, for a long time, 
to result primarily from spasm in the coronary arteries but recent research has pointed out 
the potential importance of recurrent thrombosis at the site of a ruptured atherosclerotic 
plaque (Fuster and Chesebro.,1986)
3-1-2 Acute myocardial infarction
A loss of blood supply to any part of myocardium leads rapidly to a cessation of normal 
contraction, which is followed by death of the heart muscle in the affected area. The relative 
contribution of atheromatous plaques to arterial occlusion is a a source of debate (eg: 
Stehbens.,1985).
3-1-3 Sudden cardiac death
This term is used in cases where a patient, often in apparently good health, collapses 
without warning or with only fleeting premonitory symptoms. In this case, death is usually 
the result of spontaneous ventricular fibrillation (Mitchell.,1978). Post-mortem examination 
indicates no evidence of occlusive thrombosis but severe coronary atheroma, generally with 
over 85 % stenosis of the major vessels (Davies, M.,1982). Nearly 80 % of such patients 






Fig. 5 : Drawing of a medium-sized muscular artery showing its layers.
( From Junqueira et al. 1986 ).
4- Atherosclerosis
The most common disease of coronary arteries is atherosclerosis and the consequent 
disturbance in the blood supply constitutes the essential cause of CHD (Anthony and 
Thibodeau.,1979). Atherosclerosis is a pathological alteration of the blood vessel wall (Ross 
and Glomset.,1976) affecting, in particular, large and medium sized arteries (Bowman and 
Rand.,1980), in which the intima is thickened and hardened by the development of fibrous 
tissue and accumulation of lipids (largely cholesterol and cholesteryloleate).
Unlike the media and the adventia, which remain relatively constant throughout life, the 
intima changes with age (DeSa.,1979; Velican and Velican.,1981). The morphological 
changes in atherosclerosis are accompanied by proliferation of a connective matrix of 
proteins and proteoglycans, produced by smooth muscle cells with lipid accummulation (Fig. 
6a). These changes are less developed in females than in males and women tend to 
develop plaques a decade later than men. The incidence of the disease in men is twice as 
high as in women.
4-1 Atherosclerotic lesions
The major and most important factor in the build up of lesions involved in the 
development of atherosclerosis is the incorporation of mural thrombi into the intima of 
arteries (Crawford and Levene., 1952; More and Haust.,1961; French.,1966). The damage 
to arterial endothelium is enhanced by the release of vasoactive amines from active 
platelets, which create areas of increased permeability for plasma constituents, including 
lipids and fibrinogen, into the arterial wall (Mustard and Packham.,1971). The following three 
stages constitute the sequence of events in atherosclerosis:
4-1-1 Fatty streaks
These streaks are superficial fatty yellow patches, the colour of which results from 
deposited lipids (cholesterol and cholesteryloleate) produced by smooth muscle cells 
(McGill., 1984). Fatty streaks are found even in newborn babies (DeSa., 1979; Woolf.,1982) 
and there is no evidence, so far, that these necessarily develop into plaques with age.
4-1-2 Fibrous plaques
Basically, little has changed, over the last century, in descriptions of fibrous plaque 
formation (Davies., 1976). The original hypothesis of thrombogenesis (von Rokitansky, 
1852) was reformulated by Duguid (1946, 1948 and 1949), since when no major changes 
have been made.
The plaques are formed by a superficial accumulation of smooth muscle cells, fibrous 
connective tissue (collagen, elastin and mucopolysaccharide) and a variable number of 
blood cells (macrophages, lymphocytes, neutrophils and platelets) lying under the intima. 
The smooth muscle cells are loaded with lipids (Woolf.,1977). Beneath the fibrous layer lies 
a large deposit of free extracellular lipids and cell debris (Fig.6b) Unlike fatty streaks, fibrous 
plaques protrude into the lumen of the artery leading to an obstruction of normal blood flow. 
It takes decades for these atheromatous plaques to be formed (Friedberg.,1966).
4-1-3 Complicated lesions
The most complicated form of arterial lesion occurs when fibrous plaques become 
haemorrhagic, ulcerated and calcified (Gresham and Howard.,1963). These changes lead to 
the arterial wall occlusion, with particular damage to the muscle and elastic tissue (Fig. 7).






























Fig. 6a : Illustration of the early events in atherosclerosis. 

















Fig. 6b : Transverse section through a diseased artery, partially occluded
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Fig. 7 : Pathological sequences in human atherosclerosis.
( From Houben, 1987).
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4-2 Risk factors in atherosclerosis
The multifactorial origin of atherosclerosis has been demonstrated by epidemiological 
studies which identified the adverse or "risk" factors. Risk factors reinforce one another and 
it was found that the the presence of three risk factors in a given population leads to an up to 
ten fold increase in the incidence of the development of atherosclerosis (Keys et al..1972).
Hypertension, hyperlipidemia, smoking, hypoxia and antigen-antibody complexes are 
believed to be major risk factors. Hypertension and hyperlipidemia have been particularly 
well investigated. One of the reasons for associating hypertension with atherosclerosis is its 
effect on arterial endothelium which may, in severe cases, be opened as the cells contract 
away from each other. As a result, permeability increases, leading to the infiltration of lipid 
into the intima. Hyperlipidemia is a widely accepted risk factor, because the rise in blood 
lipid (cholesterol in particular) leads to entry of lipid into the intima and atherosclerotic lesions 
contain more cholesterol than surrounding areas. Genetic disorders, leading to raised lipid 
levels in serum, predispose certain individuals to premature heart disease (Brown and 
Goldstein.,1986). Diets, high in cholesterol and saturated fats, are associated with 
populations in which heart disease is prevalent (Shekelle et al..1981). Reduction of plasma 
cholesterol levels in hypercholesterolaemic men certainly reduces their risk of Ml 
(Vines.,1989). Smoking, which can increase the incidence of CHD up to 15 times (Ramsdale 
et al..1985: Harrison.,1987) increases blood carbon monoxide resulting in hypoxia, this can 
lead to an opening in the intracellular junctions. The effect of antigen-antibody complexes on 
endothelium results mainly from their deposition on the arterial intima wall causing death of 
endothelial cells.
In addition to these major risk factors, a long list of other factors includes hormones 
(e.g: oestrogens, Kennel et al..1976). stress (Mitchell.,1984; Firth.,1985; Rozanski
- 13 -
at.,1988), congenital disorders (Brown and Goldstein.,1986), environmental risks (such as 
work), alcohol, diabetes, obesity (Cataldo.,1985; Truswell.,1985) thrombosis and clotting 
factors (Meade.,1985; Markowe et al:1985). lack and excess of physical exercise (Bassey 
and Hall.,1985; Siscovick et al.,1984) and released platelet factors (see Section 4-5).
4-3 Consequences of atherosclerosis
Atherosclerosis progresses insidiously for many years before symptoms develop, 
making it difficult to follow the early developmental stages of the disease in individuals. It is 
difficult to decide if an observed effect is of primary atherogenic or of secondary nature. The 
disease is widespread in individuals often with no clinical symptoms, making it hard to select 
real control cases. It affects many parts of the body, most dramatically the heart and the 
brain (Fig. 8).










Rupture of aortic wall
Rupture of cerebral artery
Haemorrhage Bleeding from atherosclerotic
Fig. 8 : Main consequences of atherosclerosis 
( From Taussig, 1984 ).
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4-4 Platelets and atherosclerosis
Why does a person who has lived for years, in apparently good health or possibly with 
recurrent episodes of angina, suddenly, and without any obvious precipitating cause, 
develop an Acute Myocardial Infarction (AMI)?
Modern medicine still cannot answer this problem which is compounded by autopsies 
of old patients, who have died of non vascular causes but who have vessels which are 
extraordinarily distorted or obstructed with atheroma or thrombus. A popular theory points to 
the role of activated platelets.
Platelets, the smallest blood cells, are derived from megakaryocytes (Levine., 1982) 
present in lungs and bone marrow. Each megakaryocyte is believed to release thousands of 
platelets during its lifetime (Cronkite.,1958). Many key roles have been attributed to 
platelets, including phagocytosis, chemotaxis, release of mediators (Nachman and 
Weksler.,1980) and killing bacteria (Copley.,1973).
Adhesion of platelets to the arterial wall, after endothelial injury, is generally regarded 
as one of the initiating steps in atherosclerosis (Ross and Glomset.,1973, 1976; Ross et al 
1974; Bom.,1980). The adhesion is mediated by a receptor glycoprotein (Gp1b) in the 
platelet membrane. Gp1b binds connective tissue, especially collagen (George et al..1984). 
and also von Willebrand factor (VWF) which is released by activated platelets (Jaffe M  
ai.,1973; Weiss et al..1973). The adhesion of platelets to the arterial wall leads to the 
migration of smooth muscle cells into the intima (Fig.9 ) possibly in response to chemotactic 
substances released by activated platelets (Firkin., 1984). Adhered, activated platelets 
release serotonin, ADP, platelet-derived growth factor (PDGF) and lysosomal enzymes 
which increase the local permeability of the endothelium and allow penetration of lipids.
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Platelets can be stimulated by hydrolysis of the membrane bound receptor, glycoprotein V 
(Phillips and Agin.,1977). Activated platelets release factor 4 which neutralizes heparin 
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Fig.9 : Platelet response to vascular injury 
( Adapted from Taussig, 1984).
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Platelet-Derived Growth Factor (PDGF) is a potent mitogen (Ross et al..1974). 
released during blood coagulation. It is identical to the growth factor, in human serum, that 
stimulates proliferation of cultured mouse cells (Antoniades et a l..1975). PDGF is stored in 
the granules of platelets (Kaplan et al.. 1979) and released into the surrounding medium 
following activation of platelets by thrombi, ADP, collagen, epinephrine or arachidonate 
(Linder et al.,1979.. Gerrard et al..1980). The exposure of PDGF can result in the production 
of thrombospondin, a glycoprotein that facilates proliferation of vascular smooth muscle cells 
via a heparin-sensitive mitogenic pathway (Scott-Burden and Buhler.,1988). Activated 
platelets from patients with Gray’s syndrome (deficiency of granules) release little or no 
PDGF (Gerrard et al..19801. Endothelial cells can release a potent inhibitor of PDGF 
(Rosenberg eLal-,1985).
PDGF may play an essential role in the pathogenesis of atherosclerosis because it is 
able to bind [via PDFG receptors (Heldin et al..1981)] smooth muscle cells and fibroblasts, 
stimulating their proliferation (Ross et al..1974; Antoniades et al..1975: Westermack and 
Wasteson.,1975; Rutherford and Ross.,1976). It can also act as a chemotactic factor for 
smooth muscle cells and fibroblasts (Grontendorst fiLal.,1981), stimulate LDL-receptor 
activity and cholesterol esterification in human fibroblasts, and penetrate into arterial wall 
through damaged endothelium.
Intimal response does not occur in animals in which platelet function has been 
suppressed, either by inhibitors, such as dipyridamol (Harker et al..1976) or by anti-platelet 
serum (Moore et al..1976: Friedman et al.,1977); moreover, such suppression reduces the 
rate of sudden death in humans (Forrester et al. 1987). Fuster et al. (1978) showed that 
pigs with congenital deficiency of VWF factor, a condition which prevents platelets from 
adhering to subendothelium, are protected against atherosclerosis. Blood coagulation 
proteins and the presence of VWF contribute significantly to the platelet-platelet interactions
- 1 8 -
necessary for thrombus formation (Badimon et al..1988). An increase of active platelets in 
the circulation of confirmed Ml patients has been reported ( Di Perri et a l..1971,1980; Steele 
et a l..1975: Rees.,1985).
Beside PDGF, other growth factors that stimulate smooth cells have been discovered. 
Among these are endothelial derived growth factor (EDGF) (Ross et a l..1974: Ross and 
Vogel.,1978; Heldin et al..1979) and the monocyte/ macrophage derived growth factor 




















Fig. 10 : Representation of the potential stimulation of growth factors (PDGF,
EDGF and MDGF) on smooth muscle cells. ( Adapted from Ross, 1981 ).
Healthy arterial wall is protected from platelet adhesion by the action of the 
antiaggregator and vasodilator, prostacyclin (PG12). Prostacyclin neutralizes the action of 
the aggregatory substance, thromboxane (TXA2), secreted by platelets (Raz et a l.. 1977), 
but arterial plaques do not produce PG12 (D’Angelo et al.. 1978).
It should be noted that the association of platelet hyperfunction and arterial disease, 
generally due to atherosclerosis, does not prove a causal relationship. The 
ulceration-thrombosis process can be regarded as two interlocking cycles. The first of which 
consists of a stable atheroma that progresses to endothelial ulceration accompanied by 
platelet aggregation and ulcer healing, whereas the second one starts from ulceration of 
endothelium leading to thrombus incorporation by way of partial thrombosis, occlusion and 
lysis stages (Fig. 11).
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Fig. 11 : Ulceration-thrombosis cycle of atherosclerosis.
( From Forrester et a l. 1987 ).
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4-5 Different hypotheses concerning the initiation of atherosclerosis
4-5-1 Hyperlipidemia hypothesis
This hypothesis is based on several lines of evidence that point to a relationship 
between plasma lipid or lipoprotein abnormalities and atherosclerotic cardiovascular disease. 
Epidemiological evidence is based on the observation that populations with higher blood lipid 
levels develop more atherosclerosis (Keys.,1970, 1980; Shekelle et al..1981). Experiments 
with laboratory animals have shown that feeding a diet rich in lipids leads to an increase in 
blood lipid and development of atherosclerosis (Connor et al.,1963: Constantinides.,1965; 
Armstrong et al..1969). Clinical observations on hyperlipidemic patients reinforce the 
concept that increased lipid concentration in plasma is an important etiological factor of 
atherosclerosis; the lower the fat consumption, the lower the mortality from CHD (WHO, 
1976). In 1982, the WHO Expert Committee recommended a 35 % reduction in the fat 
content of Western diets.
Plasma lipoproteins are macromolecular complexes, composed of a heterogenous 
mixture of proteins and lipids, whose main function is to transport triglycerides and 
cholesterol from their site of synthesis to their site of utilisation (Galton et al.1985: Brown 
and Goldstein.,1984, 1986. Shepherd and Packard, 1988, Fig. 12). Lipoproteins are 
classified, according to their sedimentation rates in salt solution, into five types (Hamosh and 
Hamosh, 1983). These are : Chylomicrons; High Densinty Lipoproteins (HDL);
Intermediate Density Lipoproteins (IDL); Low Density Lipoproteins (LDL); and Very Low 
Density Lipoproteins (VLDL) (Fig. 13).
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Fig. 12 : Lipoprotein transfer in the body 
( From Brown and Goldstein, 1984).
Fig.Keys : VLDL : Very low density lipoproteins 
HDL : High density lipoproteins 
IDL : Intermediate density lipoproteins. 
LDL : Low density lipoproteins.
FFA : Free fatty acids.
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Fig. 13 : The four major lipoproteins ( Adapted from Heller, 1987 ).
Normal fibroblasts and certain other cells, including smooth muscle cells, have
receptors for LDL, which is the transporter of cholesterol in plasma. LDL is digested in the
cell, by lysosomal enzymes (Fig. 14), which release amino acids and free cholesterol.
Free cholesterol is an important regulator of cholesterol synthesis. The expression of LDL
receptors is inhibited by the accumulation of cholesterol, which leads to an increase (up to 4
fold) of plasma LDLs.
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Fig. 14 : Catabolism of LDLs 
( From Brown and Goldstein, 1984 ).
A high level of LDL is observed in hypercholesterolaemia, where LDL receptors are 
absent because of genetic disorders. LDL exist in different forms which may vary in their 
atherogenicity (Sniderman et al..1980; Rudel et a l..1985 and 1986) . Severity of 
atherosclerosis increases with increasing LDL plasma concentration and decreases with 
increasing HDL plasma concentration (Jenkins.,1976; Gordon eLal-,1989). HDL is believed 
to promote a slight decrease of intracellular cholesterol and may reduce the penetration of 
LDL into smooth muscle cells (Carew eLaI-,1986). Brown and Goldstein (1986) speculated 
that, if LDL receptors in arterial walls are saturated with LDL (ie. there is an excess in the 
blood), then both cholesterol and its esters may accumulate in arterial walls by 
non-physiological bulk transfer systems.
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The process by which lipid is deposited in the intima is illustrated in Fig. 15 . This 
involves binding of LDL to connective tissue constituents and also uptake by smooth muscle 
cells with subsequent release when cells die.
Recent reports (Taylor et al..1987: Oster and Epstein., 1987) have showed links 
between lowered cholesterol intake, life expectancy and coronary artery disease. These 
relationships have, however, been subject to many criticisms ( eg. Castelli.,1988). The 
hyperlipidemia hypothesis has been attacked by pathologists for two main reasons. Firstly, 
hyperlipidemia observed in animals merely produces extracellular lipid deposits, and fails to 
generate the wide spectrum of arterial changes, characteristic of advanced human 
atherosclerosis. Secondly, the lipid deposits induced in animal arteries require extremely 
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ig. 15 : Pathways of lipid deposition in the intima 
( From Taussig, 1984 ).
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4-5-2 Response to injury hypothesis
This hypothesis was suggested in 1926 by Duguid and is essentially a synthesis of the 
two original theories of atherosclerosis described by Virchow (arterial injury and infiltration of 
lipids) in 1856 and von Rokitansky (encrustation of mural thrombi) in 1844. According to the 
hypothesis, injury or removal of endothelium is followed by exposure of the subendothelial 
area. As a result, platelets can adhere to exposed collagen, release their granule contents 
and aggregate (Ross and Glomset.,1976), thereby promoting migration of smooth muscle 
cells and other macromolecules (Ross.,1986). This series of events leads to the local 
ingrowth and division of smooth muscle cells which produce fibrous and matrix elements of 
connective tissue. Animal models have shown that the removal of the endothelium leads to 
the development of intimal lesions, resulting in atherosclerosis. A rupture in the barrier 
properties of endothelium leads to interactions of subendothelial cells with blood monocytes 
and macrophages, causing plaque formation (Ross.,1986; Fig. 16).
4-5-3 Benign tumour hypothesis
This hypothesis was based on observations of the nature of proliferating cells in fibrous 
plaques. It was found that such fibroblasts differ from typical fibroblasts in that they are 
associated with collagen-producing smooth muscle cells, (forming the stroma of the plaque). 
Benditt and Benditt (1973) suggested that the smooth muscle cells in plaques are abnormal 
and that plaques are, in fact, a benign smooth muscle neoplastic tumour, producing collagen. 
Evidence for this suggestion is provided by the finding that, in many plaques, the proliferating 
cells are apparently monoclonal in origin (Benditt.,1974).
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In 1932 Zeek suggested that immunological mechanisms might be involved in 
atherogenesis. This suggestion was later supported by experimental (Saphir.,1956; 
Levy.,1968; Minick and Murphy., 1973; Hardin et al..1973) and clinical (Beaumont and 
Beaumont., 1967; Davies et al..1969: Mathews et al..1973. 1974; Poston and Davies., 
1974; Gero et al..1975) evidence that atherosclerotic patients have immunological 
abnormalities.
Minick et al.. (1966) demonstrated that proliferative arterial injury in animals, caused by 
immune complex disease promoted hyperlipidemia, so enhancing and accelerating 
atherogenesis. In 1975, Di Perri et al showed that experimental immune complex disease, 
with vessel injuries, produced exudative lesions in small arteries or proliferative lesions in 
larger arteries, depending on its shorter or longer duration, respectively. It was shown that 
arteries can also be injured as the direct targets of immune response (Scebat et al..1964). 
Antibodies directed against certain bacterial antigens can cross-react with arterial 
components. Arteries can also be indirectly injured by immune insults, as first reported by 
Wolinsky et al.. (1973,1974), who found that, in diabetes, defects can occur in the lysosomal 
enzymic processing of lipid in the arterial wall. Smooth muscle injury, of any origin, could 
provoke secondary immune reactions that might enhance arterial pathology (Jellinek.,1974). 
Thus, prolonged hyperlipidemia can cause a rise in circulating immmune complexes, 
possibly arising from release of vascular antigens (Gero et al..1975: Hansson et al..1980).
Blood lipids can occasionally be elevated as a result of the development of 
auto-antibodies against lipoproteins, lipoprotein lipase and lipids (Walton.,1975). In 1980 
Constantinides and his colleagues pointed out the possibility that plaque necrosis might be 
initiated by autoimmune attacks against the atheroma tissue. Certain antibodies (IgA, IgE)
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raised against foreign antigens bind to the surface of basophils, mast cells, platelets and 
possibly endothelial cells. Once bound, these antibodies stimulate the release of vasoactive 
amines, causing endothelial injury (Roitt .,1988).
Recently, autoantibodies have been reported in atherosclerotic patients, especially 
against nuclear and smooth muscle cells (Basteinie et al..1977) and fibrous proteins (Gero el 
ai.,1975). Vimentin, a component of endothelial cells has been found to bind to IgG Fc 
receptors (Hansson et al..198Q and 1986). This finding is supported by the fact that 
monocyte adhesion to the vessel wall is reduced when IgG-depleted serum was in the intima 
(Hansson et al..1980). A possibility of intracellular complement activation was also reported 
(Linder.,1981). Antibodies to environmental antigens have also been reported in 
atherosclerotic patients. The most common of these are : antibodies to milk proteins 
(Davies et ai..1974). to viruses (Nicholls and Thomas.,1977; Benditt et al.,1983: 
Cunningham and Pasternak., 1988) and to tobacco glycoproteins (BecherfiLal-,1976), which 
may play an important role in human atherosclerosis.
4-5-5 The Davies Hypothesis
The Davies hypothesis is a particular immunological hypothesis. It was the initiating 
factor for work described in this thesis and will, accordingly be described separately, in the 
present section. The hypothesis suggests an association between circulating antibodies to 
cows’ milk and coronary heart disease. It arose from work of Davies and his colleagues at 
Carmarthern, Wales, UK., carried out over the last thirty years.
initial investigations were directed towards studies of erythrocyte mobility, and 
concluded, firstly, that electrophoretic mobility of erythrocytes decreases with age of donor 
(Davies., 1958); the differences disappeared when the cells were washed with saline
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solution prior to the test. These findings were subsequently extended to show that the 
electrophoretic mobility of erythrocytes differed between coronary-occluded patients and 
age-matched controls (Davies., 1959). This result was later supported by other workers 
(Begg et a l..1966). Later studies showed a significant correlation between migration mobility 
of erythrocytes and platelet adhesiveness (Davies and Lloyd.,1967; Fig. 17). From these 
observations, Davies and coworkers concluded that erythrocyte mobility is, in fact, 
atheroma-related and not age-related. Erythrocyte migration was subsequently related to 
migration of chytomicra but no correlation was found with levels of plasma cholesterol 
(Davies and Clark.,1961). In fact, Davies and Clark (1968) claimed that erythrocyte 
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Fig. 17 : Correlation between erythrocyte electrophoretic migration and 
platelet adhesiveness. ( From Davies and Lloyd, 1967 ).
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Davies argued that the reduced mobility of erythrocytes and chylomicra could result 
from their adsorption of plasma factors and set out to identify these factors. An 
immunological component was suggested by the observation that total circulating IgG was 
raised in atherosclerotic patients, compared to controls (Davies and Clark.,1968); an 
elevation that was shown, in serial studies, not to be secondary to infarction. The adherence 
of blood cells to each other and to vessel walls could accordingly be explained as a 
consequence of the raised immunoglobulins.
Davies and his colleagues went on to seek the targets of these antibodies and, in 
1969, reported that antibodies to cows’ milk were elevated in heart diseased patients. The 
group later confirmed these conclusions (Davies et al.,1974) and and showed, moreover, 
that the differences were more significant for patients who died within six months after 
infarction. These dramatic results were obtained by haemagglutination assays in which red 
blood cells were coated with whole dried cows’ milk as antigen. The nature of the target 
antigen was clarified by Davies et al.. (1980), who showed a good correlation of anti-(whole 
dried milk) antibodies with anti-(washed cream) antibodies, but not with anti-(skimmed milk) 
antibodies. The anti-(cream) antibodies were subsequently shown (Davies et a!..1982: 
Rees.,1985) to be directed towards the membrane surrounding the fat droplets in milk, i.e : 
the bovine milk fat globule membrane (BMFGM) (see Section, 5).
Following these indications that the anti-milk antibodies; apparently elevated in heart 
disease, were, in fact, anti-BMFGM antibodies, Davies and his colleagues sought possible 
pathogenic cross-reactivities of these latter antibodies. Arguing that cross-reactivity might 
occur with common antigens on the membranes of different cells, they turned their attention 
to the platelet membrane in view of the generally accepted role of platelets in CHD (see 
Section, 4-5). They (Davies et al..1982: Davies.,1984; Rees., 1985) demonstrated that 
rabbit anti-BMFGM antibodies linked to a fluorescein probe cross-react with human platelets
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whereas rabbit pre-immune sera did not. It was also shown that human platelets could be 
aggregated by rabbit anti-BMFGM antiserum but not by pre-immune serum. These findings 
suggested that binding of anti-BMFGM antibodies might cause a removal of platelets from 
the circulation by the reticulo-endothelial system. This reaction could be followed by an 
increase in platelet turover resulting in a high percentage of activated platelets in the blood 
with consequent implications for atherogenesis.
4-5-6 Literature response to the Davies hypothesis
Davies and coworkers’ results, in particular their 1974 publication, initiated much 
discussion. Ellis (1974) even suggested that Davies* findings could well be "the most 
important nutritional discovery of the century". The results were confirmed by Oster and 
coworkers (Oster et al..1974) using the same tanned red blood cell haemagglutination assay 
(Boyden.,1951; Rees.,1973) but, between 1975 and 1980, three independent groups 
(Toivanen 1975a; Scott fil_a! ,1976; Gibney et al..1980) all failed to observe a 
statistically significant difference in anti-milk antibodies between Ml patients and controls. 
Toivanen et al. (1975a) assayed IgG and IgM antibodies using a radioimmunoassay. Their 
results were criticised by Poston (1975) who stated that the values in their published Table 
and text did not match and, furthermore, that the text figures (for IgM) supported Davies’ 
findings. Davies et al. (1980) also pointed out that the results of Toivanen et al (1975a) 
were obtained by using fat free milk, which would presumably not contain the important 
BMFGM antigen. Toivanen et al (1975b), in reply to Poston (1975), reiterated their 
conclusion that there was no difference between Ml patients and controls, and that IgM was 
higher in controls, when all sera were examined. Scott et al. (1976) used "National Dried 
Milk" as antigen, which was withdrawn in 1977. It was known to differs from other infant milk 
formulas (Mettler.,1976) but, unfortunately, is no longer available for study. Gibney et al.
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(1980) used spray dried milk of unknown source. Table 1 shows the different antigens and 
assays used by each research group.
Groups Davies et al Oster et al Toivanen et al Scott et al Gibney et al


















































(Ml/C) sig sig n.sig n.sig n.sig
T a b le  1 : Summary of the results of 5  groups investigating the level 
of anti-bovine milk antibodies in Ml patient and controls
Table keys:
Ml = Myocardial infarction patients 
C = Controls 
M = Male 
F = Female
sig = Ml significantly higher than C 
n.sig = Ml not significantly higher than C 
H = Haemagglutination assay 
R = Radioimmunoassay
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5- Bovine milk fat globule membrane (BMFGM1
Bovine milk fat globules have a diameter ranging from 0.2 -20 pm (Walstra.,1969). 
They are mainly composed of triglyceride and are stabilised in aqueous media by an 
interfacial layer at the globule surface, known as the bovine milk fat globule membrane 
(BMFGM).
5-1 Background
As long ago as 1674, van Leeuenhoek discovered the existence of fat globules in milk. 
In 1840, Ascheron suggested the presence of an emulsion-stabilizing substance surrounding 
the fat globules, and in 1885 Babcock compared the fat globules of milk with artificial 
emulsions of the oil-in-water type, which were known to be stabilized by an adsorbed phase. 
A few years later (1889), Babcock reported that he had identified a small percentage of 
lacto-fibrin which formed a "coat" around the globule surface. Milk, in fact, contains many 
proteins, each of which is capable of stabilizing the fat phase (Storch.,1897) and this 
probably explains the failure of early attempts to identify the nature of the "coat" surrounding 
the fat globules.
Palmer and Samuelson (1924) first isolated the BMFGM and partially characterized it, 
and later Palmer and Wise (1933) showed the presence of high concentrations of 
phospholipids (17.5--20 % of the membrane material). In 1955, King summarized the 
available data, concerning the isolation, origin, structure and composition of BMFGM and he 
proposed a two layer membrane structure, in which protein was hydrophilically bound to an 
interfacial layer of phospholipids (Fig. 18).
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Fig, 18 : Two membrane structure of BMFGM
( Proposed by King, 1955 ).
5 - 2  O r i g in  o f  th e  m ilk  fa t  g lo b u le  m e m b r a n e
Early light microscopy studies (Schmidt, 1924) showed that milk fat globules were 
surrounded by a solid line which disappeared on treatment with pepsin and hydrochloric 
acid. The introduction of electron microscopy opened a new door in understanding the origin 
of the membrane. Bargman and Knoop (1959, 1961) presented clear electronmicrographic 
evidence of the true nature and origin of the membrane. They showed the progressive 
envelopment of the emerging MFG by the apical membrane of the secretory cell (alveolus). 
The BMFG was thereby surrounded by a plasma membrane during its exclusion from the
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cell. A scheme outlining this process was presented by Bargman and Welsch (1969) and is 
shown in Fig. 19. The scanning electronmicrographs of Horisberger et al. (1977), using 
gold-labelled lectins, showed that the greater part of the globule is covered by the the 
BMFGM.
Keenan et al.. (1970) used polyacrylamide gel electrophoresis (PAGE) to demonstrate 
the presence of nine major polypeptides in BMFGM and showed that these are similar to 
those isolated from bovine mammary cell membrane. SDS-PAGE patterns of BMFGM have 
commonly shown 5-7 major polypeptide bands (Anderson et al..1974: Anderson.,1974; 
Kobylka and Carraway.,1972, 1973; Mather and Keenan., 1975), althought Basch el 
ai ,(1985) recently delinated 13 bands divided into three zones according to the molecular 




Fig. 19 : Origin of bovine milk fat globule membrane
( From Bargman and Welsch, 1969 ).
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The first two zones (A and B) were reported to be independent of the method of 
preparation of BMFGM unlike zone C, which represented caseins. Fourteen of 
carbohydrate-containing bands were detected by with periodate-Schiff stain, of which nine 
were glycoproteins (Basch et al..1985b).
Thompson et al. (1961) showed the presence, in BMFGM, of phospholipids, 
triglycerides (including many with melting points higher than 50 °C), mono and diglycerides, 
free fatty acids, cholesterol esters, carotene and squalene-like substances. The distribution 
of individual phospholipids in BMFGM was shown to be similar to that of the plasma 
membranes (PM) of the secretory cell (Table 2).








Lyso derivatives 1.8 2.3
Table 2 : Comparison of phospholipids in BMFGM and PM of secretory cells.
( From Mohanna, 1981 ).
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The gross composition of BMFGM is given in Table 3. Protein and lipids together 
represent over 90 % of the dry weight of the membrane material (Swope and Brunner, 1970; 
Thompson et al..1961). Many factors, including season, diet, and stage of lactation are the 
cause of the great variability in the relative proportions of protein and lipids (Patton and 
Keenan, 1975). The method of membrane isolation is also relevant in this context (Anderson 
and Cawston, 1975).
Constituents Amount
Protein 25-60 % of dry weight
Total lipids 0.5-1.1 mg/mg protein
Neutral lipids 56-80 % of total lipids
Flydrocarbons 1.2 % of total lipids
Sterols 0.2-5.2 of total lipids
Sterol esters 0.1-0.8 % of total lipids
Glycerides 53-74 % of total lipids
Free fatty acids 0.6-6.3 % of total lipids
Cerebrosides 3.5 nmol/mg protein
Gangliosides 6 nmol/mg protein
Sialic acid 63 nmol/mg protein
Flexoses 0.6 umol/mg protein
Flexosamines 0.3 umol/mg protein
Table 3 : Gross composition of BMFGM
( from Patton and Keenan, 1975 ).
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Many enzyme activities have been reported to be associated with BMFGM (Table 4). 
Plasma membrane markers have been detected with high specific activity (Solyom and 
Trams.,1973; de Pierre and Karnovsky.,1973; Morre el al.. 1974; Trams and Lauter.,1974). 
Mitochondrion (Morton.,1954; Bailie and Morton.,1958; Dowben et al..1967). and 
endoplasmic reticulum markers (Kitchen.,1974; Dowben et al..1967: Keenan and Huang., 
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Table 4 : Enzymes present in BMFGM.
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6- Production of monoclonal antibodies
6-1 Historical background
Since the birth of experimental immunology, at the end of the last century, scientists 
have exploited the specificity of antibodies to detect, isolate and analyse biological materials. 
The year 1975, however, was marked by an event that changed the scope of immunology. 
This was the introduction of somatic cell hybridization by Kohler and Milstein. (1975), which 
allowed the production of monoclonal antibodies, by combining the nuclei of normal 
antibody-forming cells with those of their malignant counterparts. We thereby gained an 
unprecedentedly powerful way of analysing and purifying individual molecules within the 
complex mixtures encountered in biological membranes.
Kohler and Milstein were awarded the Nobel Prize in physiology and medicine in 1984 
for their work, which was the fruit of an excellent line of research. This essentially started in 
1958 with the publication of the proof of the clonal selection theory (Nossal and 
Leberberg.,1958) and was followed by the development of cell fusion techniques 
(Okada.,1962; Littlefield., 1964), the artificial induction of plasmocytomas (Potter and 
Boyce.,1962) and their adaptation to tissue culture (Horibata and Harris.,1970). Finally, 
came the demonstration that two different plasma cell tumour lines could be fused with 
retention of both sets of antibody production (Cotton and Milstein., 1973).
6-2 Preparation of mouse monoclonal antibodies
Mouse hybridomas are prepared in vitro by fusion of antibody- producing immune 
mouse cells (eg. B lymphocytes) with a mouse myeloma cell line (Kohler and Milstein., 1975, 
1976). Hybridomas (heterokaryons) lose some chromosomes, but retain some of the
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properties of each of the parental cells. They inherit immortality from myeloma cells and the 
ability to produce antibodies from the lymphocytes. Clonal selection ensures the permanent 
availability of monoclonal, monospecific antibodies. The general protocol for the preparation 
of mouse-mouse hybridoma cells, producing monoclonal antibodies, is illustrated in Fig.20.
Over the last decade, a number of myeloma cell lines have been used successfully for 
the generation of hybridomas. Not all myeloma cell lines are suitable. Moreover, certain 
sublines of known good lines have given poor results. The first cell lines to be successfully 
fused were the murine tumours, MOPC-21 and MPC-11, of BALB/c strain origin (Cotton and 
Milstein.,1973). These two cell lines have the disadvantage that they secrete lgG1 and 
lgG2b respectively (Melchers et al.. 1978) and, in 1976, Kohler and Milstein described a 
variant of MOPC-21, (P3-NS1-Ag4-), which does not secrete heavy chains. Subsequently 
other mouse cell lines were found which produce neither heavy nor light chains, but, 
nevertheless, allow production of antibody secreting hybridomas, when fused with 
lymphocytes. These cell lines are: SP 2/0-Ag-14 (Shulman et al..1978). X63-Ag 8.653 
(Kearney et al..1979) and NSO/1 (Galfre and Milstein.,1981).
Of these, the X63-Ag 8.653 line is preferred because of its high fusion frequency, wide 
availability and ready growth in culture. Table 5 shows the most common mouse fusion 
partners presently available together with their immunoglobulin secretion specificity. Rat 
myeloma cell lines are also available for fusion with spleen cells of appropriately immunised 
rats. Some of these are also shown in Table 5.
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Cell line Cell type Secreted Ig Fusion Freq.(x 10"6)
(Mouse)
P3-X63-Ag8 myeloma igG * 1 0
NS1 myeloma light chains ~  10
X63 myeloma none * 1 0
SP2/0 myeloma none *  10
NSO myeloma none - 1 0
(Rat)
Y3.Ag.123 myeloma light chains ^ 1 0
YB.Ag .20 myeloma none * 1 0
Table 5 : Rodent fusion Partners.
( Adapted from Galfre and Milstein, 1981; Kozbor and Roder, 1983 ).
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6-3 Preparation of human monoclonal antibodies
6-3-1 Human-Mouse heterohybridomas.
As early as 1973, Schwaber and Cohlen reported the fusion of mouse myeloma 
TEPC-15 cells with human PBLs, from which they succeeded in cloning a hybrid, secreting 
both human and mouse immunoglobulins. This was followed by the fusion of human 
neoplastic B cells with mouse P3-X63-Ag cells (Levy and Dilley., 1978), from which hybrids 
were cloned. These hybrids secreted, in large quantities, human immunoglobulin of the 
same light chain type as that found on the surface of the neoplastic parent lymphocytes.
Human heavy and light (lambda and kappa) immunoglobulin chain genes are carried 
on chromosomes 14, 22 and 2 respectively (Croce et al..1979: Hobart et al..1981; Erikson 
et al..1981). The fusion of human lymphocytes with a mouse cell line results in the 
preferential loss of human chromosomes (Croce et al..1980: Koskimies et al..1979) and, 
clearly , this constitutes a disadvantage if the genes coding for human antibodies are lost. 
Nevertheless, within the last few years, a number of human monoclonal antibodies have 
been successfully produced by fusing human PBLs with mouse cell lines (most commonly 
X63-Ag8.653). Antigens giving rise to such antibodies include the Forssman antigen 
(Nowinski et al..1980). human cellular antigens (Schlom et al..1980: Cote 983),
keyhole limpet haemocyanin (Lane et al..1982). tetanus toxoid (Kozbor 982; Butler at 
al., 1983; Tiebout et al..1985: Ho et al..1985). influenza virus (Gigliotti et al..1984). hepatitis 
B surface antigen (Tiebout et al..1985: Matsumoto et al..1986) and sperm-coating antigen 
(Kyurkchiev et al.,1986). The stability of these hybridomas ranges from a few weeks to 
several years.
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6-3-2 Human-Human hybridomas
The first suggestions that human-human hybridoma technology might follow that of 
rodents arose in 1980 from two independent publications (Croce et al..1980a: Olsson and 
Kaplan., 1980): Croce et al..(1980a) hybridized an (HPRT)-deficient human B cell line, 
derived from a patient suffering from multiple myeloma, with PBLs obtained from a patient 
with subacute sclerosing panencephalitis. The hybridomas obtained were found to secrete 
human IgM for Measles virus nucleocapsids. Olsson and Kaplan (1980) fused 
(HPRT)-deficient U266 human myeloma cells with lymphoid cells from patients with 
untreated Hodgkin’s disease. Some of the hybrids obtained secreted specific IgG from the 
lymphoid cells.
For ethical and safety reasons, humans cannot routinely be immunised solely for 
scientific purposes and, clearly, human spleens are not generally available. Sources of 
human antibody-producing cells are accordingly restricted to blood and lymph node tissue 
from unimmunised individuals. The percentage of B lymphocytes producing specific 
antibody in these sources is very low compared with that in spleen cells of an optimally 
immunised animal. This situation can be alleviated by in vitro immunisation (Osband 
al-,1981; Foon et al..1983: Cavagnaro and Osband., 1983), pre-stimulation of cells with 
polyclonal activators (Chiorazzi et al..1982: Shoenfeld et al..1982) or by pre-selection of 
antigen-specific cells (Kozbor and Roder.,1981). Moreover, in spite of ethical considerations, 
a number of in vivo immunisations of humans against different antigens, have been exploited 
over the last few years. Such immunisations include those against bacterial antigens 
(Gigliotti et al..1984: Boyd et al..1984b: Tiebout et al..1984 and 1985; Schwaber £i 
a!-,1984), viral antigens (Matsumoto et al.. 1986; Paire et al..1986: Masuho et al..1986: 
Haspel et al..1985a and 1985b), and other antigens such as HLA (Hulette et al.,1985: Effros 
et al..1986). Characteristics of an ideal cell line for fusion include: good growth properties;
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robustness in culture; high efficiency of fusion; ability to support the secretion of large 
amounts of immunoglobulins; lack of immunoglobulin production; generation of hybrids that 
clone easily and stability of hybridomas over long periods of time. While these criteria are 
fulfilled by a number of rodent cell lines (Foon et al..1983: Kozbor and Roder.,1983), no 
human line, currently available, fulfils them all. Most common deficiencies include poor 
hybridization and cloning efficiency, instability of human Ig-secreting cell lines, secretion of 
immunoglobulins by the myeloma cell lines and production of low amounts of monoclonal 
antibody. Nevertheless, many human lines have successfully been used for fusion, a 
selection of which is shown in Table 6.
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Fusion cell type secreted Ig references
SKO-007 myeloma igE(>o Olsson and Kaplan, 1980
RPMI 8226 myeloma X Abrams et al..1983
HFB 1 myeloma non-secretor Hunter et al.,1982
KMMI myeloma IgG Togawa fiLai-,1982





6TG-AL LCL igG2 ( k ) Croce et al..1980
6TG-OA LCL Hulette et al..1985
KR4 LCL igG2 M Kozbor et al..1982
GM 467 LCL igG2 (h) Sato et al..1972
GM 4672 LCL IgG (K) Croce et al..1980
ARH-77 LCL IgG (*) Burk et al.,1978
LICR-LON-
-Hmy2 LCL igG i (*) Edwards et al..1982
W1-L2 LCL Emanuel et al..1984
H35-1-1 LCL igMOO Chiorazzi et al.,1982
W1-L2-729
HF2 LCL IgM ( k ) Strike et al..1984
W1-L2-727 LCL IgG (k ) Emanuel et al..1984
UC 729-6 LCL IgM (K) Glassy et al..1983
MC/CAR LCL None Ritts et al..1983
MC/MNS-2 LCL IgGi (*) Ritts et al..1983
LTR 228 LCL IgM (k ) Larrick et al..1983
LSM 2-7 LCL Schwaber et al., 1984
HS Sultan LCL None Lazarus et al.,1982
GK-5 LCL Satoh et al..1983
HO-323 LCL Ohashi et al..1986
KR-12 h/h hybrid lgG2 (K+A) Kozbor et al.,1984
SHM-D3
myeloma 
m/h hybrid Non-secretor Teng et al..1983
SBC-H20
myeloma 
m/h hybrid Non-secretor Foung et al.,1985a
3 HL
myeloma 
m/h/h hybrid IgM (A) Teng et al.. 1985a
Table 6 : Available human fusion partners with their immunoglobulin 
secretion specificity. ( From James and Bell, 1987 ).
h/h = human hybrids used as fusion partners.
m/h and m/h/h = mouse human hybrids used as fusion partners.
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6-3-3 Epstein Barr Virus transformation of human lymphocytes.
A third method of generating human monoclonal antibodies does not involve fusion of 
cells. It is based on viral transformation of lymphocytes (for review see Carson and 
Freimark.,1986; Roder et al..1986).
Epstein Barr Virus (EBV) is a large gamma (170 Kb genome) herpes virus, originally 
isolated, in 1964, from a cultured cell line, derived from an African Burkitt’s lymphoma biopsy 
(Epstein et al.,1964). EBV has been shown to be the etiological agent of infectious 
mononucleosis (Henle and Henle., 1966, 1969) and preferentially infects human B 
lymphocytes (Johdal and Klein.,1973), inserting into their genome and causing 
transformation (Baer et al..1984). Several human cancers have been associated with EBV 
(Kieff et al..1983). Although it can bind to all B cells, via C3d complement receptor (Frade 
al-,1985), only a small proportion of target cells are transformed (Johdal et al.. 1976). During 
transformation only a small fraction of the genome is expressed (Kallin et al..1986: Ricksten 
fiLai.,1988).
This lymphotropic virus is capable of polyclonal activation of normal human B 
lymphocytes and of converting them into immortal cell lines (Miller and Lipman.,1973; Rosen 
et al.. 1979). It was first used, to transform B cells, by Steinitz et al. (1977). They used EBV 
to infect lymphocytes from volunteers with a high natural antibody titre to a specific nuclear 
antigen (NNP). After a month, permanent lines were obtained which secreted anti-NNP 
antibodies. Despite the fact that EBV-transformed B lymphoblasts often grow inefficiently at 
low density, even in the presence of feeder layers and exogenous growth factors, a series of 
human monoclonal antibodies has since been produced by this method (Table 7), although a 
number of difficulties have been encountered, including problems of cloning and low 
production or total loss of antibody production (Zurawski et al..1978: Kozbor and
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Roder.,1981).
The EBV-infection of blood mononuclear cells leads to an anti-viral response 
consisting of interferon release and generation of cytotoxic T cells (Tsoukas et al..l982). To 
achieve effective EBV transformation, it is, therefore, frequently necessary to remove T 
lymphocytes prior to transformation, or to include a T cell specific immunosuppressive agent, 
such as cyclosporin or phytohaemagglutinin A in the culture medium (Bird et al..1981). EBV 







Tetanus toxoid PBL G >6
M •« M N PBL G1 (K)
•• W M M PBL G3 >10
Pneumococcal
polysacharide TON M >3
Chlamydia
salpingitis PBL G1 (k+x) >12
Herpes Simplex II PBL G1 + G2 <2
Herpes Simplex
glycoprotein D BM G1 Ck ) >24
Hepatitis Be PBL
Influenza virus PBL G1 (K) >?2
Cytomegalovirus PBL G(X) >12
Cytomegalovirus PBL G1 (k+A)
Epstein-Barr PBL.LN,
capside and TON.SP G1 (K) >8
membrane
Plasmodium
falciparum PBL M + G 12
Rhesus (D) PBL M 1.5
M H PBL G1 (K) >9M H PBL G1 + G4 >10
Melanoma ITL M + G
Transitional cell
carcinoma PBL M >1
Lung tumour LN M
Gastric tumour LN M(K)
OFA-1 PBL M (k )
T cell Leukaemia LN G1 >2
DNA PBL M >36
DNA.sperm
erythrocytes PBL M + G >1
Thyroid antigens PBL M,G,A >6
Neurofibrillary
plaques and PBL M + G >4
tangles
N.N.P. PBL M (k) —
Table 7 : Human monoclonal antibodies produced by EBV transformation. 
( From James and Bell, 1987).
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6-4 Uses of human monoclonal antibodies
Human monoclonal antibodies have potential use as clinical and therapeutical tools, 
including, for example :
1- targeting of drugs to specific cells, eg.,cancer cells, pathogenic microorganisms and 
lymphocytes that mediate autoimmune responses or allergic reactions (Blair and 
Ghose.,1983; Levy and Miller.,1983)
2- diagnostic imaging to identify malignant cells,damaged tissues, embryonic 
abnormalities and infectious agents.
3- passive immunization to prevent haemolytic disease of the new born, to neutralise 
toxins and drugs or to opsonize virus and bacteria.
4- active immunization with anti-idiotypic antibodies to elicit antibodies against 
pathogens which are not suitable for conventional vaccines.
5- modulation of autoimmune and endocrine conditions with anti-receptor antibodies.
6- human MCAs are preferable for gamma-globulin therapy because of the risk of 
sensitization with xenoantisera. Almost half the patients treated with murine MCAs have 
developed an antibody response to the mouse immunoglobulins, which prevented effective 
treatment (Miller fiLal ,1982; Dillman et al.,1982: Sears et ai..1982).
Generation of human monoclonal antibodies also has diagnostic applications in 
analysis of antibodies in human serum. Specific immunoassays of serum are complicated by 
the sheer complexity of serum components leading to non-specific binding in both ELISAs 
and immunoblots. Detailed characterisation of particular serum antibodies can be achieved 
following affinity purification or better still, by cloning the relevant PBLs and raising 
monoclonal antibodies. The latter approach has been used in this thesis to study 
naturally-occuring anti-(bovine milk fat globule) and anti-(xanthine oxidase) antibodies in 
human serum.
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7- Aims of the project.
The initial aim of this project was to investigate the Davies hypothesis (Sect.4-6-6) that 
anti-(cows’milk) antibodies have a pathogenic role in coronary heart disease. The basis of 
Davies contention was his consistent finding, in a number of studies, that such antibodies are 
elevated in patients, following a myocardial infarction. Although these elevations were not 
always statistically significant (Davies,1984) and were not always confirmed by others 
(Sect.4-6-6), there were reasons to believe that reinvestigation might be profitable. Thus, 
following their main clinical studies, Davies et al (1980) had shown that anti-(cow’s milk) 
antibodies, as assayed by their haemagglutination method, were, in fact, anti-(bovine milk fat 
globule membrane) antibodies. Moreover, Davies (1984) felt that assay of serum samples 
shortly after infarction showed more marked elevations in antibody levels. It seemed, 
therefore, that direct assay of anti-(BMFGM) antibodies in Ml patients immediately fellowing 
heart attack, might lead to more clear cut differences between Ml patients and controls. 
Moreover, the haemagglutination assay is crude and it was felt that use of ELISA, allowing 
specific detection of IgG, IgM and IgA levels, would be more informative.





The Mistral-6L-centrifuge was from MSE. The Sorval RC-5B refrigerated superspeed 
centrifuge was supplied by Du Pont Instruments and the ultracentrifuge (model L5-50) was 
from Beckman. Bench centrifuges and Micro-centaur centrifuges were made by MSE.
b- Spectrophotometers
UV absorptions were measured by a CE 212 variable wavelength monitor and chart 
recorder (Gilford instruments) or by a Pye Unicam model SP6-450 UV/Vis with chart recorder 
(Phillips). Columns were connected to the UVICORD model 4700 (LKB) with chart recorder. 
The ELISA reader was a Titertek Multiskan MCC with automatic recorder.
c- Microscope
A Zeiss light microscope, with incident UV facility was, used for cell counting.
2- Immunological reagents
Horse radish peroxidase (HRPO) and alkaline phosphatase conjugated to goat 
anti-(human immunoglobu!ins)-lgG were obtained from Sigma (Poole, UK). HRPO, used to 
prepare the goat anti-(human lgG)-lgG conjugate, was obtained from Sigma.
3-Amino-9-ethy!carbazole (AEC), dimethylformamide (DMF), 5-Bromo-4-chloro-3-indolyl
phosphate (BCIP) and nitroblue tetrazolium (NBT), used as substrates for the above two 
enzymes were obtained from Sigma. Goat anti-(rabbit lgG)-lgG-HRPO conjugate was 
obtained from Sigma. Mancini agar plates, containing anti-human IgM antibodies were 
obtained from The Binding Site Company, Birmingham, UK.
3- Chromatography media
CNBr-activated Sepharose 4B was obtained either from Sigma or Pharmacia. 
Sephadex A 25 was from Pharmacia. Calcium phosphate gel was from Sigma and 
DEAE-Cellulose (DE 52) was obtained from Whatman, Mandstone, Kent, UK. The 
AH-Sepharose 4B-folate affinity gel was a gift from Dr.R.C.Bray, Department of Molecular 
Sciences, University of Sussex, U.K.
A - Buffers and Solutions
Buffers and solutions were made with Analar grade reagents and distilled water. 
Where not detailed in Methods, buffers and solutions were prepared according to "Data for 
Biochemical Research" (Dawson et al..1974).
5- Cells and cell culture materials
The Myocoplasma-free, marmoset cell line B95-8 was a gift from Andrew Quinn, 
Biochemistry Department, University of Bath. The HAT-sensitive mouse myeloma X63 
Ag8.653 line was originally purchassed from Flow Laboratories (Irvine, Scotland) and was a 
gift from Dr.A.Jehanli, Biochemistry Department, University of Bath. Sterile media and 
supplements {RPMI 1640; myoclone (heat inactivated) FCS; L glutamine (200 mM); 50 x 
HAT; 50 x HT concentrates; PHA and disposal plastic ware} were obtained from Nunc
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Gibco, Flow Laboratories and Sterlin. PEG (4000) and DMSO, used in fusions, were 
purchassed from Merck and BDH Chemicals (Poole, U.K) respectively. 8-Azaguanine was 
obtained from Sigma. Lymphocyte separation media were obtained from Flow Laboratories 
(Irvine, Scotland, UK.). Filters for sterilisation of heat-sensitive liquids (0.22 urn) and 
marmoset B95-8 cell supernatants (0.45 urn) were obtained from Sera Lab. Ltd (Crawley, 
Sussex, U.K).
6- Human blood and organs
Blood samples, from patients with myocardial infraction (at different stages after heart 
attack) and from normal controls were obtained with the cooperation of Dr.R.Thomas (Royal 
United Hospitals, Bath). Human liver was kindly supplied by Dr.T.Steiner (Charing Cross 
Hospital, London) and Dr. R.Thomas (Royal United Hospitals, Bath).
7- General reagents
Molecular weight markers for SDS polyacrylamide gels (MW-SDS-200) and native gels 
(MW-ND-500) were obtained from Sigma. Phosphate Buffered Saline (PBS) was supplied in 
the form of tablets from Oxoid, UK. DMSO, Tween 20, fish gelatine, casein, BSA, trypsine, 
PMSF, benzamide, N-ethylmaleimide, Leupeptin pepstatin, bacitracine, guanine, salicylate, 
dithioerythritol, EDTA, PEG (8000), SDS, acrylamide and NN'-Methylene bis-acrylamide 
were from Sigma. AgNOa , glycine and MgCl2 were from BDH. Trichloroacetic acid was 
obtained from Koch-Light Ltd.U.K. All other reagents were from Sigma, BDH, Fisons or 
Aldrich.
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METHODS
METHODS
1- Preparation of bovine milk fat globule membrane (BMFGM1.
Uncooled milk (12 L) was collected from Friesian cows in mid-lactation, care being 
taken to avoid undue mechanical agitation. The temperature of milk (or cream) was 
maintained as close as possible to 37 °C  throughout the collection and processing, which 
was carried out essentially as described by Mather and Keenan.,(1975).
Milk was centrifuged at 170 g for 12 min, and the cream was removed by aspiration 
then washed four times by centrifuging each time with an equal volume of distilled water 
(37°C) at 300 g for 12 min. The upper layer of washed cream was resuspended in 50 mM 
Tris-HCI, pH 7.5, cooled on ice, then churned in a blender until butter was formed (2-4 min). 
To release trapped membrane from the butter, the mixture was warmed to 37°C  in a water 
bath, then centrifuged at 100.000 g for 1h The supernatant was discarded and the 
membrane pellet (containing two layers, brown and white) was stored until use.
In some preparations, a cocktail of protease inhibitors, listed below, was included in all 
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2- Extraction of lipids from BMFGM
2-1 Crude Lipid Extract
The extraction is based on that described by Stein and Marcus. (1977) and is outlined 
in Fig. 1. Membrane pellet (2.6 g; white fraction) was dispersed in water (5ml) and 
homogenized with chloroform-methanol (95 ml; 1:1 V/V) at room temperature in a Sorvall 
Omnimix. The suspension was centrifuged (1000 g; 30 min), and the pellet was reextracted 
with distilled water (5 ml) and chloroform-methanol (95 ml; 1:2 V/V) as above. The two 
supernatants were combined, evaporated to dryness at 40°C  (water bath) on a rotary 
vacuum evaporator and redissolved in chloroform- methanol (10 ml, 1:1 V/V) at 37°C  with 
low power sonication. The resulting suspension was filtered through a sintered glass filter 
and the residue was washed twice with chloroform-methanol (5 ml, 1:1 V/V). The combined 
filtrates were freeze-dried to give Crude Lipid Extract (OLE).
2-2 Water-soluble lipid extract
The extraction was carried out according to a modification (Hakomori et al..1974) of the 
method of Folch et al. (1957). The procedure is outlined in Fig. 2. The crude lipid extract 
(300 mg) in chloroform-methanol (10 ml; 2:1) was mixed throughly with distilled water (2 ml), 
and allowed to separate without inter-facial fluff, either by allowing it to stand for 4 h at room 
temperature or by centrifugation at 150 g for 20 min. The upper phase (40 %) was removed 
and the lower phase (60 %) was repartitioned twice with chloroform-methanol-water 
(3:48:47). The resulting three upper phases were combined, concentrated to 5 ml (rotary 
evaporator) and freeze dried. The residue was dissolved in distilled water (5 ml), dialysed for 
2 days at 4 °C  against distilled water (3 L), and then lyophilized to a white fluffy powder of 
crude glycolipids.
BMFGM (2.6g; white layer) 
distilled water (5ml) 
chloroform-methanol (95ml)
homogenize and centrifuge
(1000 g, 30 min)
pellet 1supernatant 1
add distilled water (5ml)
and chloroform-methanol(95ml, 1:2)
homogenize and centrifuge
(1000 g, 30 min)
V  4 ^
supernatant 2 pellet 2
extract 1
< -
evaporate to dryness at 40°C
dissolve in chloroform -methanol (10 ml, 1:1) 
and filter
I
filtrate 1 residue 2
wash (2x) chloroform-
-methanol (5 ml; 1:1)
filtrate 2 residue 3
filtrate 1 and 2
evaporate and lyophilise
\ /
Crude Lipide Extract (CLE)
Fig. 1 : Illustration of different stages in membrane lipid extraction.
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Crude lipid extract (300 mg) in chloroform-methanol (10 ml, 2:1) 
+ distilled water (2 ml)
centrifuge (150g, 20 min)
















Crude glycolipid mixture (white fluffy powder)
Fig.2 : Illustration of different stages in the extraction
of "water-soluble lipids" from crude lipid extract.
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2-3 Separation of acidic lipids from the crude lipid extract
An anion exchange resin was used to separate acidic lipids from neutral and 
zwitterionic lipids, according to the method of Yu and Ledeen (1972). Solvent A : 
Methanol-chloroform-water (60:30:8). Solvent B : Methanol-chloroform-0.8 M Na or K 
acetate (60:30:8). DEAE-Sephadex A 25 (5g) was ddded to solvent A with intermittent 
mixing over 10 min. The resin was allowed to settle and the supernatant fluid was removed 
by aspiration. This washing step was repeated three times and the resin was allowed to 
stand overnight at 4 °C  in solvent B. The supernatant was removed, the resin was packed 
into a column (30 ml), left to settle (3 h) and then eluted with solvent A (90 ml) at a flow rate 
of 0.3 ml/min.
Crude lipid extract (200 mg) was dissolved in solvent A (30 ml) and added to the 
column at a flow rate of 0.2 ml/min. From time to time, the top layer was gently agitated with 
a glass rod. Uncharged lipids (Fraction NL) were eluted with Solvent A (100 ml) at 0.3 
ml/min, and acidic lipids (Fraction AL) were eluted at 0.4 ml/min with Buffer B. Fractions NL 
and AL were separately concentrated (to 5 ml) using a rotary evaporator. Fraction AL 
containing acidic lipids and sodium/potassium acetate was dialysed against distilled water (2 
L) for 18 h . Fractions AL and NL were then separately lyophilized and stored at -4 °C . The 
column was regenerated by washing with an excess of Solvent A, containing 0.1 %  sodium 
azide.and stored at 4°C.
3- Incorporation of lipid fractions into liposomes
The incorporation was carried out according to the method of Feizi et al. (1978) (see 
also Marcus and Schwarting.,1976). Lipid fractions were mixed with phosphatidylcholine and 
cholesterol in chloroform-methanol (2:1) in the ratio of 1:2:2 (by weight). The lipid mixture 
was deposited as a thin.film on the wall of a round bottomed flask by rotary evaporation and
then freeze-dried overnight. Lipids were resuspended in PBS, pH 7.3, (final concentration of 
lipid fraction : 0.001- 2 mg/ml) by shaking in a wrist shaker for 1 h at 37 °C . The resulting 
suspension was heated at 50 °C  in a water bath and then sonicated in a Decon-bath type 
sonicator for 30 min. Liposomes were used immediately after sonication (Naiki et al..1974). 
For comprehensive reviews of the properties and preparation of liposomes, see Szoka. 
(1980); Van Rooijen and Nieuwmgen (1983).
4- Bovine milk xanthine oxidase (BXQ1
4-1 Purification
Buffer A ; 0.2 M Na2HPC>4 containing 2.5 mM dithioerythritol, 1mM EDTA 
(dissodium salt) and 1.25 mM sodium salicylate, pH 6.0
Buffer B ; 0.2 M K2HPO4 containing 2.5 mM dithioerythritol, 1 mM EDTA 
(dissodium salt) and 1.25 mM sodium salicylate.
The enzyme was prepared from fresh cow’s milk according to the method of Nakamura 
and Yamazaki (1982) with slight modification : Milk containing 1 mM EDTA, 2.5 mM 
dithioerythritol and 1.25 mM sodium salicylate was centrifuged (3000 g, 30 min) at 6 °C  and 
the upper layer of cream was collected. An equal volume of Buffer B was added to the 
cream and the mixture was cooled to 5 °C  before adding 15 % (V/V) butan-1-ol (-20 °C ). 
This was followed by the gradual addition of 15 % (W/V) ammonium sulphate to a gently 
stirred mixture over 1 h . The mixture was further stirred for 1 h and then centrifuged (13000 
g, 20 min) at 4 °C . The aqueous bottom solution was collected and a further 15 %  (W/V) 
ammonium sulphate was added. The mixture was stirred for 1 h at 4 °C , allowed to stand 
for 2 h at 4 °C , after which the top phase was centrifuged (10,000 g, 30 min). A small 
amount of Buffer A was added to the top phase to give a final volume of approximately 30 
ml, which was then dialysed overnight against Buffer A (2 L) at 4 °C . The dialysate was
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centrifuged (20,000 g, 60 min) and the supernatant (orange-brown) was applied to a calcium 
phosphate gel column preequilibrated with buffer A as follows:
Calcium phosphate gel (Sigma, Poole, UK) was resuspended in Buffer A (1 : 4, V/V)
five times and fines were removed. The gel was poured into a column (3 cm x 60 cm) and
allowed to settle overnight under gravity at 4 °C  and then washed with buffer A (2 bed 
volumes). The loading capacity used for this gel was 1 mg/ml with a maximum flow rate of 
10-12 ml/h. The centrifugd dialysate above was applied to the column, and allowed to enter 
the gel before connecting the pump. The column was then washed with Buffer A until no 
more protein (monitored at 280 nm) was eluted. Bound xanthine oxidase was eluted from 
the column either by gradient of ammonium sulphate concentration in Buffer A (0-10 %, W/V) 
or with successive isocratic washes with Buffer A containing 2 %  and 5 %  ammonium 
sulphate, (see Results, Section 5-1). Enzyme fractions were dialysed, overnight at 4 °C , 
against Buffer A (3 L).
4-2 Assay of enzymic activity
Bovine XO exists in the oxidase and dehydrogenase forms. Dithioerythritol was added 
to all purification media in order to convert the oxidase to dehydrogenase form (Batteli 
al.,1973). The activity of both forms was assayed according to the methode of Nakamura 
and Yamazaki (1982). All enyme assays were carried out at room temperature.
Solution A : Xanthine (15.2 mg, Sigma) in 0.2 N NaOH (2ml) was diluted to 
100 ml with aerated sodium pyrophosphate buffer.
Solution B : NAD+ (3.317 mg/ml, Sigma) in sodium pyrophosphate buffer.
Buffer : 0.1 M sodium pyrophosphate, pH 8.3.
Xanthine oxidase activity was measured spectrophotometrically by the increase in 
absorbance at 292 nm under aerobic conditions, correspoding to the oxidation of xanthine to 
uric acid. The assay mixture (2 ml) contained 100 pM xanthine (0.2 ml of Solution A) and 
pyrophosphate buffer (1.7 ml). A suitable amount of enzyme (100 pi) was added, quickly 
mixed by inversion, and the absorbance was monitored at 292 nm. A unit of xanthine 
oxidase was defined as the amount of enzyme yielding 1 pmole of uric acid per min. (E for 
uric acid at 292 = 12.2 mM-1 cm-1, BDH catalogue, 1989).
Xanthine dehydrogenase activity was measured as the increase in absorbance, at 340 
nm, in the presence of NAD+. The assay mixture (2 ml) contained 100 pM xanthine (0.2 ml 
of Solution A), 500 pM NAD+ (0.2 ml of Solution B) and pyrophosphate buffer (1.5 ml). A 
suitable amount of enzyme (0.1 ml) was added, quickly mixed by inversion, and the 
absorbance was monitored at 340 nm corresponding to the formation of NADH. A unit of 
xanthine dehydrogenase activity was defined as the amount of enzyme yielding 1 pmole of 
NADH per min (6  for NADH at 340 nm = 6.22 mM-1 c n r1, Dawson et al..1974)
The Total enyme activity was measured at 292 nm as the formation of uric acid, similar 
to the oxidase form assay, in the presence of NAD+ (500 pM). The assay mixture was 
exactly the same as for measuring dehydrogenase activity.
5 Affinity purification of human anti-XO antibodies
5-1 Preparation of CNBr-activated Sepharose 4B gel.
CNBr-activated Sepharose 4B was purchased from Pharmacia. The dry gel (4 g) was 
allowed to swell in 1 mM HCL for 3h, and the slurry (approximately 12 ml) was washed three 
times with 1 mM HCI (250 ml each) to enhance its stability (Goding et al..1986). The use of 
HCI preserves the activity of reactive groups, which hydrolyze at high pH. The gel was
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washed with coupling buffer, 0.1 M NaHCC>3, pH 8.3 (5 ml/ml of gel). This step was carried 
out as quickly as possible because the reactive groups on the gel hydrolyze at the coupling 
pH (Pharmacia catalogue : Affinity Chromatography, Principles and Methods, 1988).
5-2 Coupling of XO to CNBr-activated Sepharose 4B gel
Purified BXO (24 mg in Buffer A) was dialysed against 0.1 M NaHC03, pH 8.3, and 
mixed with activated gel (at a ratio of 2 : 1 respectively) for 12 h. at 4 °C  with end-over-end 
mixing. Coupling efficiency was calculated by measuring the amount of protein in the 
supernatant and washings (three) from the gel. The remaining active sites on the beads 
were blocked by incubating the gel with 0.1 M glycine (2 ml) for 2 h at 4 °C  with gentle 
mixing. The gel was then washed three times with 0.1 M Na acetate, pH 4.0, containing 0.5 
M NaCI, then with coupling buffer and a column (15 ml) was packed. Before use, the column 
was washed thoroughly with PBS. The coupling procedure was adapted from Goding (1986) 
and Pharmacia catalogue (1988).
5-3 Affinity chromatography
The source of anti-XO antibodies was a pooled serum (6ml) from five individuals with 
high antibody titers. The serum was loaded onto the column and recycled for 4 h to allow 
maximum binding. The column was washed with PBS (200 ml) until the absorbance at 280 
was negligible. PBS has no effect on Ag-Ab interactions (Goding and Herzenberg.,1980; 
Shneider eLai.,1982). Bound anti-XO antibodies were eluted with 0.15 M glycine-HCI, pH 
2.3. The eluted antibodies were quickly neutralized by adding drops of NaOH before 
dialysing against PBS (2 L). The column was regenerated by elution with PBS (100 ml), then 
with 0.1 mM HCI (30 ml) and finally with PBS containing 0.01 % (W/V) sodium azide before 
being stored at 4 °C . The purified antibodies were assayed by ELISA and dot 
immunobinding assay against BMFGM and BXO.
6- Purification of human xanthine oxidase (HXO)
6-1 Preparation of calcium phosphate gel
Equal volumes of 0.63 M CaCl2 and 0.75 M potassium phosphate (K3PO4) solutions 
were mixed and the resulting gel was washed by suspension in distilled water (2 vol) and 
allowed to settle for 2-3 h. Supernatant was removed by siphoning and the washing 
procedure was repeated until an aliquot of the supernatant fluid no longer showed a 
precipitate with an equal volume of 0.1 M AgNCte . indicating the absence of chloride ions. 
The volume of the suspension was adjusted to give 32 mg dry weight/ml. The gel was 
stored at 4 °C .
6-2 Preparation of Crude Extract
A crude extract of HXO was prepared from human liver according to the method of 
Krenistsky et al. (1986): Liver was kindly supplied by the Royal United Hospitals, Bath and 
Charing Cross Hospital, London. All operations were carried out at 4 °C , unless otherwise 
stated, and all buffer solutions contained 0.1 mM EDTA. The liver (680g and 820g) was cut 
into small pieces (approximately 1 cm3) and homogenized in 10 mM potassium phosphate 
buffer (1 L), containing 1 mM dithioerythritol and 0.2 mM PMSF, pH 7.7, in a Waring blender 
for 1 min intervals (alternately low and medium speeds), then for 2 min at high speed. The 
homogenate was incubated in a shaking water bath at 55 °C  for 30 min and then centrifuged 
(4200g; 1h). Cold deionized water and calcium phosphate gel slurry (32 mg/ml) were added 
to the decanted supernatant at a ratio of 1: 2: 1 (by vol). The mixture was stirred for 2 h, 
and then allowed to settle under gravity overnight. The supernatant was discarded and the 
gel slurry was washed twice with 0.1 M potassium phosphate, pH 7.7 (3 vol). The gel was 
then centrifuged (1500g; 10 min) and the slurry was resuspended in 0.2 M potassium
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phosphate (2.5 vol) containing 5 % (W/V) ammonium sulphate, pH 7.7. The suspension was 
centrifuged (1500g; 10 min) and ammonium sulphate was added slowly to the resulting 
supernatant (to 60 % saturation) over a period of 40 min. The final mixture was stirred for 1 
h and then centrifuged (7800g; 10 min). The pellet was resuspended in a minimal amount 
of cold deionized water and dialysed overnight against cold deionized water (5L). The 
suspension was clarified by filtration through glass wool to give crude extract. The final 
concentration was brought to 30 mg protein/ml of deionized water.
6-3 Further purification of Crude Extract.bv affinity chromatoraphy using guanine
6-3-1 Preparation of the affinity column
The affinity column was prepared essentially according to the method of Baker and 
Siebeneick. (1971) except that, instead of 9-(p-aminoethoxyphenyl) guanine, guanine 
(2-amino-6-hydroxypurine) was coupled to CNBr-activated Sepharose-4B, which was 
purchased from Sigma. The dry gel was allowed to swell in 0.1 M NaHC03, pH 9.6 buffer, 
then washed thoroughly with the same buffer. Guanine (50 mg) in DMF/DMSO (25 ml, 2:3, 
v/v), pH 11 was stirred for 2h and then filtred. The filtrate (0.148 mM guanine) was stired 
with CNBr-activated Sepharose-4B (20 ml) for 24 h at room temperature. The gel was 
washed with DMF (3 x 50 ml) then with 0.1 M tetrasodium pyrophosphate, pH 8.5 until no 
more absorption at 275 nm was detected. The amount of guanine in the filtrate and the 
washes was determined by UV absorbance at 275 nm ( £  = 8.1 mM"1c n r1 , BDH 
catalogue.,1989). A column was packed and stored at 4 °C .
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6-3-2 Affinity chromatography
Crude HXO (300 mg) was diluted with 0.1 M tetrasodium pyrophosphate (Buffer A, 
50ml), pH 8.5, and then dialysed overnight against the same buffer. The dialysate (15ml) 
was loaded onto the column (Section 6-3-1) and left to enter the gel under gravity. The 
column was washed with Buffer A (5 x bed vol) until no absorbance was recorded at 280 nm. 
The bound enzyme was then eluted with buffer A containing 5mM salicylic acid. Fractions 
showing absorbance at 280 nm were tested for activity, pooled and then the enzyme (HXO) 
was precipitated by adding solid ammonium sulphate to 60 % saturation. After centrifugation 
(7800g; 15 min) the pellet was dissolved in Buffer A (2ml) and dialysed overnight against the 
same buffer (3L).
6-4 Further purification of Crude Extract bv affinity chromatography using folate
Buffer A: A mixture of 0.1 M Na4P207 buffer, pH 8.5, adjusted with acetic acid, (20%, 
v/v) and 0.05M Tris-HCI buffer, pH 7.8 (80%, v/v) containing 0.2 mM EDTA.
Buffer B: A mixture of 0.1 M Na4P207  buffer, pH 8.5, adjusted with acetic acid, (30%, 
v/v) and 0.05M Tris-HCI buffer, pH 7.8 (70%, v/v) containing 0.2 mM EDTA.
6-4-1 Preparation of the affinity column
AH-Sepharose 4B folate was a gift from Dr.R.C.Bray, Department of Molecular 
Sciences, University of Sussex, UK. The general procedure for preparing such a gel is as 
follows : AH- Sepharose 4B (10 g) is allowed to swell in 0.5 M NaCI and washed with 0.5M  
NaCI (1 L). 2mM folate in 50 %  (V/V) dimethylformamide pH 5.8 (60 ml) and 1 ethyl-3-(3 
dimethylaminopropyl) carbodiimidine (0.4 g) are added to AH-Sepharose 4B and stirred 
overnight at room temperature in the dark. The gel is washed sequentially with 50 %  DMF, 
pH 7.0 (200 ml); 0.01 N NaOH (500 ml); 0.1 M Tris- HCI, pH 7.0 (500 ml) and finally with
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distilled water (1 L). The gel is stored and used in the dark at 4 °C . (see Nishino et al..1981; 
Nishino and Tsushima.,1986).
6-4-2 Affinity chromatography
The gel (22 ml) was packed into a small column in the dark, allowed to settle under 
gravity and then washed with Buffer A (200 ml). The gel was protected from light by 
alluminium foil at all stages. HXO crude extract (6.2 mg/ml) was dialysed overnight against 
Buffer A (2 L) and then loaded onto the folate column (3-4 mg protein/ml of gel). The gel 
was washed with Buffer B until no absorbance was recorded at 280 nm. The bound enzyme 
was eluted from the column with Buffer B, containing 0.5 mM hypoxanthine. Enzyme 
fractions were collected, concentrated by dialysis against polyethylene glycol 8000 to a final 
concentration of 1mg protein/ml and finally dialysed overnight against 0.1 M pyrophosphate 
buffer, pH 8.5 (1L) containing 0.2mM EDTA. After each use the affinity gel was washed with 
0.1 M Na4P2<>7, pH 8.5 buffer (100 ml) then re-equilibrated with Buffer A containing 0.02 %  
(W/V) sodium azide.
6-5 Assay of enzvmic activity
Like bovine XO, human XO exists in two active forms : oxidase and dehydrogenase. 
The activity of both forms of the enzyme was measured according to the method of Krenitsky 
fits!-,1986:
Solution A : Xanthine (15.2mg) was first solubilized in 0.2N NaOH (2ml) 
then made up to 100 ml with aerated potassium phosphate buffer, pH 6.8.
Solution B : NAD+ (3.317 mg/ml) in potassium buffer, pH 6.8.
Buffer : 0.05 M potassium phosphate containing 0.03 mM EDTA pH 6.8.
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Xanthine oxidase activity was monitored spectrophotometrically by measuring the rate 
of change in absorbance at 300 nm (E = 6.78 mM-1crrr1) coresponding to the oxidation of 
xanthine to uric acid. The assay mixture (1 ml) contained 100 uM xanthine (100 ul) and 
Buffer (0.8 ml). A suitable amount of enzyme (0.1 ml) was added, the cuvette was quickly 
inverted several time and absorbance was monitored at 300 nm. A unit of xanthine oxidase 
was defined as the amount of enzyme catalyzing the oxidation of 1 umole of xanthine per 
min.
Xanthine dehydrogenase activity was spectrophotometrically measured as the 
increase in absorbance at 340 nm in the presence of NAD+, as electron acceptor. The 
assay mixture (1ml) contained 100 uM xanthine (0.1 ml), NAD (0.1 ml of Solution B) and 
Buffer (0.7 ml). The enzyme (0.1 ml) was added, mixed and the absorbance was measured 
at 340 nm. A unit of xanthine dehydrogenase was defined as the amount of enzyme yielding 
1 umole of NADH per min.
These assays were performed on purified, concentrated fractions of enzyme. For the 
crude extract and the diluted fractions of the enzyme, it was difficult, if not impossible, to 
measure the enzymic activity. A more sensitive method was required. For this purpose, the 
method reported by Baker and Wood (1969), which was originally used by Avis et al. 
(1956b), was followed. The method is based on the reduction of 2,6 
dichlorophenolindophenol (DCPI) at 600 nm as xanthine or hypoxanthine is oxidised. The 
assay mixture (1 ml) contained 320 uM hypoxanthine or xanthine (50 ul of 6.4 mM 
xanthine/hypoxanthine in 0.05 M Tris), DCPI (0.1 ml, 0.1 mg/ml; Sigma, Poole, UK) and 0.05 
M Tris; pH 7.4 (0.75 ml). A suitable amount of enzyme was added, and mixed by inversion, 
and the decrease of absorbance was monitored at 600 nm (E = 16.1 mM_1cm_1, Dawson el 
21,1974).
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7- Preparation of goat anti-(human IgGI-IgG conjugated with HRPO
Conjugate was prepared according to the method of Williams. (1984): Horseradish 
peroxidase (HRPO, 4 mg) was dissolved in distilled water (1 ml) and freshly prepared 0.1 M 
Nal04 (0.2 ml) was added. The mixture was stirred for 20 min at room temperature and then 
dialysed against 1 mM sodium acetate, pH 4.4. The pH was adjusted to 9.5 with 0.2 NaOH 
and goat (anti-human IgG) IgG (8-10 mg), a gift from Dr A. Jehanli, in 10 mM sodium 
carbonate, pH 9.5 (1 ml) was immediately added. The mixture was stirred for 2 h before the 
addition of freshly-prepared sodium borohydride solution (100 pi,4 mg/ml) and an equal 
volume of saturated ammonium sulphate was added. The solution was then stirred for 1 h 
and centrifuged (1500g, 15min). The pellet was dissolved in PBS (1-2 ml) and dialysed 
overnight against the same buffer (2 I). Unconjugated HRPO and IgG were removed by 
chromatography on Sephacryl G-200 column collecting fractions at a flow rate of 30 ml/h in 
20 mM sodium phosphate buffer pH 7.4. The IgG-HRPO fraction was concentrated to 5 
mg/ml in equal volume of PBS and glycerol and stored at -40 °C  for further use.
8- Enzvme linked immunosorbent Assay (ELISA1
8-1 Reagents : - Coating buffer: 50 mM sodium carbonate.pH 9.6.
- Blocking buffer: 0.1 M PBS containing 0.05-1 % Tween 20.
- Staining buffer: 1%(V/V) TMB stock solution [1 % (W/V)
TMB in DMSO] in 0.1 M sodium acetate/ citric acid, pH 6.0. 30%
Hydrogen peroxide (0.1 pl/ml) was added immediately before use.
- Goat(anti-human lg)lgG-HRPO: conjugates based on goat 
anti-[human Ig (G, M, A and polyvalent)] were purchased from
Sigma, Poole, UK. For some experiments goat anti-(human IgG)- 
IgG was prepared as described in Section 7.
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8-2 Standard ELISA (Engvall and Perlman.,1971: Engvall.,1980: Brennand.. 1987).
The conditions outlined below were established partly by other members of the 
laboratory and partly as a result of the present study (See Results, 1 and 6-2) Antigens 
(BMFGM or purified BXO) were suspended or dissolved in coating buffer at concentration of 
0.2 and 0.02 mg/ml respectively. The resulting mixture (100 pi) was added to each well of a 
flat-bottomed polystyrene microtitre plate (Flow Laboratories) and plates were incubated 
overnight at 4 °C . Wells were then washed by incubation at room temperature (20 min) with 
three successive portions of PBS-(0.05-0.1 %) Tween 20 (250 pl/well) to block free binding 
sites. Standard serum (100 pi) diluted 50-51800 times in PBS-0.05 % Tween 20 was placed 
in a series of wells and serum samples, to be assayed, were diluted 1:100 in PBS-0.05 % 
Tween and placed in different wells. The plate was incubated for 1 h at 37 °C . In the case 
of cell culture supernatants, supernatants (300 pi), instead of serum, were placed in the 
appropriate wells and the plate was incubated at 4 °C  overnight. After incubation, the plate 
was washed as described earlier and goat anti-[human Ig (G, M, A and 
polyvalent)]-lgG-HRPO conjugate (diluted 1:1000 in PBS-0.05 % Tween 20) was added to 
each well (100 pl/well). The plate was incubated for 2 h at room temperature and then 
washed three times, as in previous steps. Staining buffer was added to each well (100 
ul/well) and the colour was allowed to develop for 20-30 min. Finally, the reaction was 
stopped by addition of 1 M sulfuric acid (50 pi). After 5-10 min incubation, to ensure 
adequate mixing of the solution, absorbance was recorded at 450 nm (Titertek Multiskan 









n d a b .
1h,37 °C 2h,RT
or overnight 4 °C goat anti-(human lg)lgG-
substrate sulphuric acid
yellow colour  ■— ^  blue colour
20- 30 min.
FigJa : Outline of the main steps in the ELISA 
(adapted from Kemeny eLal.,1986).
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S : S u b s t r a t e
1* Antigen immobilized on plastic wall of well
(hydrophobic attraction)
2- Primary antibody
3- Secondary antibody (specific for primary
antibody) conjugated to HRPO
4- Colorimetric assay of HRPO to determine the
concentration of the secondary antibody,and 
hence of the primary antibody
Fie.3b : Principle of ELISA.
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8-3 Competitive ELISA
Wells were coated either with BMFGM or purified BXO overnight at 4 °C  and treated 
with blocking buffer, as described in Section 8.2. Standard serum, at appropriate dilutions, 
was incubated with different concentrations of inhibitory antigens (2h, 37 °C ), with constant 
shaking, before being applied to the wells. The ELISA was otherwise carried out as 
described in Section 8.2.
For inhibitions by liposomes, these were, in some experiments removed from serum by 
centrifugation (100,000 g, 3h.) after incubation and just before addition of serum to the wells.
9- Protein estimation
9-1 Modified Lowry method (Laemmli.1970: Carruthers and Melchior.1983)
Reagent A : 2 % (W/V) Na2C03 in 0.1 N NaOH containing 0.16 % (W/V) KNa 
tartrate and 1 % SDS.
Reagent B : 4 %  (W/V) copper sulphate (CuS04. 5 H2O).
Reagent C : Folin-Ciocalteau solution,diluted 1:1 with distilled water 
Standard protein solution : bovine serum albumin (BSA) 2 mg/ml
Duplicate standard solutions, containing from 0-100 ug BSA were made up to 200 pi 
with 0.1 M NaOH and appropriately diluted samples (200 pi) were added to clean dry tubes. 
Reagent B (1 ml) was added to Reagent A (99 ml) and an aliquot (1.2 ml) of this reagent 
mixture was added to each tube. After mixing, the samples were allowed to stand at room 
temperature for 20 min, then Reagent °C  was added (100pl/tube). Tube contents were 
vortexed and allowed to stand for 45 min at room temperature. Each assay tube was well
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mixed before reading the absorbance at 750 nm. A calibration line was obtained by plotting 
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ug protein (BSA)/100 pi
Fig. 4 : Calbration plot for the modified Lowry method.
9-2 Bradford method (Bradford.,1976)
This method was based on the binding of CBB-G 200 dye to proteins in the presence 
of ethanol and phosphoric acid. The method was used to determine protein concentration in 
samples free of detergent (SDS), which interferes with the assay at high concentrations. The 
buffer used for diluting the standards was the same buffer in which test samples were 
diluted. This method is also known as the Bio-rad assay. The dye reagent was supplied by 














9-2-1 Standard assay (2Q-140 pg protein/100 yl)
Standard protein solutions (100 pi) and appropriately diluted test samples were 
prepared in duplicate in clean dry tubes. Sample buffer (100 pi) was used for the blank . 
Dye regent (5ml, diluted 1:4 in distilled water) was added to each tube and mixed gently 
several times by inversion. Optical density at 595 nm was measured for each sample to give 
a calibration plot of OD versus concentration of standard proteins was plotted (Fig. 5a). The 
concentrations of test samples were obtained from the plot.
1. 0 -
pg protein (BSA)
Fig. 5a : Calibration plot for Bio-rad standard assay.
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9-2-2 M icro-assay (up to 25 jig protein/ml)
Standard protein solutions (800 pi) and appropriately diluted test samples were 
prepared in duplicate; sample buffer (800 pi) was used as a blank. Dye reagent (200 pi) 
was added to each tube and mixed by inversion. A calibration line was obtained by plotting 
OD 595 nm against the amount of protein (pg) in the standards (Fig. 5b). The 
concentrations of test samples were derived from the plot.
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pg protein (BSA)/ml
Fig. 5b . Calibration plot for Micro Bio-rad assay.
9-3 Ultraviolet light absorption method (Lavne. 19571
The absorbance of appropriately diluted protein solution was measured at both 260 nm 
and 280 nm against a diluent blank. The protein concentration in mg per ml was calculated 
according to the formula below:
(O D 280 nm  x 1.55) - (O D 260 nm x 0.76) = mg protein/ml.
This assay was used to estimate protein concentrations in detergent-free samples, 
prior to a Bio-rad assay.
10 Polyacrylamide gel electrophoresis
Slab gels were prepared by using a vertical slab gel apparatus [Bio-rad apparatus 
(Proteam TM II)]
10-1 Non-denaturing gels
The method of Davis (1964) was followed for non-denaturing gels containing 7.5 and 
10 % (W/V) acrylamide. The resolving gel buffer was 0.375 M Tris-HCI, pH 8.8, and the 
buffer used for the stacking gel [3 and 5 % (W/V) acrylamide] was 0.125M Tris-HCI, pH 6.8. 
The polymerization was achieved by using ammonium persulphate [0.0337 %  (W/V)] and 
TEMED [0.000625 % (V/V)]. Depending upon the staining method to be employed, protein 
sample, (4-40 ug in 30-50 ul) in reservoir buffer (5 mM Tris, 38mM glycine;pH 8.3) containing 
10 % (W/V) sucrose and 0.001 % bromophenol blue, was applied to each track of the gel. 
The samples were run at 7-10 mA/gel until the dye bands had traversed the stacking gel. 
The current was then increased to 15 mA/gel for the remainder of the run.
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10-2 SDS-Polyacrylamide gel electrophoresis (SDS-PAGE1
SDS-gels [7 % and 10 % (W/V) acrylamide] were prepared according to the method of 
Laemmli (1970). The reservoir buffer was 0.192 M glycine containing 0.025 M Tris and 0.1 
% (W/V) SDS, pH 8.3. Buffers for the resolving and stacking gels were respectively 0.375 M 
Tris-HCI, pH 8.8 and 0.125 M Tris-HCI, pH 6.8, each containing 0.1 % (W/V) SDS. 
Polymerization was achieved by addition of ammonium persulphate and TEMED ; exactly as 
above. Protein samples were dissolved in sample buffer [62.5 mM Tris-HCI, pH 6.8 
containing 1 % (W/V) SDS, 50 % (V/V) glycerol, 0.1 %  2-mercaptoethanol and 0.005 % (V/V) 
bromophenol blue]. Samples were boiled for 2-4 min (Maizel.,1969) then loaded onto the gel 
and electrophoresed at 70 volts (15 mA/gel), until they reached the resolving gel, then at 170 
volts (30 mA/gel) until the bromophenol blue reached the bottom of the gel.
10-3 Staining of polyacrylamide gels
10-3-1 Coomassie Brilliant Blue stain
Samples containing more than 10 ug protein were stained with Coomassie Brilliant 
Blue (CBB). Gels were fixed in 45 %  (V/V) methanol /1 0  % acetic acid for 2h to crosslink 
the acrylamide polymers and prevent diffusion of proteins, followed by staining in 0.1 %  
(W/V) CBB in the fixing solution at room temperature overnight with constant shaking. Gels 
were then destained in 5 % (V/V) methanol / 7.5 % (V/V) acetic acid. Destaining solution 
was changed three times daily during the two days before the gel was completely destained 
and ready to be photographed or dried onto filter paper (under vacuum).
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10-3-2 Silver stain
For samples containing less than 10 ug protein, a more sensitive staining method was 
required. Silver staining was carried out according to the modification, by Morrissey (1981), 
of the original method of Switzer et al. (1979). This modified method is independent of 
lighting conditions, making it easy to perform, and it is a hundred fold more sensitive than the 
CBB stain.
The slab gel was incubated successively for 30 min each in 50 % methanol / 10 %  
acetic acid, in 5 % methanol / 7 %  acetic acid and finally in 10 %  (V/V) glutaraldehyde. The 
gel was washed overnight in distilled water (1 L/gel), then incubated for 30 min in 5 ug/ml 
dithiothreitol (100 ml/gel). Excess solution was removed and immediately , without rinsing, 
silver nitrate [AgN03, 0.1 % (W/V)] was added (100 ml per gel) and left to incubate for 30 
min.
The gel was rinsed with developing solution [20 ml; 37 %  formaldehyde (50 ul) in 3 % 
(W/V) sodium carbonate (100 ml)], then soaked in developer until the desired level of 
staining was obtained. Staining was stopped by adding 2.5 M citric acid (5 ml) directly to the 
developer and shaking for 10 min. The solution was discarded and the gel was washed (5 
times) with distilled water, then soaked in 0.3 % Na2C03 for 10 min . Finally the gel was 
washed in distilled water and stored in the dark at 4 °C.







10-4 Molecular weight determination bv SDS-PAGE
The molecular weight of a protein was calculated by comparing its electrophoretic
mobility with those of standards. Plots of molecular weight against mobility are shown in
Fig.6. Mobility was calculated according to the method of Weber and Osborn (1969).
distance of protein migration
Mobility = ____________ _______________
length of the gel after destaining
length of the gel before staining
x  ___________________________
distance of dye migration
Swelling of the slab gel in acidic solutions (fixer.stain and destain solutions) was 
about 5 % and length of the gel before staining : length of the gel after destaining was 
equal to 0.94. Accordingly,
distance of protein migration 
M obility* 0.94 x __________________________
distance of dye migration
0.94.
G a la c to s id a s e
% P h o s p h o ry la s e  b
M y o s in
E g g  A lb u m in
BS A
C a rb o n ic  A n y d ra s e
u -
U2 »
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M O B I L I T Y
Fig.6 : Calibration plot for slab SDS polyacrylamide gels (10 %) 
using standards of known molecular weights
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11 Protein (Western) blotting with immuno-detection
Western blotting is frequently used to study antigen antibody interaction, especially 
when the antigen is not available in a pure form (Towbin et al..1979: 1984). After
electrophoresis in SDS polyacrylamide gels, protein bands were transferred onto 
nitrocellulose paper, which is more stable than polyacrylamide and immobilises the proteins. 
The transfer process removes SDS, allowing polypeptides to regain conformation and 
antigenicity.
11-1 Electroblotting
Proteins were transferred from polyacrylamide gels by electrophoresis according to the 
method of Tsang et al. (1983) : The gel was placed on a top of a sheet of filter paper 
(Whatman 3MM) already saturated in blotting buffer (20 mM Tris, 150 mM glycine; 20 %  
methanol, pH 8.3). The methanol prevents the gel from shrinking or expanding. The 
nitrocellulose sheet was also saturated in blotting buffer then placed on top of the gel, 
followed by a a second filter paper sheet. This sandwich was placed between two sponge 
pads, and supported between parallel electrodes in a reservoir buffer (Fig. 7). Current (70 
mA/gel) was passed for 8-10 h. This reduced transfer time helps to minimise diffusion 
effects. The sandwich was positioned so that the nitrocellulose sheet was between the gel 
and the anode. The transfer was carried out at 4 °C  to minimise heating effects. 
Transferred patterns can be stored in PBS at 4 °C  for several weeks prior to their use 
(Gershoni and Palade.,1983) and the same pattern can be used for multiple successive 
analyses (Legocki and Verma.,1981).














Fig. 7 : Electroblotting sandwich.
1 1 -2  S ta in in g  o f  p ro te in s  o n  n itro c e llu lo s e  p a p e r
11-2-1 Ponceau S stain
Following transfer of proteins, the nitrocellulose sheet was stained with Ponceau S [0.1 
% (W/V) in 3% (V/V) TCA] to facilitate visualisation of the transferred protein bands (Coudrier 
et al.,1983). Transferred bands appeared within 20 min and the nitrocellulose was quickly 
destained with PBS or distilled water.
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11 -2-2 Indian ink stain
The method reported by Hancock and Tsang (1983) was followed : Stain [Indian ink (1 
ul/ml) in 0.05 % PBS-Tween 20] was applied overnight at room temperature after which the 
nitrocellulose paper was washed three times (30 min each) in 0.05 % PBS-Tween 20.
11 -2-3 Amido black stain
According to the method of Towbin et al. (1979), nitrocellulose strips were incubated 
for 1 h at room temperature in amido black solution [0.1 % (W/V) amido black (naphthol a.b) 
in 45 %  methanol and 10 % acetic acid] and destained by three washes (15 min each) in 90 
% methanol containing 2 % acetic acid.
11-2-4 Coomassie Brilliant Blue (CBB1 stain
The staining procedure was carried out according to the method of Yuen et al. (1982). 
Nitrocellulose strips were incubated for 1 h in staining CBB solution [0.1 % (W/V) CBB in 40 
% methanol containing 9 % acetic acid] then destained by three 15 min. washes in 90 %  
methanol, containing 2 % acetic acid.
11 -2-5 Fast green stain
Nitrocellulose strips were stained according to the method of Reinhart and Malamud 
(1982) for 1 h in 0.1 % (W/V) Fast green in 25 % ethanol /10 % acetic acid, then destained 
by a 15 min wash in 25 % ethanol /10 % acetic acid, followed by two washes (15 min each) 
in 10 % ethanol/10 % acetic acid.
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11-3 Immunological detection of protein blots
11-3-1 Using a single enzyme-conjugated second antibody
The detection was achieved according to the method of Towbin et al (1979; 1984) with 
some modifications. Electrophoretic blots were washed with PBS, pH 7.3, (Nancy et al.. 
1988) for 15 min then rinsed twice with PBS and stained in Ponceau S [0.1 % (W/V) in TCA] 
to visualise the transferred bands, which appeared within 20 min. The nitrocellulose sheet 
was cut into appropriate sections and washed with PBS to remove the stain. Blots were 
soaked in Blocking buffer (2 % BSA in 0.05 %  PBS-Tween 20, containing 0.01 % fish 
gelatine, pH 7.3) for 2 h at room temperature to saturate additional protein binding sites, then 
rinsed in 0.05 % PBS-Tween 20 and incubated in Blocking buffer containing appropriately 
diluted probing antibody (serum, IgG and cell culture supernatants) overnight at 4 °C  with 
constant shaking (before use, cell culture supernatants were concentrated two fold in 
polyethylene glycol 8000). Nitrocellulose strips were then washed four times in 0.05 %  
PBS-Tween 20 containing 1.8 %  NaCI, to remove non-specifically bound antibodies or serum 
proteins. The strips were then incubated in recommended (Sigma) dilution of 
enzyme-conjugated developing antibody in Blocking buffer (1:1000 dilution) for 2 h at room 
temperature. After incubation, blots were washed four times, as previously, and stained in 
substrate solution until the colour developed (Fig. 8) and washed four times (10 min each) 
with distilled water.
The staining procedure, using horse radish peroxidase conjugates, is as follows. 0.4 
% 3-Amino-9-ethylcarbazole (AEC) in dimethylformamide (DMF) was diluted with 0.05 M 
sodium acetate buffer, pH 5.0, to give a final concentration of 0.03 %  AEC, 30 %  Hydrogen 
peroxide (0.5 pl/ml) was added and nitrocellulose strips were immediately incubated in the 
substrate solution until the brown-purple colour developed. The strips were then washed 
three times (15 min each) with distilled w ater.
The staining procedure, using alkaline phosphatase conjugate, involves
5-Bromo-4-chloro-3-indolyl phosphate (BCIP) and nitro blue tetrazolium (NBT). Alkaline 
phosphatase converts BCIP to the corresponding indoxyl compound which precipitates, 
tautomerizes to the ketone and dimerizes to form a blue indigo. As a result the NBT salt was 
reduced to the corresponding diformazan, which is intense purple. This compound is 
therefore deposited, along with the indigo blue, giving an enhanced colour. Substrate 
solution was prepared as follows : stock solution (1 ml) of BCIP (5 mg/ml of
dimethylformamide) was added to 0.15 M veronal acetate buffer, pH 9.6, (20ml), followed by 
addition of a freshly prepared solution (2 ml) of NBT (1 mg/ml) in veronal acetate buffer, and 
2 M MgCl2 (40 pi). Nitrocellulose strips were incubated in the substrate solution until a blue 
indigo colour was developed (20-30 min) then washed three times (15 min each) in distilled 
water.
11-3-2 Staining of a single nitrocellulose strip by using different enzyme-conjugated developing 
antibodies
This was made possible by removing the probing antibody-developing antibody 
complex, according to the method of Legocki et al (1981). After the first immunological 
detection, nitrocellulose strips were washed three times (5 min each) with eluting buffer (0.1 
M glycine-HCI, pH 2.2, containing 20 mM magnesium acetate and 50 mM potassium 
chloride). The strips were then reincubated with the same serum ( first antibody) followed by 
a different enzyme-conjugated antibody (second antibody) as described in Section, 11-3-1.
s u b s tra te c o lo u re d  p ro d u c t
nitrocellulose sheet
A - Protein bound to nitrocellulose
X- First antibody
x - Second antibodynr Enzyme (either horse radish peroxidase
or alkaline phosphatase)
Fig. 8 : A schematic representation of the double antibody technique 
used to identify proteins on nitrocellulose paper.
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12- Immunodot assay for cell culture supernatants
This is the screening method used to characterize different classes of antibodies 
secreted by EBV-transformed human B lymphocytes and purified human anti-BXO 
antibodies (Section, 5). The assay is based on that reported by Hawkes et al (1982) and 
Holmberg et al (1983). Discs (4 mm of diamater) were cut from nitrocellulose paper (0.22 
pm pore size) and placed in microculture plates (one disc per well). Discs were spotted in 
duplicate with BMFGM (2 pi, 15 mg membrane pellet/ml of 50 mM sodium carbonate, pH 
9.6) or purified BXO (2 ul, 2 mg/ml 50 mM sodium carbonate, pH 9.6) and left to dry at 37 °C  
for 1-2 h. Discs were washed three times with blocking buffer (0.05 % PBS-Tween 20 
containing 0.25 % fish gelatine, 250 pl/well) then incubated with the same blocking buffer 
(250 pl/well) for 2h. at 37 °C  to block free binding sites on nitrocellulose support. After 
blocking, discs were washed as above. Concentrated (4 fold) cell culture supernatants (50 
ul) of antibody-producing transformed B lymphocytes or affinity purified human anti-XO 
antibodies (100 pi, 35 ug/ml) were incubated with the discs for 18 h. at 4 °C , folowed by 2 h. 
at 37 °C . Control discs were incubated with supernatant of non-producing (anti-BMFGM 
antibodies) transformed B lymphocytes, SSM and buffer alone (200 pl/well). Discs were 
washed 4 times with 0.05 % PBS-Tween 20 (15 min. each). Goat anti-[human Ig (G, M and 
A)] IgG conjugated to HRPO (Sigma, Poole, UK) was diluted 1:1000 in 0.05 % PBS-Tween 
20 then added to the wells and incubated for 2 h. at room temperature. This solution was 
removed by aspiration and discs were thoroughly washed, as before. The enzyme substrate 
solution was prepared fresh and added to the wells (100 pl/well) with gentle agitation, as 
described in Section 11-3-1. Usually the colour was developed within 30 min of substrate 
application. The reaction was stopped by several washes with distilled water and the discs 
were dried between filter papers.
13- Antibody preparation
13-1 Immunization procedures
Rabbits were immunized initially with Complete Freund’s Adjuvant (400 ul) containing 
immunizing antigen (200 pg BMFGM protein, purified BXO or BSA). A similar injection in 
Freund’s incomplete adjuvant was given two weeks after the first one, followed by injections 
of 200 pg protein antigen in PBS, pH 7.3, on days 30 and 38. On day 36, a blood sample 
(10-15 ml) was taken from peripheral ear veins and the serum antibody level was assayed by 
the ELISA procedure (pre-immune serum was used as control). One week after the final 
injection, rabbits were sacrified and about 100 ml blood per rabbit was collected.
13-2 Preparation of serum
Rabbit blood was collected in centrifuge tubes, left at room temperature for 3-4 h to 
clot, then overnight at 4 °C  to shrink the clot (Baltz et al..1985). The following day, blood 
was centrifuged at 3000 rpm for 30 min, in a bench MSE centrifuge, to sediment cells. 
Serum was collected in small aliquots and stored at -20 °C  until use.
13-3 Immmunoglobulin purification
The purification was based on the method of Wide (1969). Anyhdrous Na2SC>4 (18 %, 
W/V) was added to antiserum with constant stirring at 25 °C  over 30 min. The mixture was 
stirred for a further 1 h, then allowed to stand for 1 h before centrifuging at 3000 g for 30 min. 
The pellet was washed twice by centrifugation with 18 % (W/V) Na2S04 in 0.1 M NaHCC>3 
(5 ml/ml of antiserum). The final pellet was dissolved in either 0.1 M NaHC03 or 30 mM
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phosphate buffer, pH 8.0 (for further purification) at 1 ml/ml serum and dialysed overnight at 
4 °C  against the appropriate dissolving buffer.
Further purification was performed by ion-exchange chromatography on 
DEAE-Cellulose (DE 52). A column (20 ml) was packed and equilibrated with 30 mM 
phosphate buffer, pH 8.0. The dialysed crude immunoglobulin preparation was loaded onto 
the column and eluted with the same buffer at a flow rate of 15-20 ml per h. The IgG fraction 
was eluted in a single asymmetric peak and impurities were bound and retarded by the 
exchanger. Fractions (IgG) were concentrated in polyethylene glycol (8000) to half the 
original volume of antiserum and aliquoted. Glycerol was added to the aliquots (1:1 V/V) 
which were then stored at -20 °C .
14 Cell culture
All cell culture was carried out by using aseptic procedures, under sterile conditions in 
a laminar flow hood in an air conditioned tissue culture room. Disposable plastic ware, all 
media and their supplements, were supplied sterile. All other reagents were either 
autoclaved (120 °C , 20 Lb/in2 , 30 min) or filtered through sterile filter units (pore size 0.22 
urn diameter) before use.
14-1 Preparation of human peripheral blood lymphocytes (PBLs)
Fresh heparinised Human venous blood (or packed cells) was diluted (1:1) in sterile 
PBS, then added slowly to conical tubes containing Ficoll (2 ml). After centrifugation (2000 
rpm, 25 min), the interface white layer (B and T lymphocytes) was taken and diluted (1:1) 
with PBS. At this stage, an aliquot (300 pi) was taken for cell counting. Cells were then
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diluted in PBS and centrifuged (2000-3000 rpm for 15 min then 1600 rpm for 10 min), to 
remove Ficoll, leaving a pellet of white cells.
14-2 Serum Supplemented Medium (SSIVD
Serum supplemented medium comprised 89 % RPMI 1640 medium, 10 % Foetal Calf 
Serum (FCS) and 1 % 200 mM glutamine. In this work, the addition of antibiotics (penicillin 
and streptomycin) was omitted and the medium was stored at 4 °C . Before use, SSM was 
warmed to 37 °C  in a water bath. This tissue culture medium was stored, protected from 
direct sunlight or room fluorescent light, because light generates highly toxic photoproducts 
(Stoien and Wang.,1974; Wang.,1976; Griffin eLai., 1981).
14-3 Production of Epstein-Barr Virus (EBV1 from B 95-8 cells
The B 95-8 cell line has been established by exposure of marmoset blood leucocytes 
to EBV, extracted from a human leucocyte line (Miller and Lipman.,1973). B95-cells were 
seeded (10s cells/ml) in SSM in a 75 cm3 flask and maintained in 5 % CO2 at 37 °C  and 95 
% humidity, in an incubator, until growth approached confluence (10-15 days). Cells were 
centrifuged (4000 rpm; 5min) and the supernatant (source of EBV) was filtered twice by 
positive pressure through a 0.45 pm millipore membrane, then stored in aliquots (20 ml) at 
-40 °C  until use.
14-4 Transformation of human PBLs with EBV
Activation was carried out according to the method of Thompson et al. (1986): (see 
also Karpas et al..1982 a.b). A pellet of human PBLs was suspended in B 95-8 cell 
supernatant (2.106 cells/ml) and incubated for 2 h at 37 °C (5 % CO2 and 95 % humidity
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incubator). After incubation, PBLs were washed twice with SSM then suspended, in SSM 
containing 1 % Phytohaemagglutinin A (PHA) (106 cells/ml) in order to activate B 
lymphocytes and to suppress growth of T lymphocytes. The transformed lymphocytes were 
then cultured (100 pl/well) in 96 well polystyrene microculture plates. On the second day, the 
medium was replaced by SSM, without PHA, and cells were thereafter maintained in SSM, 
which was changed whenever it became acid (yellow colour), usually every 4-7 days. After
3-4 weeks of growth, cell culture supernatants were tested for specific antibody production 
(anti-BMFGM antibodies) by ELISA (Section 8). Positive cells were expanded to 24 well 
culture plates and retested, one week later, before fusion or cloning.
14-5 Mveloma cell line P3-X63-Ag8
Cloned BALB/c myeloma cells, P3-X63-Ag8 (X 63), which do not produce any 
immunoglobulin chains, were cultured in SSM in 25 cm3 flasks until the growth was near 
confluence. In order to ensure that the cells remain HPRTase negative, 0.13 mM 
8-azaguanine was periodically included in the SSM to eliminate reverted cells. This cell line; 
provided by Dr A.Jehanli, had a doubling time of about 24 h. Care was taken to ensure that 
cells were healthy and growing in logarithmic phase . Their density was kept around 0.5 x 
106 cells/ml by regular subculturing (every 2-3 days).
14-6 Cell viability
Viability of lymphocytes was tested in terms of their ability to exclude Trypan blue. 
Cells were counted in a haemocytometer counting chamber (improved Neubauer ruling). 
Before counting, cells were washed with RPMI 1640 medium to remove FCS, the protein of 
which binds Trypan blue and complicates the assay (Kruse et al..1973). The plasma 
membrane of viable cells does not permit the entry of non-electrolyte dye, such as Trypan
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\blue. Trypan blue in 0.85 % saline (100 pi) was added to a lymphocyte suspension (100 pi) 
and cells were counted within 3 min of mixing. Non-viable lymphocytes were stained blue. 
In some assays, instead of Trypan blue, 0.01 % methylene blue in 1 % acetic acid was used 
and the results were comparable. Viability of mouse myeloma (X 63) cells was tested as for 
lymphocytes except that the stain was 0.2 % Toluidine (W/V) in 0.85 % saline solution. Cell 
viability was higher than 94 % before fusion.
14-7 Preparation of thvmocvte feeder layers
Feeder layers were prepared one day before their use in fusion or cloning. A 3-4 week 
old BALB/c mouse was killed by CO2 asphixation or ether inhalation (not by cervical 
dislocation, as this causes blood leakage into the thoracic cavity contaminating the thymus), 
then sprayed with disinfectant (75 % ethanol, 1 % hibitane). Hair was removed and the 
thoracic cavity was opened by cutting the skin from under the diaphragm up to the throat 
(care was taken to avoid damaging any of the internal organs). The thymus, a two lobed 
organ just above the heart, was removed and placed in sterile PBS in a plastic dish. 
Obvious blood vessels were removed without damage to the organ, which was transferred to 
a sterile dish containing PBS, where it was crushed until the solution turned white. Large 
pieces of debris were removed and the remaining cells, in PBS, were transferred into a 
sterile tube, made up to 20 ml with PBS, and centrifuged (2000 rpm, 10 min). The 
supernatant was discarded and the cell pellet was resuspended in PBS (20 ml), irradiated for 
4 min 10 sec ( irradiation, 2000 rads) and then centrifuged, as above. The supernatant was 
discarded and the cells were resuspended in a small volume of SSM (3-4 ml). A cell count 
was performed and the thymocytes were diluted to a suitable volume (5.10s cells/ml) with 
SSM and seeded in culture plates (100 pi per well for the 96 well plates and 200 pi per well 
for 24 and 4 well plates), (see Fazekas and Scheidegger.,1980; Oi and Herzenberg., 1980).
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14-8 Fusion of antibody-positive.transformed human PBLs with mouse myeloma X 63 cells
14-8-1 Polyethiene glycol (PEGVDimethylsuIphoxide (DMSO) fusion agent
PEG is required for fusion (Galfre et al..1977: Wojciezsyn et al..1983) although its 
mechanism is still unknown. PEG (MWt 4000, 4.5 g) was melted in PBS (5.5 ml) in a water 
bath (70 °C ) to give a final concentration of 45 % (W/V). The solution was autoclaved at 120 
°C  and 20 Lb/in2 pressure for 30 min then cooled in an ice bath before adding DMSO (0.5 
ml) (see Norwood et al..1976: Fazekas and Sheidegger.,1980). The resulting solution was 
stored at -4 °C .
14-8-2 Fusion procedure
Equal numbers of cells (5.107) from each of the fusion partners were harvested, mixed 
and then centrifuged (2100 rpm, 20 min) to give a common pellet. The pellet was suspended 
in PBS and centrifuged as above. The supernatant was discarded and the pellet was gently 
agitated so that no cells were sticking to the bottom of the tube. PEG-DMSO (1 ml) was 
added dropwise with constant agitation, at room temperature, to the pellet, which then then 
agitated in a water bath at 37 °C  for 90 sec. The cell suspension was diluted slowly with 
PBS (1 ml over 1 min, then 3 ml over 1 min) and the rate was increased until 20 ml were 
added. Cells were centrifuged (1200 rpm, 10 min) and the pellet was washed twice with 
SSM, then resuspended in the same medium (20ml). Finally, the suspension (100 pi, 105 
cells) was added to each well of a 96 well polyestyrene plate which had been coated with a 
mouse thymocyte feeder layer on the previous day.
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14-8-3 Growth inhibition of non-hybridomas
The day after fusion, SSM (100 ul) containing 100 uM hypoxanthine, 0.4 uM 
aminopterin and 16 pM thymidine, together with 1 pM ouabain, was added to each well 
containing fused cells. Cells were subsequently fed similarly every 3-5 days. For the first 
week, SSM-HAT-Ouabain medium was used (after this it is safe to assume that all parental 
myeloma cells will be dead and that any growing cells will be hybrids). Inspection of the 
plates at this time usually revealed considerable cell death, with debris accumulating around 
the circumference of the wells. Heterohybridomas were then fed with SSM-HT for the 
second week (Goding.,1986) and therafter with SSM alone. Two to three weeks later, the 
culture supernatants were tested for specific antibody production (anti-BMFGM antibodies) 
and positive hybridomas were expanded to larger wells, already coated with mouse 
thymocytes as feeder layer, then retested after 1-2 weeks. Positive cells were cloned in 
conditions of limiting dilution (down to one cell/well).
14-8-4 Cloning under conditions of limiting dilution
Cells producing anti-BMFGM antibodies were cloned by limiting dilution down to 1 
cell/well. Cloning was carried out on positive heterohybridomas as well as on 
EBV-transformed lymphocytes. Mouse thymocyte cells were used as feeder layers in all 
cloning stages. Cells were usually cloned three times before expanding the clones into 25 
cm3 flasks. It is widely believed that, after three cloning stages, antibodies produced by a 
dilution of 1 cell/well are very likely to be monoclonal antibodies. Two weeks after the first 
cloning, cell culture supernatants were tested for anti-BMFGM antibodies, and the positive 
cells were recloned as above. After this cloning stage, positive cells were expanded to 24 
well culture plates, retested for specific antibody production and then expanded to 25 cm3 
flasks. The general cloning procedure is as follows:
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The heterohybrids in selected wells were counted for viability and serially diluted in 
fresh SSM until their theoretical concentration was 5, 10 or 50 cells/ml. Each of these 
dilutions was distributed (200 ul/well) over freshly thymocyte-conditioned 96 well plates. For 
the EBV-transformed positive human lymphocytes the first cloning was at higher 
concentration (20, 50 or 100 cells/well) and the following clonings were as for the fused cells.
14-8-5 Crvopreservation of cells
Cells were brought to a density of 107 cells/ml in 50 % RPMI 1640/50 % FCS. The 
suspension was placed on ice for 1 h and then diluted (1:1) with ice-cold "freezing mixture" 
(80 % RPMI 1640/20 % DMSO) and maintained on ice (DMSO is cytotoxic at ambient 
temperature). Cells were then aliquoted into 2 ml sterile screw-top cryotubes on ice 
(0.25-0.5 ml/cryotube; 1.25 to 2.5 x 106 cells/cryotube) and placed in a freezer at -70 °C  for 
24 h. Aliquoted cells were then transferred into liquid nitrogen, in which they were stored 
until u s e .
14-8-6 Thawing of cells
Cells, frozen in liquid nitrogen, were thawed, as quickly as possible, in a water bath (56 
°C), then diluted (to 20 ml) gradually with cold RPM11640. The suspension was centrifuged 
at 4 °C  (2000 rpm, 5 min) and the pellet of cells was washed twice with cold RPM11640 and 
centrifuged as above. The pellet was resuspended in fresh (37 °C ) medium (80 % RPMI 
1640 /  20 % FCS) at room temperature and incubated in a 25 cm3 flask at 37 °C  (5 % CO2 , 
95 % humidity incubator) for 24 h before replacing the medium with SSM. Growth of cells 
was checked and the medium was changed when required.
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15- Statistical analyses.
15-1 Kolmogorov-Smirnov (K-S) test (Siegel.1956).
The test was applied to compare levels of anti-BMFGM antibodies (IgG, IgM, IgA and 
all immunoglobulins) and anti-(BXO) antibodies (IgG, IgM and IgA) in myocardial infarct 
patients and controls with no history of coronary heart disease. To test wether two 
independent samples have been drawn from the same population, the Kolmogorov-Smirnov 
(K-S) two sample test was applied. The K-S two-tailed test considers the difference between 
cumulative frequencies of two samples of populations. The test identifies the part of the 
distribution in which the maximum difference (Dmax) occurs. The value of Dmax obtained is 
compared with a theoritical value of D, which depends upon the number of samples in each 
population and the required level of significance:
If the two samples have been drawn from the same population distribution, then the 
cumulative distribution of both samples is expected to be fairly close to each other, in as 
much as they both should show only random deviations from the population distribution. In 
other words, the observed that the two set of samples have been drawn from the same 
population, holds true.
If two sample cumulative distributions are too far apart at any point this suggests that 
the samples came from different populations. Thus, sufficiently large deviation (D) between 
the two set of samples, compared to the theoretical value of D, is evidence for rejecting the 
hypothesis (Ho) that the two samples have been drawn from the same population.
[ Dmax = maximum { Sni(A)-Sn2(B )} ],
Where A and B are the two populations with m  and n2 samples respectively.
When ni and n2 are both larger than 40 (true of all cases studied in this thesis), Table 
1 is used to calculate the theoretical value of D at a certain given degree of significance. If D 
is equal to or larger than the critical value of D (Table 1) the hypothesis (Ho) that the two 
samples are from the same population is rejected at the level of significance (p) associated 
with that expression.
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Level of significance Critical value of D
,1 1.22 I ni + n2 
\ J  r.in2
.05 1.36 /n i  + n2 
\J  n-jn2
.025 1 48 „ /  ni + n2 
\ /  nm 2
.01 1.63 , /n i  + n2 
\ /  n in 2
.005 1 .73 j  ni + n2
\J  nin2
.001 1.93 „ I ni + n2 
\ J  nin2
Table 1 : Estimation of critical values of D at different levels of significance for
populations with more than forty samples. (Smirnov.,1948).
15-2 C o r r e la t io n  m e th o d  (Parker.,1983).
The test was used to compare the correlation between two variables (x and y) of the 
same set of samples (n members). Under the assumption that the distribution of x and y are 
normal, the sample correlation coefficient (r) is a measure of the linear relation between the 
two variables. If, however, the values of x and y are not normally distributed, r is calculated 
from the formula below. The critical value of r to show significance at a chosen level of 
significance, for a particular number of samples, is obtained from the " Rank Table " (Basic 
formulae and statistical Tables, School of Mathematics, University of Bath.,1983).
Xx y
'  -  "3ax*Zy~)
The coefficient r can have values ranging from 1 to -1 corresponding to a rectilinear 
relationship of the form y = a + bx. A value of 1 indicates a perfect rectilinear agreement 
between the two variables (x and y), a value of -1 corresponds to a rectilinear relationship in 




1- Development of an ELISA for human anti-BMFGM antibodies
The ELISA described in Methods (Section, 8-2) was largely developed by other 
members of the laboratory (Bryson, 1989 in particular). The assay was based upon the 
standard protocol used in most ELISA systems (see Brennand, 1987). Microtitre plate wells 
were coated with a suspension of BMFGM in 50 mM NaHC03  buffer, pH 9.6 and incubated 
overnight at 4 °C . Plates were washed three times (20 min each, 250 pl/well) with 0.05 %  
PBS-Tween 20 then incubated with appropriate dilution of human serum in washing buffer 
for 2 h. at 37 °C . The wells were washed three times, as above and incubated with goat 
anti-[human immunoglobulins (G, M, A and polyvalent)] IgG-horseradish peroxidase 
conjugate, at an appropriate dilution, for 1-2 h. at room temperature. Finally the plates were 
washed as above and the substrate [416 pM tetramethylbenzidine (TMB) in 0.1 M sodium 
acetate/citrate buffer, pH 6 containing 0.8 mM H2O2 , TMB was first solubilised in 
dimethylsulphoxide (DMSO) at 41.6 mM] was added (100 pl/well) and the plates were 
incubated at room temperature until a blue colour was developed (15-30 min). The reaction 
was stopped by the addition of 2 M H2SO4 (50 pl/well) and the absorbance was read at 450 
nm.
The ELISA conditions were optimased in terms of antigen (BMFGM), antibody (serum) 
and conjugate [goat anti-(human immunoglobulins)] IgG-HRPO concentrations:
The optimum coating concentration of BMFGM was determined by coating different 
plates with various antigen concentrations and pooled sera (A1 or A2) at 1:100 dilutions in 
0.05 % PBS-Tween 20, were used. The maximum absorbance was obtained at the antigen 
concentration of 25 pg BMFGM protein/ml of coating buffer (100 pl/well)
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The optimum conjugate concentration was achieved by fixing the amount of antigen (25 
pg BMFGM protein/ml; 100 pl/well) and the serum dilution (standards A1 or A2; 1:100 
dilution). The conjugate (Sigma) concentration ranged from 0.05 pl/ml to 2 pl/ml and the 
results showed that a conjugate concentration of 1 pl/ml (100 ul/well) provided a sufficient 
colouration after 15-30 min incubation with the substrate.
By fixing the two above parameters and using serial dilutions of standard human sera 
(Al or A2) ranging from 1:25 to 1:800, the optimum dilution was determined to be 1:100 
dilutions. A serial study on 40 samples, diluted 1:100 in 0.05 % PBS-Tween 20, in three 
separate experiments, showed a consistent titres of the samples from one experiment to 
another.
/
Standard sera (A1 or A2) were used to derive a standard curve for each plate and titres 
of sera were expressed as a % of the standard serum (% std). Standard serum (A1 or A2), 
at different dilutions, and samples to be tested were always assayed in triplicates (3 wells 
each) and the mean value was quoted. When differences in absorbance, among triplicates, 
were higher than 0.05 units the samples were retested. A serial study on 20 samples in five 
separate experiments showed that the variation within the same sample was less that 8 % of 
the standard. A second pooled serum was prepared and assayed, in triplicate, in each plate 
and if its titre deviated greatly from the mean, the samples of that plate would be reassayed.
Fig. 1 : Optimization of anti-BMFGM antibody ELISA’s using different 
concentrations of coating antigen (BMFGM).
 •------ •  100 p g ; °— °  50 pg; * ------*  20 pg; and
♦  10 pg of membrane /well; 100 pl/well.
A- using goat anti-(human IgG) IgG-FIRPO conjugate.
B- using goat anti-(human IgM) IgG-FIRPO conjugate.
C- using goat anti-(human IgA) IgG-FIRPO conjugate.
D- using goat anti-(human polvalent) IgG-HRPO conjugate.
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2- Comparison of human anti-BMFGM antibodies in M I patients and controls.
Anti-BMFGM antibody levels were assayed (Results,1) in serum samples taken from 56 
male patients (40-65 years) within 24 h. of myocardial infarction and compared with those of 
44 male controls (40-65 years) with no history of coronary heart disease. Distributions for all 
immunoglobulins, IgG, IgM and IgA are shown in Figs 2a, b, c and d respectively. A 
Kolmogorov-Smirnov (K-S) analysis was performed on each set of results (Methods, 15). 
Table 1 shows, in each case, the point at which the greatest difference between cumulative 
frequencies of the two populations occurs and the K-S D value for the point. Table 2 shows 
critical values of D for various levels of significance.
Points where D is maximum 
(% compared to standard sera)
value of 
D
Anti-polyvalent Ig above 6 % 0.23
Anti-IgG above 25 % 0.284
Anti-IgM above 25 % 0.154
Anti-lgA above 12.5 % 0.142
Table 1 : Representation of maximum D of the cumulative 
frequencies between Ml and control populations.
-103-







Table 2 : Critical values of D at different levels of significance (ni=56, n2=44).
For polyvalent antibody measurement,the greatest value of D was obtained above 6 % 
of the standard (71 % Mis and 95 % controls). A K-S value of 0.23 calculated was below the 
value of 0.245 necessary for significance at p < 0.1.
For IgG, the greatest difference occured above 25 % of the standard (13 % Mis and 41 
% Controls). A K-S value of 0.284 calculated was above the critical value of 0.274 
necessary for the significance at p = 0.05 , indicating a significant elevation of IgG 
anti-BMFGM antibodies in controls compared to Ml patients. This difference is not significant 
at levels lower than p < 0.05.
For IgM, the greatest difference occured above 25 % of the standard (27 % Mis and 11 
% Controls). A K-S value of 0.154 calculated was below the critical value of 0.245 necessary 
for significance at p < 0.1.
For IgA, the greatest difference occured above 12.5 % of the standard (64 % Mis and 
50 % Controls). A K-S value of 0.142 calculated was below the critical value of 0.245 
necessary for significance at p = 0.1.
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Fig. 2 : Comparison of anti-BMFGM antibodies in Myocardial infarction 
patients (56 samples) and non-cardiac controls (44 samples). 
The samples are all from males aged between 40-65 years.
The levels of these antibodies in the samples are expressed 
as percentages compared to standard sera (A1 or A2). 
Percentages are represented in the following seven categories:
A : less than 6 %
B: 6.25-12.5%
C : 12.5-25%
D : 25-50 %
E : 50-75 %
F: 75-100%
G : higher than 100 %.
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3- Antigenicity of BM FGM  lipids.
Crude lipid extract (CLE) and water soluble lipid extract (WSLE) of BMFGM 
(Methods,2) were used as inhibitors in the competitive ELISA for anti-BMFGM antibodies 
(Methods, 8-3) with standard serum (A1) at 1/50 dilution (in PBS). Fig. 3a shows that both 
extracts significantly inhibited the ELISA. BMFGM and phosphatidylcholine were similarly 
tested as controls (Fig. 3a).
CLE and WSLE were also incorporated into liposomes (Methods.3) before competitive 
ELISA, as above. Experiments in which liposomes were not (Fig. 3b) or were (Fig. 3c) 
removed by centrifugation, prior to assay (Methods,8-3) again showed inhibition by both 
extracts. Liposomes alone showed no inhibition (Fig. 3b and 3c).
Analysis (Methods, 9-1) of the lipid extracts, CLE and WSLE, showed that 9.9 % and 
4.6 % respectively of the dry weight was protein. Further separation of CLE into acidic and 
neutral lipids using DEAE-Sephadex A25 (Methods, 2-3) gave fractions, AL and NL, which 
failed to inhibit the ELISA for anti-BMFGM antibodies, whether (Fig. 4bc) or not (Fig. 4a) 
they were incorporated into liposomes prior to incubation with test serum.
The Sephadex A 25 column, used in the above separation, showed a retained yellow 
band after the fractionation. This band was eluted by washing the Sephadex, in a beaker, 
with chloroform-methanol (40 ml, 2:1) and lyophilising to give a residue containing 62 % dry 
weight protein. The eluted lipid fractions AL and NL were found to be free of protein. In view 
of the above data, it was concluded that the apparent antigenicity of CLE and WSLE lipid 
fractions was caused by contaminant protein and that the lipid itself, as represented by AL 
and NL fractions, was not antigenic in the system.
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Fig. 3 : Inhibition of human anti-BMFGM antibodies by BMFGM lipids 
a : direct inhibition.
b : lipids were incorporated into liposomes, 
c : centrifugation of liposomes before inhibition assay.
• ----- — • BMFGM
o ------— o CLE
* — — K WSLE
m— — ■ Phosphatidylcholine
* — — * liposomes


















































210 . 10 . 0 1
a n t i g e n  c o n c e n t r a t i o n  (mg /  m l ) 
-  110  -
-111





























Fig. 4 : Inhibition of human anti-BMFGM antibodies by membrane lipids . 
a : direct inhibition with different lipidic fractions.
b : lipid fractions were incorporated into liposomes before the assay, 
c : liposomes were centrifuged before the assay.
• ------- ------- • BMFGM
o -------— o CLE
★ — — * WSLE
#------ -------- * Acidic Lipids (AL)
☆------- ---------<r Neutral Lipids (NL)
* ------- -------- * Liposomes
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4- Antigenicity of BMFGM protein
4-1 SDS PAGE analysis of BMFGM.
Analysis of BMFGM (Methods, 9-1) showed 10-15 % dry weight to be protein. 
Coomassie Brilliant Blue (CBB) stained SDS-PAGE patterns of BMFGM (Methods, 10-3-1) 
are shown in Fig. 5, with a corresponding gel scan (LKB 2202 ULTROSCAN, Laser 
Densitometer) in Fig. 6 (see also Table 3). Silver staining (Methods, 10-3-2) showed at 
least 17 polypeptides (Table 4). The Mr. values of separated proteins were estimated by 
comparing protein mobility against a set of standards : myosin 205,000; galactosidase 
116,000; phosphorylase b 97,400; BSA 66,000; ovalbumin 45,000 and carbonic anhydrase 
29,000.
4-2 Western blots of human sera against BMFGM.
SDS-PAGE patterns of BMFGM polypeptides were transferred to nitrocellulose sheets 
(Methods, 11-1) and stained with Ponceau-S (Methods, 11-2-1, Fig. 7). Optimum transfer 
was achieved after 8-10 h at 70 mA/slab gel. Whereas Ponceau S stain is reversible and 
suitable for staining nitrocellulose sheets prior to immunoblotting, a permanently stained 
record of the nitrocellulose is required. For this purpose four stains were examined. These 
were Indian ink, Amido black, Coomassie Brilliant Blue and Fast green (Methods, 11-2-2 to 
11-2-5). Of these, Amido black was found to be most suitable (Fig. 8).
Polypeptide blots on nitrocellulose sheets were immunoblotted with human sera and 
goat anti-(human IgG) IgG conjugate (Methods, 7) as described in the Methods (11-3-1). 
The blocking buffer used (2 % BSA in 0.05 % PBS-Tween containing 0.01 % fish gelatine) 
was found to give the lowest background of fifteen buffer systems tested (Table 5). A series
- 1 1 5 -
of human sera of varing anti-BMFGM antibody titre and corresponding IgG preparations 
were immunoblotted (Methods, 11-3-1) against BMFGM polypeptides (Fig. 9ab). The blots 
using IgG (Fig. 9b) were clearer than those using serum, but both blots showed major 
staining at Mr 205 and 150 with a limited number of weaker bands (particularly in the higher 
titre sera) at 88, 60 ,56  and 52 KD.
4-3 Western blots of rabbit anti-BMFGM antiserum against BMFGM.
Rabbit anti-(BMFGM) antiserum was raised (Methods, 13-1 ;13-2) and tested by ELISA 
(Fig. 10) as described in Methods (8-2) except that goat-anti-(rabbit IgG) IgG conjugated to 
HRPO (Sigma Co,Poole,U.K) was used in place of goat anti-(human Ig) IgG HRPO 
conjugate. Rabbit anti-BSA antiserum was similarly raised and used, together with 
pre-immune serum as control. The rabbit antiserum (1:50 dilution) was used to immunoblot 
SDS-PAGE patterns of BMFGM polypeptides (Methods, 11-3-1), using goat anti-(rabbit 
lgG)-lgG-HRPO conjugate. The patterns (Fig. 11) show that, in contrast to blots using 
human serum (Fig.9), all major protein bands of BMFGM react with rabbit antiserum.
- 1 1 6 -
M.Wt x 103
Fig. 5 : 10 % SDS-PAGE (slab gel) of BMFGM.
tracks 2-7 : different loading amounts of BMFGM 
from 60 ug to 10 ug respectively, 
tracks 1 and 8 : Molecular weight markers (Sigma).
-117 -
of 10 % SDS-PAGE of BMFGM pattern (CBB stain). 




Height area % area
0.28 495462 2725921 (o) 16.70433557
0.50 3167 28716 0.1759707
0.85 3520 42740 0.2619093
0.97 2077 15816 0.0969199
1.03 4662 12910 0.0791120
1.13 2401 28351 0.1737340
1.28 8793 81898 0.5018682
1.43 4821 109174 0.6690147
1.73 10759 127317 0.7801944
1.88 16593 285641 1.7503988
2.26 108036 2440201 (C) 14.9534727
2.34 107712 3100375 (C) 18.9989977
2.76 3851 9395 0.0575722
2.93 31178 435649 2.6696429
3.08 131392 2484228 (b) 15.2232688
3.67 7798 48771 0.2988671
3.87 3395 42332 0.2594091
3.94 6426 50268 0.3080406
4.13 2799 13388 0.0820412
4.31 200215 3959932 (a) 24.2663352
4.49 13369 38972 0.2388191
4.75 7991 74987 0.4595179
4.87 26993 161642 0.9905369
Total 16318624 100.0000000
Table 3  : P e rc e n ta g e  o f  each  o f  th e  m e m b ra n e  b a n d s  on S D S - P A G E  ( 1 0 % )  
(CBB stain) compared to the total stained area.
(LKB 2202 ULTROSCAN, Laser Densitometer)
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Table 4 : Different protein bands of BMFGM and their approximative molecular weights.
(gel stained with silver stain).
-120-
M . W t x  l O 3 M . W t x  103
Fig.7 : A)- SDS-PAGE (10 %) of BMFGM (CBB stain)^rack 2.
B)- Membrane protein pattern transferred from SDS- 
-polyacrylamide gel (A) to nitrocellulose sheet 
(Ponceau S stain), track 2.
M.Wt. markers are shown in Irak 1.
-121 -
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a b c d e
Fig.8 : Staining of membrane proteins on nitrocellulose 
sheet (track 2).
M.Wt. markers are shown in track 1.
a : Indian ink. 
b : Amido black, 
c : Coomassie Brilliant Blue, 
d : Fast green, 
e : Ponceau S.
-122-
blocking buffer system
1 0.05 % PBS-Tween 20
2 0.05 % PBS-Tween 20 + 1-5 % BSA
3 0.05 % PBS-Tween 20 + 1-5 % NGS
4 1-5 % BSA in PBS
5 1-5%  NGS in PBS
6 0.01 % fish gelatine in PBS
7 0.05 % PBS-Tween 20 + 0.01 % gelatine
8 buffer 7 + 1-5 % BSA
9 buffer 7 +  1-5%  NGS
10 buffer 7 + 1-2 % casein
11 buffer 6 + 1-5%  BSA
12 buffer 6 + 1-5%  NGS
13 buffer 6 + 1-2 % casein
14 1-2 % casein in PBS
15 1-2 % casein in 0.05 % PBS-Tween 20
Table 5 : Different blocking systems used to saturate free protein 
binding sites on nitrocellolose sheets.
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Fig.9ab : Immunoblotting of human sera against BMFGM 
a : human sera
b : IgG prepared (Methods.13-3) from the correspondingly 
numbered serum samples.
Anti-BMFGM antibody titres of serum samples, compared to standard 
serum (A1), are as follows:
2 : 30.1 %
3 : 36.2 %
4 : 46.6 %
5 : 64.3 %
6 : 7 1 . 2 %
7 : 79.6 %
8 : 86.4 %
9 : >100%
Blanks (b1-b4) represent the following :
b1 : direct addition goat anti-(human immunoglobulins)IgG-HRPO conjugate to
membrane pattern after blocking free protein sites on the nitrocellulose sheet. This shows 
that the conjugate does not bind (non-specifically) to membrane protein on nitrocellulose. 
b2 : BMFGM + Serum (A1) or IgG preparation (no conjugate). 
b3 : M.Wt. markers + conjugate (no serum). 











































Fig.10 : ELISA for anti-BMFGM antibodies raised in rabbit,
wells were coated with BMFGM (0.02 mg/ml;100 pl/well)
rabbit anti-BMFGM antiserum 
M rabbit anti-BSA antiserum 
e « rabbit pre-immune antiserum
-126 -
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Immunoblotting of rabbit anti-BMFGM serum against 
BMFGM protein pattern (track 2).
M.Wt.markers are shown in track 1
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5- Bovine xanthine oxidase
5-1 Purification and characterisation of bovine xanthine oxidase
Enzyme was prepared from fresh milk as described in Methods (4-1). Elution of 
xanthine oxidase from the calcium phosphate column with a gradient (0-10 % w/v) of 
ammonium sulphate (Fig. 12a) or directly with 5 % (w/v) ammonium sulphate (Fig. 12b) 
gave similar yields and purities of product. Insertion of an additional washing step, using 2 % 
ammonium sulphate (w/v) (Fig. 12c), gave increased enzyme purity and this was routinely 
used. Table 6 shows the mean results obtained from three preparations. SDS-PAGE 
patterns of components in the crude dialysate, initial washing (peak 1, Fig. 12c) and pure 
enzyme (peak 2) are shown in Fig. 13. Fig. 14 presents comparison of SDS-PAGE 
patterns of purified enzyme, BMFGM and molecular weight markers, in which it can be seen 
that purified enzyme shows essentially one band at 150 KD, with a minor contaminant at 140 
KD A densitometer scan of the gel with purified enzyme is shown in Fig. 15. A native 
polyacrylamide gel of purified xanthine oxidase is shown in Fig. 16 and its UV absorbance 
spectrum in Fig. 17.
- 1 2 8 -
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Absorbance (280  run)
A
1.0
0 .5  --
lo a d in g  + w ashing
- / / —
Peak 1
c o n c e n tra t io n  g ra d ie n t  o f  
ammonium s u lp h a te  in  b u f f e r .
%
Fig.l2a : Elution of bovine xanthine oxidase from calcium phosphate 
gel using a gradient (0-10 %,w/v) of (NH4)2S04.
A
- ■  10
s t a r t  o f  (N H  ) SO 
g r a d ie n t  ^ ^
Peak 2
- -  7 .5
5
- -  2 .5
40 ■ >
Fraction ( a / 2.8 ml)
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EijUlh : Elution of bovine xanthine oxidase from calcium phosphate
Absorbance (280 run)





B u f fe r  + 5
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Fig. 12c : Addition of one washing step with 2 % (w/v) (NH4)2S04 before




















(unit x  10’3 /  ml)
N A D * O 2 ♦  N A D * 0 2
Specific activity 
(unit x IO '3 /m g  P)
N A D * O 2 ♦ N A D *




Whole milk 4000 32 57.6
64.9 102.4 1.8 2.03 3.2 63.7 ND
Cream 950 5.7 143
156 272.5 25.1 27.4 47.8 57.3 N D
!•* butanol- 
-{N H ah S O a 930 2.1
82.7 155 224 39.4 73.8 106.7 69.2 N D
fractionation
2 ^  (N H 4)2S 04  
fractionation 65 3.4 547.6 870.3
1218.9 134.6 255.9 358.5 71.4 N D
Dialysate 45 2.7 530.4 584.1
781.9 159.4 216.3 289.6 74.7 111 2 .1
Peak 1 ♦  peak 2 ’ 50 2.1 957.6 121.1
210.2 45.6 58.6 100.7 58.2 2 1 1 3.2
Purified enzyme
\
45 0.75 277.5 983.3 1208
370.6 1319.5 1621.2 81.4 6 .2 1 0 .3
(Peak 2)
T a b le  6 : Summary o f  th e  p u r i f i c a t i o n  o f  BXO u s in g  c a lc iu m  phosphate  g e l
( d a ta  a re  th e  means o f  th r e e  e x p e rim e n ts  ) .  P = p r o t e i n  
( 1 cm /  22 cm column ) .
SDS-PAGE (10 %) of the major fractions in the purification
process of bovine xanthine oxidase.(CBB stain).
Tracks 2-3 : dialysate (crude enzyme extract). 
Tracks 4-5 : washes of the column.
Tracks 6-7 : eluted enzyme.
M.Wt. markers are shown in track 1.
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M.Wt x 10
(A) (B)
Fig. 14 : SDS-PAGE (10 %) of purified enzyme (A2, B3) and BMFGM (A3.B2).
M.Wt. markers are shown in track 1.














: Native polyacylamide gel (7.5 %) of purified xanthine oxidase (2). (CBB stain).
M.Wt.markers : Urease (jack bean);hexamer 545,000, trimer 272,000 
















W a v e le n g t h  ( nm)
Fig. 17 : Absorption spectrum (250-700 nm) of purified bovine XO 
(0.74 mg/ml) showing the absorbance of the flavin at 
approximately 450 nm.
This spectrum pattern of xanthine oxidase (dehydrogenase form) is similar to that 
reported by Nakamura and Yamazaki. (1982) but differs from that reported by Ventom el 
a]. (1988) for the demolybdo-(xanthine oxidase) and by others (Hart et al..1970: Massey el 
a!-,1969, 1970; Massey and Edmonson., 1970) for the oxidase form of the enzyme.
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5-2 Stability of purified bovine xanthine oxidase.
Freshly-purified bovine xanthine oxidase was frozen at -40°C and stored for up to two 
weeks. Following rethawing, the enzyme activity (dehydrogenase) was found to have 
decreased by 43 % compared with the value before freezing. SDS-PAGE (Fig 18) of frozen 
and thawed enzyme showed an additional polypeptide with M.Wt of approximately 80 KD.
Freshly prepared enzyme was allowed to stand at room temperature for periods of 8, 
24 and 72 h. before analysis by SDS-PAGE. Fig. 19 shows that further polypeptide bands 
with approximate M.Wts of 80 KD, 60 KD, 35 KD and less than 29 KD appeared, already 
after 8 h at room temperature. In some experiments, an additional band occured at 
approximately 105 KD (see eg. Fig 20a, track 2).
- 1 3 8 -
1 2  3
Fig 18 : SDS-PAGE (10 %) of freshly prepared BXO (3) and frozen and thawed 
(once) enzyme (2).
M.Wt.markers are shown in track 1.
(CBB stain).
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M . W t x  1 0 3
1 2 3 4  5 6 7  8 9
Fig.19 : SDS-PAGE (10 %) of BMFGM and degraded xanthine oxidase.
(CBB stain).
Tracks 1-2: BMFGM.
Tracks 4-5 : BMXO allowed to degrade for 8 h.
Tracks 6-7 : BMXO allowed to degrade for 24 h.
Tracks 8-9 : BMXO allowed to degrade for 72 h.at room temperature. 
M.Wt.markers are shown in track 3.
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5-3 Comparison with commercial enzvmes
The activities of the enzyme, prepared as described in Results (5-1) and of a number 
of commercial enzyme preparations are shown in Table 7. SDS-PAGE patterns are shown 
in Fig. 20ab in which it can be seen that the Biozyme enzyme, prepared without using 
pancreatin (XO-2) shows a pattern very similar of that of the enzyme prepared as described 
in Results (5-1), but which has been allowed to degrade by standing at room temperature for 
12 h. The Biozyme enzyme (XO-2B), prepared by using pancreatin, shows no band at 150 
KD, but major bands at 83 KD, 60 KD and 2 bands less than 29 KD. The Sigma enzyme, 




oxidase + dehydro, 
forms (lU/mg protein)
% of dehydro .form
(SIGMA)
EC 1.2.3.2 grade 1 0.75 27.3
EC 1.2.3.2 grade 3 0.69 20.7
EC 1.2.3.2 grade 4 0.27 16.4
(BIOZYME)
XO-2 1.48 39.4
XO-2 B 1.06 23.1
This thesis 1.67 81.4
Table 7 : Comparison of the activities (oxidase and dehydrogenase) of 
purified xanthine oxidase with those of commercial enzymes.
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M . W t  x 1 0 3
M.Wt x 1 0 3
Fig. 20a : SDS-PAGE (10 %) of bovine xanthine oxidase supplied by Biozyme 
compared to enzyme prepared as described in this thesis.
(CBB stain).
Track 1 : M.Wt.markers.
Track 2 : degraded XO (own preparation, left for 12 h. at room
temperature to degrade).
Track 3 : XO-2 ( prepared without using pacreatin, from Biozyme).
Track 4 : BMFGM.
- 142 -
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Fig. 20b : SDS-PAGE (10 %) of bovine xanthine oxidase supplied by 
Biozyme. (CBB stain).
Tracks A : XO-2 (pancreatin free, from Biozyme).
Tracks B : XO-2B (prepared by using pancreatin, from Biozyme). 
Track M : BMFGM
- 143 -
a b c
F ig. 20c : SDS-PAGE (10 %) of bovine xanthine oxidase supplied by Sigma, 
b : grade 1 
c : grade 3 
M.Wt. markers are shown in track a
-144 -
6-1 Inhibition, by bovine XO. of ELISA for human anti-BMFGM antibodies.
Purified xanthine oxidase (Results, 5-1) was used as an inhibitor in the competitive 
ELISA for human anti-BMFGM antibodies (Methods, 8-3) with standard serum (A1) at 1/50 
dilution (in PBS). Fig. 21 shows that the enzyme was capable of totally inhibiting the ELISA 
in a manner similar to that of BMFGM itself, and in marked contrast to BSA or casein. 
Similar plots for the commercial enzyme preparations are shown in Fig. 22 in which it can be 
seen that XO-2 (prepared without using pancreatin) inhibits more effectively than XO-2B 
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a n t i g e n  c o n c e n t r a t i o n  ( m g / m l )
Fig. 2 1 : Inhibition of human anti-BMFGM antibodies by purified bovine XO
«--------- •  BMFGM. # --------- *  BSA.
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6-2 Inhibition, by xanthine oxidase, of ELISA for human anti-XO antibodies.
A standard ELISA for human anti-XO antibodies (Methods, 8-2) was developed along 
the lines outlined for human-anti-BMFGM antibodies (Results.1). The amount of antigen was 
optimised by plotting standard curves (Methods, 8-3) using pooled sera A1 and A2 (see 
Results 1) and five different conjugated second antibodies (see Results, 1). For each 
conjugate, standard curves were obtained at four different XO concentrations (Fig. 23) and, 
in all cases, a concentration of 0.02 mg XO/ml (100 ul/well) was found to be appropriate.
Purfied xanthine oxidase (Results, 5-1) and a number of commercial preparations were 
used as inhibitors in the competive ELISA for human anti-XO antibodies (Methods, 8-4) with 
standard serum (A1) at 1/50 dilution (in PBS). Fig 24 shows that both purified XO and XO-2 
(from Biozyme) inhibited the ELISA to more than 80 %, as does BMFGM itself. XO-2B 
(Biozyme) and X0 grade 1 (Sigma) gave a lower inhibition. Casein and BSA, used as 
controls, gave less than 20 % inhibition (Fig. 24).
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Fig.23 : Optimization ot anti-XO antibody ELISAs using different 
concentrations of coating antigen (XO).
(•-------- • lO pg.o-------o 5pg, * ------* 2 p g , a n d  «— * 1 pg XO/well).
A)- using goat anti-(human IgG) IgG-HRPO second antibody.
B)- using goat anti-(human IgM) IgG-HRPO second antibody.
C)- using goat anti-(human IgA) IgG-HRPO second antibody.
D)- using goat anti-(human Igs) IgG-HRPO second antibody.
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Fig. 24 : Inhibition of human anti-XO antibodies by various XO preparations
BMFGM
o--------— o XO-2 (Biozyme)
«— — * prepared XO.
* — — * X0-2B (Biozyme).




6-3 Western blots of human sera against xanthine oxidase.
SDS-PAGE patterns of xanthine oxidase were transferred to nitrocellulose sheets 
(Methods, 11-1) and immunoblotted with human sera, using goat anti-(human Igs) IgG 
conjugate (Methods, 7) as described in the Methods (11-3-1).
Immunoblots of human serum against freshly-prepared enzyme (Fig. 25a), frozen and 
thawed enzyme (Fig. 25b) and enzyme degraded at room temperature (Fig. 25b) show that 
the human antibodies interact with all polypeptides derived from bovine xanthine oxidase. 
Further immunoblots of commercial enzyme preparations (Fig. 25b) again show staining of 
all XO-derived fragments
- 1 5 2 -
Immunoblotting of human sera (2-4) against freshly- prepared XO.
A : SDS-PAGE (10 %) (CBB stain)
B : electroblotting of the enzyme from polyacrylamide gel to 
nitrocellulose (0.45 urn of porosity),amido black stain.
C : immunoblotting of three (2-4) human sera, with different 
anti-BMFGM antibody titers (57.4, 68.32 and > 100 % 
respectively compared to standard serum A1),
5-6 : application of sera (2 and 3) to XO without adding 
second antibody conjugate.(controls).
7 : application of conjugated second antibody directly 
to XO. (control).
1 2 3  4 5  1 2 3 4 5
A B
: Immunoblotting of human serum (A1) against purified XO thawed 
once (3), commercial XO from Biozyme : XO-2 (4) and XO-2B (5)
Track 2 : BMFGM.
M.Wt. markers are shown in track 1.
A : SDS-PAGE 10 % (CBB stain).
B : the corresponding blot.
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6-4 Western blots of rabbit anti-XO antibodies against XO and BMFGM
Rabbit anti-XO antiserum was raised (Methods, 13-1,13-2) and tested by ELISA (Fig. 
26) as described in Methods (8-2) except that goat anti-(rabbit lgG)lgG conjugated to HRPO 
(Sigma, Poole, UK) was used in place of goat anti-(human lgG)lgG-HRPO conjugate. Rabbit 
anti-BSA serum was similarly raised and used, together with pre-immune serum and 
anti-BMFGM rabbit antiserum (Results, 3-3), as controls (Fig. 26).
It is interesting to note (Fig. 26) that the anti-BMFGM and anti-XO antiserum showed 
essentially the same strength of interaction with xanthine oxidase.
Rabbit anti-XO antiserum (1/50 dilution) was used to immunoblot SDS-PAGE patterns 
of BMFGM and purified XO as described in the Methods ( 11-3-1) except that goat 
anti-(rabbit lgG)lgG-HRPO conjugate was used. The patterns (Fig. 27a) show that anti-XO 
antiserum binds to all BMFGM polypeptides with the striking exception of the band at 
approximately 60 KD [cf. rabbit anti-BMFGM antibodies, Fig. 27b)]. The anti-XO antiserum, 
like anti-BMFGM antiserum, bound to all polypeptides derived from purified or commercial 
bovine xanthine oxidase.















1/SO 1/100 1/200 1/400 1/800 1/1600
serum d i l u t io n  in  PBS
: ELISA for rabbit anti-xanthine oxidase antibodies, 
(wells were coated with prepared enzyme)
rabbit anti-BMFGM antiserum.
n----- — * rabbit anti-XO antiserum.
* — — * rabbit anti-BSA antiserum.
*— — * rabbit pre-immune serum.
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Fig. 27a : Immunoblotting of rabbit anti-XO antiserum (1/50 dilution) against:
track 1 : M.Wt markers 
track 2 : BMFGM
track 3 : purified BXO (12 h. at room temperature) 
track 4 : XO-2 (from Biozyme) 
track 5 : XO-2B (from Biozyme)
track b : blank conjugate directly applied to BMFGM pattern.
- 157 -
M .V t  x  103
1 2 3 4 5 b
Fig.27 b : Immunoblotting of rabbit anti-BMFGM antiserum (1/50 dilution) 
against:
track 1 : M.Wt.markers 
track 2 : BMFGM
track 3 : purified BXO (12h.room temperature) 
track 4 : XO-2 (from Biozyme) 
track 5 : XO-2B (from Biozyme)
track b : blank conjugate applied directly to BMFGM pattern.
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6-5 Cross-reactivitv of rabbit anti-XO antiserum and anti-BMFGM antiserum.
Rabbit anti-XO antiserum and rabbit anti-BMFGM antiserum were compared in ELISA, 
(Results, 4-3 and 6-4) using BMFGM, purified XO (Results 5.1), Biozyme XO-2B and 
Biozyme XO-2 as antigens. Both antiserums reacted equally well with BMFGM or XO 
whatever the source of bovine XO (data not shown).
6-6 Inhibition of bovine xanthine oxidase enzvmic activity bv human serum.
A solution of bovine xanthine oxidase (2.2 mg/ml in 0.1 M sodium pyrophosphate, see 
Methods, 4.1) was incubated with human serum (10 and 20 ul/250 ul of the enzyme solution) 
for 5 min. at room temperature, following which the enzymic activity was assayed, as 
described in Methods (4-2). For the purpose of this experiment, the addition of 
dithioerythrithol was omitted in the preparation of the enzyme which showed a 
dehydrogenase/oxidase ratio of 3:2. Inhibitions of dehydrogenase (Fig. 28a) and oxidase 
(Fig. 28b) activities were expressed relative to those of preparations to which no serum was 
added. Goat serum was used in otherwise identical experiments as a control.
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Fig. 28 : Inhibition, by human serum, of bovine xanthine oxidase 
a : dehydrogenase activity 
b : oxidase activity
The activity was measured 5 min.after addition of serum (10,20 ul) to bovine xanthine 
oxidase preparation (2.2 mg/ml).
Anti-BMFGM titers in the ten sera (1-10) used in this experiment, compared to 
standard serum (A1),were as follows:
1 : 6.27 %  
2 :  14.39%  
3 :  21.06%  
4 :  24.31 %  
5 : 28.97%  
6 :  41.69%
7 : 67.38 %
8 : 84.56 %
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6-7 Affinity purified human anti-bovine XO antibodies.
Purified bovine XO (Methods, 4-1) was coupled to CNBr-activated Sepharose 4B gel 
(Methods, 5-2). Using this affinity column, human anti-bovine XO antibodies were purified 
from pooled human serum (from 5 individuals with high titers of anti-bovine XO antibodies, 
Methods, 5-3). Purified antibodies were assayed, by ELISA, against BMFGM (Fig. 29a) and 
purified bovine XO (Fig. 29b) by using four different conjugated second antibodies [goat 
anti-(human IgG, IgM, IgA and all three)lgG-HRPO (Sigma)] under the same conditions as in 
Results (1) in order to determine immunoglobulin class of the purified antibodies . The 
results showed that the purified antibodies are IgG and IgM, which were confirmed by 
immunodot blot assay (data not shown).
Fig. 30 shows that when these purified human anti-bovine XO antibodies were 
immunoblotted against BMFGM or purified bovine XO, they reacted mainly and strongly 
against the 150 KD polypeptide band. Clearer blots were obtained with the purified 
antibodies compared to the ones with human serum (Results, Fig. 9).
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Fig.29 : ELISA on purified human anti-(bovine XO) antibodies using
four different goat anti-(human immunoglobulins) IgG-HRPO 
conjugates (Sigma,1/1000 dilution in ;100 pl/well).
* — ------- * anti-human all immunoglobulins
e------- -------- * anti-human IgM
---------------& anti-human IgG
* ------- --------* anti-human IgA
a : plate coated with BMFGM (0.2 mg/ml;100 ul/well). 
b : plate coated with purified bovine XO (0.02 mg/ml; 
100 ul/well).
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FigJ30 ; Immunblot of affinity purified human anti-(bovine XO) 
antibodies against BMFGM (1) and freshly prepared 
bovine XO (2). 
b = blank
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7- Comparison of anti-(bovine XQ) antibodies in M I patients and controls.
Anti-(bovine XO) antibody levels were assayed (Results, Fig. 23) in serum samples 
taken from 57 male patients (40-65 years) within 24 h. of myocardial infarction and 
compared with those of 57 male controls (40-65 years) with no history of coronary heart 
disease. All the samples used in the anti-BMFGM study (Results, 2) were included in the 
above figures. Serum samples were diluted 1:1000. Distribution of titres for IgM, IgG and 
IgA are shown in Figs 31a, b and c respectively. A K-S analysis was performed on each set 
of results (Methods, 15). Table 8 shows, in each case, the point at which the greatest 
difference between cumulative frequencies of the two populations occurs and the K-S D 
value for this point. Table 9 shows critical values of D for various levels of significance. 
Anti-(bovine XO) antibodies showed no significant differences for IgG and IgA. For IgM, 
however, the difference was significant at p < 0.001.
point were D is maximum 
(% compared to standard sera)
value of D
IgM above 25 % 0.439
IgG above 25 % 0.106
IgA above 25 % 0.104
Table 8 : Representation of the points were D is maximum
between the two populations (Ml and control samples)
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Table 9 : Critical values of D for different levels of significance, (ni = n2 = 57).
For all antibody measurements the greatest difference between Ml and Control 
samples occured above 25 % of the standard (Table 8).
For IgM, (49 % of Mis and 28 % of Controls). A K-S value of 0.439 was well above all 
the values of D, at all levels of significance, (Table 9).
For IgG (21 % of Mis and 32 % of Controls). A K-S value of 0.106 calculated was well 
below the necessary level of 0.228 significance at p < 0.1.
For IgA (39 % of Mis and 28 of Controls). A K-S value of 0.104 calculated was well 
below the necessary level of 0.228 to show significance at p < 0.1.
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Fig. 31 : Comparison of anti-(bovine XO) antibodies in myocardial infarction patients 
(57 samples)and controls (57 samples).
The samples were all from males aged between 40-65 years.
The levels of antibodies in the samples are expressed as percentage compared to 
standard sera (A1 or A2). Percentages are represented in the following seven categories :
A : less than 6 %
B : 6-12.5%
C : 12.5-25%
D : 25-50 %
E : 50-75 %
F : 75-100%
G : higher than 100 %.
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Anti-(bovine XO) antibody titres were assayed in serum samples of 107 male patients 
(40-65 years) taken within 24 h. of myocardial infarction and compared to those of 86 male 
controls (40-65 years) with no history of coronary heart disease. The samples used in the 
first study (Results, 7-1) were included in this study. Distribution titres for IgM, IgG and IgA 
are shown in Figs 32a, b and c respectively. A K-S analysis was performed on each set of 
results. Table 10 shows, in each case, the point at which the greatest difference between 
cumulative frequencies of the two population occurs and the K-S D value for this point. 
Critical values of D at different levels of significance are shown in Table 11. As in the 
previous study (7-2), no significant differences were observed when considering IgG or IgA 
antibodies. Differences were, however, very significant with IgM.
Point were D is maximum 
(% compared to standard sera)
value of D
igM above 50% 0.365
IgG above 50 % 0.088
igA above 75 % 0.093
Table 10 : Representation of the points where D is maximum between the two 
populations (Ml and Control samples).
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Table 11 : Critical values of D for various levels of significance.
(n i = 107; n2 = 86).
For IgM, the greatest difference occurred above 50 % of standard (53 % of Mis and 14 
% of Controls). A K-S value of 0.365 calculated was higher than the critical values of all the 
represented levels of significance (Table 11).
For IgG, the greatest value was obtained above 50 % of the standard (40 % of Mis and 
31 % of Controls). The calculated K-S value of 0.088 was below the critical values of D at all 
the 6 levels of significance represented in Table 11.
For IgA, the greatest difference occured above 75 % of the standard (32 % of Mis and 
25 % of Controls). A K-S value of 0.093 calculated was well below the critical values of D at 
all the levels of significance represented in Table 11.
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Fig. 32 : Comparison of anti-(bovine XO) antibodies in myocardial infarction patients 
(107 samples) and controls (86 samples).
The samples were all from males aged between 40-65 years.
The levels of antibodies in the samples are expressed as percentages compared to 
standard sera (A1 or A2). Percentages are represented in the following seven categories:
A : less than 6 %
B : 6-12.5%
C : 12.5-25%
D : 25-50 %
E : 50-75 %
F : 75-100%
G :: higher than 100 %
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7-3 Total IgM  levels in M I and control samples.
In order to investigate the possibility that elevated IgM anti-XO antibodies in Ml 
patients might simply reflect elevation of total IgM in such patients, the latter were assayed 
and compared with controls. Total levels were determined by the Mancini procedure 
(Johstone and Thorpe, 1987) in 50 Ml and 50 control serum samples, chosen at random 
from those used previously in comparison of anti-(bovine XO) antibody levels (Fig. 32). 
Statistical comparison (Kolmogorov-Smirnov test, Methods, 15-1) showed that IgM levels 
were actually higher in controls than Ml patients, although not significantly so. As can be 
seen in table 12, maximum differences in cumulative frequencies occur at 1001-1500 ug/ml 
and at 2501-3000 ug/ml. These differences (0.12) are clearly less than the critical value 
(0.272) necessary to demonstrate significance at p = 0.05.
In order to further confirm the lack of association of IgM anti-(bovine XO) antibody 
levels and total IgM, these were plotted against each other for Ml (Fig. 33a) and controls 
(Fig. 33b) samples. Correlation coefficients (Methods, 15-2) for these sets of samples were 
0.106 (Ml) and 0.127 (controls), both of which were well below the value of (0.279) 
necessary for significant (p = 0.05) correlation (Basic Formulae and Statistical tables, School 
of Mathematics, University of Bath, 1983).
The IgM anti-XO antibody levels in Ml samples and controls were reassayed for this 
comparison and, yet again, showed the levels in Ml samples to be significantly (p < 0.001) 
higher (data not shown)
7-4 Serial studies of IgM anti-BXO antibodies following MI
Serial studies on anti-BXO antibody levels following Ml showed no consistent patterns 
of variation over periods of two weeks (Figs 34a,b) or 6 months (Figs 35 a.b) after Ml.
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Table 12 : Comparison of total IgM levels in Ml (50) and control (50) samples.
The levels were deduced from Mancini agar plates, containing anti-human IgM 
antibodies, (The Binding Site, Birmingham, UK).
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S am ples T o ta l Ig M  co ncentra tion  (u g /m l)
<  5 0 0 501 -1 0 0 0 1 0 0 1 -1 5 0 0 1 5 0 1 -2 0 0 0 2 0 0 1 -2 5 0 0 2 5 0 1 -3 0 0 0 3 5 0 1 -4 0 0 0 > 4 0 0 0
M I  sam ples (5 0 ) 3 4 19 12 6 5 0 1
C o n tro ls  (5 0 ) 3 6 11 14 3 6 2 1
C u m u la tiv e  freq uen cies
<  5 0 0 5 0 1 -1 0 0 0 1 0 0 1 -1 5(X) 1 5 0 1 -2 0 0 0 2 0 0 1 -25(H ) 2 5 0 1 -3 0 0 0 3 5 0 1 -4 0 0 0 > 4 0 (X )
M l  sam ples 3 /5 0 7 /5 0 2 6 /5 0 3 8 /5 0 4 4 /5 0 4 9 /5 0 4 9 /5 0 5 0 /5 0
(x ) 0 .0 6 0 .1 4 0 .5 2 0 .7 6 0 .8 8 0 .9 8 0 .9 8 1
C o n tro ls 3 /5 0 9 /5 0 2 0 /5 0 3 4 /5 0 3 7 /5 0 4 3 /5 0 4 9 /5 0 5 0 /5 0
(y) 0 .0 6 0 .1 8 0 .4 0.68 0 .7 4 0 .8 6 0 .9 8 1
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Fig. 33 : Comparison of total IgM levels versus IgM anti-BXO antibody levels.
a )  i n  5 0  c o n t r o l  s a m p le s
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F igs 35a.b : Variation of IgM anti-BXO antibody levels in Ml patients up to 
six months following Ml
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8- Human xanthine oxidase
8-1 Preparation
A crude extract of human xanthine oxidase was prepared by the method of Krenitsky 
2i. (1986) outlined in Methods (6-1,6-2):
Initial purification was attempted by using a guanine affinity column. The column was 
prepared as described in Methods (6-3-1). Approximately 74 %  of the added guanine was 
bound to the column (assessed from the absorbance of washes at 275 nm or 246 nm), 
resulting in a bound content of 0.23 mg guanine/ml gel. Crude enzyme was loaded onto the 
affinity column (Methods, 6-3-2), washed and eluted with salicylic acid. Pooled fractions 
were precipitated with ammonium sulphate, redissolved and dialysed (Methods 6-3-2) to give 
final product. Enzyme activities and protein/flavin ratios for different stages in the procedure 
are listed in Table 13. By using the Sepharose 4B-folic acid affinity gel (Methods 6-4-1; gift 
from Dr R.C.Bray of Sussex University) an alternative purification procedure of human 
xanthine oxidase was pursued as outlined in Methods (6-4-2). Enzyme activities and 
protein/flavin ratios for different stages in the procedure are listed in Table 14.
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Crude extract 13.3 0.044 ND
Eluted enzyme 7.4 0.567 6.23
: Summary of human xanthine oxidase purification.
( using guanine affinity chromatography column, n=1 ) 
ND = not determined.











57.8 0.002 ND ND
Cal.P.gel
supernatant
29.6 0.025 ND ND
Crude extract 14.8 0.051 ND ND
Washes 3.4 0.018 ND ND
Eluted enzyme 8.2 1.29 6.075 T 0.025 26.2
TabkJ.4 : Summary of human xanthine oxidase purification.
( using folate affinity chromatography column, n = 2 ). 
ND = not determined.
-183 -
8-2 SDS-PAGE of purified enzvme.
SDS-PAGE patterns of xanthine oxidase, purified by guanine and folate affinity 
chromatograpy, are shown in Figs 36 together with corresponding patterns of BMFGM, 
bovine xanthine oxidase and crude human xanthine oxidase extract.
The enzyme purified by the guanine affinity chromatography shows bands of 
approximate M.Wt. of 70 KD, 55 KD, 38 KD, and < 38 KD (Fig. 36a) while that from the 
folate column shows bands of approximately M.Wt of 90 KD, 70 KD, 55 KD, 35 KD and < 29 
KD (Fig. 36b).
8-3 Western blotting of human sera against purified human xanthine oxidase.
SDS-PAGE patterns of purified human xanthine oxidase were transferred to 
nitrocellulose paper (Methods, 11-1) and immunoblotted as described in the Methods, 
11-3-1) using high titre (anti-BMFGM antibodies) human serum and goat anti-(human 
immunoglobulins) IgG-HRPO (Sigma).
Fig. 37 shows that immunoblots of both guanine and folate affinity-prepared xanthine 
oxidase, show only one band (55 KD) that interacts with the human serum.
8-4 Inhibition, by human XO. of ELISA for human anti-BMFGM and anti-fBXOI antibodies.
Purified xanthine oxidase (Results, 8-1) was used as inhibitor in the competitive ELISA 
for human anti-BMFGM and anti-XO antibodies (Methods, 8-4) with standard serum (A1) at 
1/25 dilution (in PBS). Figs 38a,b shows the results obtained for the guanine and the folate 
purified enzymes. Plates were coated with BMFGM (20 pg/well) (a), or purified bovine XO (2
- 184-
pg/well) (b) . Goat anti-(human Igs, i.e polyvalent) IgG-HRPO-conjugate was used. It is 
clear that neither human xanthine oxidase preparation inhibits either antibody assay, in 
contrast to BMFGM or bovine xanthine oxidase.
: SDS-PAGE (10 %) of human xanthine oxidase using guanine affinity column.
(CBB stain).
Track 1 : M.Wt. markers.
Track 2 : BMFGM.
Track 3 : purified human xanthine oxidase.
Track 4 : crude human XO extract.
Track 5 : purified bovine MXO.
-185-
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Fig. 36b : SDS-PAGE (10 %) of purified human xanthine oxidase (HXO) using 
folate affinity column (CBB stain).
Track 1 : BMFGM.
Track 2 :  M.Wt. markers.
Track 3 : purified human XO.
Track 4 : bovine XO.
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Fig. 37 : Immunoblotting of human serum, with high titre of anti-BXO antibodies, 
against purified human xanthine oxidase (HXO)*
a : HXO purified by folate affinity chromatography (track 3). 
b : HXO purified by guanine affinity chromatography .
Track 1 : against M.Wt. markers.
Track 2 : against BMFGM.
Track 4 : against BMXO.
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Fig. 38 : Inhibition of anti-BMFGM (a) and anti-BXO (b) antibody ELISA by incubation 
of human serum (A1) with purified human XO at the shown concentrations. BMFGM, 
purified BXO and casein were used as controls.
 *   BMFGM.
15 *  BMXO.
CHXO (Crude Human XO extract).
O -------O  HXO (folate affinity purification).
 *----------» HXO (guanine affinity purification).
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9- Human Monoclonal Anti-BMFGM Antibodies.
9-1 Generation.
9-1-1 Cloning of human-mouse heterohvbridomas.
Human peripheral blood lymphocytes (PBLs) were transformed with EBV (Methods, 
14-4) and selected for anti-BMFGM antibody production (Methods, 14-4) by ELISA 
(Methods, 8) using goat anti-(human immunoglobulins)IgG-HRPO conjugate. Positive 
transformed cells were fused with mouse X63-8Ag myeloma cells (Methods, 14-8), tested for 
anti-BMFGM-antibody production and positive cells were expanded (Methods,14-8).
Table 15 shows the results obtained, following EBV transformation of PBLs, in five 
separate experiments. Of the original wells seeded with transformed cells, 47.7 % showed 
growth after 3-4 weeks and 7-18 % of the total seeded wells were producing anti-BMFGM 
antibodies. One week after expansion of positive cells, 6-17 % of the total wells were still 
positive for antibody production.
Table 16 shows the results of fusion of antibody-producing transformed PBLs in the 
five experiments. 2-3 weeks after fusion, 26-37 % of seeded wells showed growth but, of 
these growing wells, only 18-36 % were antibody positive and 1 week after expansion these 
percentages dropped to 18-28 %.
Table 17 shows the survival of cloned antibody-positive cells. 2-3 weeks after the first 
cloning (1 cell/well), a proportion (14-29 %) of seeded wells in all the 5 experiments showed 
growth but in only 2 experiments were antibody-positive cells detected (13 % and 16 % of 
growth wells). 2-4 weeks after the second cloning, 33 % and 29 % of seeded wells showed 
growth but, of these, only 5 % and 3 % were antibody-positive and, following the third 
cloning, all anti-BMFGM antibody production was lost, although heterohybridomas continued 
to grow.
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Experiment
rv irter
Level o f anti-lMFCM antibody 
compared to  standard serum (A l)
seeded w ells w ells w ith growth
(3-4  w*
positive  w ells  
aeks)
p o sitive  w ells a fte r  expansion 
(1 week)
1 48.18 288 134 52 49
2 57.27 192 72 28 28
3 72.1 192 112 2S 23
4 58.32 192 93 14 12
5 16.54 288 139 47 41
Totals 1152 550 167 153
Table IS : EBV transformed human PBLs producing anti-BMFGM antibodies.
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Fusion Lynrphccytes fined seeded w ells w ells  w ith  
growth
(3-4  v>
p o sitive  w ells  
eeks)
p o sitive  w ells a fte r expansion 
(1 week)
1 2 .6  x 10 7 288 86 25 17
2 1 .9  x 107 192 49 9 9
3 1 .6  x 107 264 61 22 17
4 2 .3  x 107 192 97 31 19
5 1 .8  x 107 192 52 17 11
Totals 1.02 x 108 112R 345 104 73
Table 16 : Fusion of EBV transformed positive human PBLs with mouse X 63 cell line.
Experiment
nurber
F irs t cloning Second cloning Third cloning
seeded w ells w ells v/ith  
growth
positive w ells seeded w ells w ells w ith  
gpowth




1 288 51 0 — — — — — —
2 192 38 6 288 96 5 192 69 0
3 288 46 0 — — — — — —
4 288 83 11 384 112 3 96 43 0
5 192 27 0 — — — — — —
Totals 1248 245 17 r 207 8 288 112 0
Table 17 : Cloning of positive fused heterohybrids secreting human anti-BMFGM antibodies.
9-1 -2 Cloning of EBV-transformed PBLs.
EBV transformed PBLs (Methods,14-4) were cloned directly without prior fusion.
Table 18 shows the data from three experiments. 3-4 weeks after seeding of 
transformed cells in 96 well plates, 11 %, 15 % and 16 % of seeded wells were 
antibody-positive and these percentages fell to 10 %, 13 % and 14 %,one week after 
expansion.
Cloning of transformed cells at less than 5 cells/well was found to lead to death of 
some 90 % of cells and so positive cells were seeded at 20, 50, and 100 cells/well initially.
Table 19 shows the results from this first and subsequent clonings in three 
experiments. 2-3 weeks after the first cloning (at 20 cells/well), 26 %, 18 % and 20 % of 
wells were antibody-positive and corresponding values after the second, third and fourth 
clonings (all at 1 cell/well) were : 19% , 10 %, 14 % ; 42 %, 61 %, 66 % ; 59 %, 63 %, 76 % 
respectively.
After the fourth cloning stage in the second and third experiments (Table 18), 15 of the 
fastest-growing most stongly antibody-producing clones were expanded into 25 ml "T" flasks. 
The expanded cells were subcultured and their supernatants used in further studies. Cells 




Level o f anti-BMFT}4 antibody 
oanpared to  standard serum (A l)
seeded wel ls w ells w ith
growth
(3-4  we
p o sitive  w ells  
eks)
positive  w ells a fte r expansion 
(1 week)
1 62.97 384 117 42 38
2 25.06 192 97 31 26
3 100 384 201 56 48
Totals 900 315 129 112




F irs t cloning Second cloning Third cloning Forth cloning
seeded w ells p o sitive  w ells  
(20 cells / w e ll)
seeded w ells positive  w ells  
(1 c e ll /w e ll)
seeded w ells p o sitive  w ells  
(1 c e ll /w e ll)
seeded w ells positive  w ells 
(1 c e l l /  w ell)
1 288 76 192 37 192 81 96 67
2 192 34 192 19 96 59 96 61
3 288 67 192 26 96 64 96 73
Totals 768 167 576 82 384 204 288 207
Table 19 : Cloning of EBV transformed human positive B lymphocytes.
9-2 Characterisation of 15 monoclonal anti-BMFGM antibodies from EBV-transformed PBLs.
9-2-1 Determination of immunoglobulin class.
a) Using ELISA.
Supernatants from the 15 monoclonal cell lines were tested in the standard ELISA 
(Methods, 8), using each of the goat anti-(human immunoglobulins) IgG HRPO-conjugates 
(anti-IgG, anti-IgM, and anti-lgA) in turn. Table 20 shows that 13 clones showed positive 
response to anti-IgG and 5 clones showed positive response to anti-IgM ; of these, two (1 
D12 and 3 H7) were negative to anti-IgG. None of the 15 clones showed a positive response 
to IgA.
b) Using dot immunobinding assay.
Supernatants were also tested in the immunodot assay (Methods, 12), using different 
second antibody conjugates (Table 21, Fig. 39). As with the ELISA, two clones (1 D12 and 
3 H7) were clearly negative for IgG and positive for IgM, while two clones, surprisingly were 
positive for both IgG and IgM (5 H11 and 5 C11). One clone (4 G11), positive for both IgG 
and IgM in ELISA was positive only for IgM in the immunodot assay. With this last 
exception, the results paralleled exactly with those obtained by ELISA. None of the clones 
was positive for IgA.
- 1 9 7 -
(Absorbance 450 nm)
Ab.code Goat anti-(hu man immunoglobulins)lgG-HRPO conjugate
anti-lgs anti-IgG anti-IgM anti-lgA
1A2 0.374 0.316 <0.05 <0.05
1D8 0.495 0.384 <0.05 H ••
1D12 0.488 <0.05 0.238
2E1 0.458 0.431 <0.05
2G9 0.437 0.287 <0.05
2B10 0.474 0.353 <0.05
3H7 0.381 <0.05 0.176 „„
3G11 0.812 0.473 <0.05 ....
4A5 0.278 0.228 <0.05 ....
4C8 0.519 0.417 <0.05
4D5 0.445 0.424 <0.05
4G11 0.470 0.236 0.251
5H3 0.428 0.378 <0.05
5H11 0.404 0.198 0.085
5C11 0.548 0.217 0.151 " "
Table 20 : Immunoglobulin class determination,of the fifteen clones, using ELISA.
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Ab.code Goat anti-(human lgs)lgG-HRPO-conjugate.
anti-lgs anti-IgG anti-IgM anti-lgA
1A2 + + - -
1D8 + + - -
1D12 + - + -
2E1 + + - -
2G9 + - -
2B10 + + - -
3H7 + - + -
3G11 + + - -
4A5 + + - -
4C8 + + - -
4D5 + + - -
4G11 + - + -
5H3 + + - -
5H11 + + + -
5C11 + + +
Table 21 : Immunoglobulin class determination,of the fifteen clones, 
by dot-immunobinding assay.
b la n k s
Fig. 39 : Dot immunobinding assay of the fifteen clones, using :
a) goat anti-(human lgG)lgG-HRPO conjugate
b) goat anti-(human lgM)lgG-HRPO conjugate 
blanks are obtained by applying negative clone supernatants.
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9-2-2 Interaction of monoclonal anti-BMFGM antibodies with xanthine oxidase.
a) ELISA
The 15 monoclonal-containing supernatants were tested by ELISA, using purified 
bovine xanthine oxidase (Results, 5) as antigen (Methods, 8-2). The experiment was 
repeated except that purified human xanthine oxidase (Results, 8) was used as antigen. The 
results (Table 22) show that all monoclonal anti-BMFGM antibodies were positive for purified 
bovine xanthine oxdase and negative for purified human xanthine oxidase.
b) Western blot analysis.
The 15 monoclonal anti-BMFGM antibody-containing supernatants were examined by 
Western blot analysis (Methods, 11-3-1) using goat anti-(human Igs) IgG-HRPO conjugate 
against SDS-PAGE patterns (Methods, 10-2) of BMFGM, purified and degraded bovine 
xanthine oxidase (Results, 5) and purified human xanthine oxidase (Results, 8).
Fig. 40 shows that all 15 monoclonal antibodies reacted with 150 KD and 140 KD 
bands on BMFGM patterns. Of the other polypeptides mainly: 200 KD (1D12, 3H7, 4C8, 
4D5, 4G11 and 5C11); 88 KD (1D12 and 3H3); 60 KD (all except 1A2, 2E1, 2G9, 4A5, 4D5 
and 5H11) and 52 KD (1A2 and 2G9).
Fig. 41a shows blots using purified bovine XO. Again, the 150 KD and 140 KD bands 
are strongly stained. Fig. 41b shows blots using degraded bovine xanthine oxidase in which 
it can be seen that beside 150 KD and 140 KD bands further banded were stained. These 
bands are mainly : 88 KD (1A2, 1D12, 2G9, 4G11 and 5H3) and 60 KD (1A2, 1D12, 4C8 
and 5C11). bands When purified human xanthine oxidase SDS-PAGE patterns (Results,
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8-2) were used in immunoblotting experiments, none of the four bands (Results, 8-2) was 
stained with any of the 15 supernatants
The blots shown in Fig. 40 and Fig. 41b are obtained using the stored stored clone 
supernatant (stored at -40 °C  for nearly a year). The blots of Fig. 41a were obtained with 




Ab.code Bovine XO Human XO
1A2 0.267 <0.08
1D8 0.392
1D12 0.412 . . . .
2E1 0.194 . . . .
2G9 0.329 „ „
2B10 0.486
3H7 0.310
3G11 0.612 . . . .
4A5 0.114 M H
4C8 0.474 . . . .
4D5 0.386
4G11 0.445 . . . .
5H3 0.467 H »
5H11 0.392 M II
5C11 0.239 II 99
Table 22 : Cross-reactivity of anti-BMFGM monoclonal antibodies with 
prepared bovine and human xanthine oxidase.
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Fig.40 : Immunoblotting of the fifteen (tracks 1 -15) monoclonal anti-BMFGM
antibody containing supernatants against SDS-PAGE patterns of BMFGM.
(b : blank obtained by using supernatants from growing negative well).
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Fig.41ab : Immunoblotting of the fifteen (tracks 1-15) monoclonal
anti-BMFGM antibody-containing supernatants against 
SDS-PAGE patterns of freshly purified (a) and degraded 
(b) bovine milk xanthine oxidase. 
b=blank.
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DISCUSSION
DISCUSSION
1- M ilk consumption and cardiovascular diseases.
Over the past years, a number of studies have linked cardiovascular disease to milk 
consumption. For example, a United Nations study in 1974, involving 44 countries, 
established a direct link between the quantity of milk consumed and the incidence of 
coronary heart disease (CHD). Finland, where CHD is endemic, was found to have the 
highest rate of cardiovascular mortality for middle aged men, whereas lower mortalities were 
found in the Netherlands and France where milk and milk products are less frequently used 
(Segall.,1977). Extremly low rates of atherosclerotic complications occurred in the 
developing nations of Tailand and South Korea, where milk is only rarely consumed and 
which have no dairy industries (Lee et al..1963: Annand.,1967). A plot, showing excellent 
correlation between rate of CHD and consumption of unfermented milk products 
(Seely.,1981) is shown in Fig. 1. Among many particular instances, leading to the same 
conclusions, it is worth mentioning Switzerland, where, between 1951-1976, a dramatic and 
mysterious decline of cardiovascular disease occurred. Males showed a 22 % decline and 
women a 43 % decline in mortality and a simultaneous 46 % drop in milk consumption was 
the only direct correlation established (Guberan.,1979). Furthermore, this decrease occured 
during the period when total consumption of animal fats rose by 20 % and smoking 
increased among women. This period also saw a marked increase of women entering the 
more stressful professional occupations (Rank.,1986).
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Fig. 1 : Correlation between milk consumption and heart disease rates
( From Seely, 1981 ).
Antibodies to cows' milk in normal "healthy individuals" have frequently been reported 
(Gunther et al..1960: Larose et al.. 1962: Annand.,1967; DeLire et a l.,1978: Shakib el 
a l, 1984; Fallstrom et al..1984.1986: Knoflach et al..1987: Firer et al.. 1987) but their 
possible pathogenic role in CHD was first proposed, in 1969, by Davies and his colleagues at
-208-
the West Wales Hospital, Carmarthen. They initially observed that levels of serum IgG were 
significantly raised in CHD patients (50 samples) compared to controls (78 samples) (Davies 
and Clark.,1968); a finding that was later confirmed independently (Gray eLal-,1978). The 
raised levels bore no relationship to the time following infarction, which suggested that the 
increase was not a result of infarction. A year iater, 1969, Davies et al showed that male 
patients with CHD had significantly raised levels of antibodies to cows’ milk compared to 
age-matched controls (25 CHD samples/25 controls). These findings were subsequently 
confirmed in a series of studies (Davies et al..1974: Davies.,1984) carried out with the 
collaboration of the MRC Epidemiology Unit, Cardiff. The 1974 paper, involving 216 Ml 
patients and 144 controls, additionally showed that mortality, within six months after 
infarction, was increased threefold if anti-cows’ milk antibodies were present at high levels. 
These results stimulated a great deal of interest (eg. Ellis.,1974) and were quickly confirmed 
by another group (Oster et al..1974) but subsequently refuted by three others (Toivanen o i 
a!.,1975; Scott et al..1976: Gibney eLal.,1980).
In 1980, Davies et al. examined the possibility that the above descrepancies might 
arise from different antigen preparations (Introduction, 4-5*6) and a good correlation was 
shown between anti-cows’ milk antibodies and anti-cream antibodies, but not skimmed milk 
antibodies. This led to the conclusion that anti-cows’ milk antibodies are directed to the fat 
globules and, more specifically (Davies et al..1982). to the bovine milk fat globule membrane 
(BMFGM). This was independently confirmed by Reid (Flow Laboratories) and more 
recently by Bryson (1989) using ELISA. In view of these advances, it was considered 
opportune to investigate Davies findings but assaying for anti-BMFGM antibodies.
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3- Assay used to detect human anti-BMFGM antibodies.
The haemagglutination assay, used by Davies and colleagues is crude and it was 
decided to use an ELISA, assaying specifically for IgG, IgA and IgM anti-BMFGM antibodies. 
Such an ELISA was largely developed, in this laboratory, by Bryson (1989). The assay was 
optimized in terms of concentrations of antigen (BMFGM), antibody (serum) and conjugate 
[anti-human immunoglobulins (G, M, A and all three together)]. A series of blocking buffers 
was tested to block free receptors on the polystyrene wells, and it was found that 0.05 % 
Tween in PBS, pH 7.4, was preferable to BSA, casein, normal goat serum or normal rabbit 
serum. The addition of casein to the blocking buffer (PBS-Tween) was found to cause 
non-specific reduction in all titres. The nature of BMFGM-anti-BMFGM antibody binding was 
investigated by using IgG Fc and IgG Fab’ fragments separately in the ELISA. Binding was 
thereby shown to be Fab’ mediated and titres were found to be independent of total IgG 
levels (Bryson.,1989). For the purposes of this study, the antigen (BMFGM) concentration 
was optimised (2.5 ug protein/well) for each of the five conjugates to be used. The 
reproducibility of the assay was shown to be acceptable. Titres varied less than 8 % from 
day to day and coefficients of variation among triplicates of the same samples, carried out in 
the same experiment, were less than 5 %.
4- Anti-BMFGM antibody levels in MI patients and controls.
Investigations of the levels of serum IgG anti-BMFGM antibodies showed those in 
controls to be significantly higher than in Ml patients (Results, 2). This surprising result was 
confirmed in larger studies carried out, by Bryson (1989), on subjects from South Wales, 
although differences were, in that case, not found to be significant.
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IgM anti-BMFGM antibodies, in contrast, were found to be higher in Ml samples than in 
controls but the difference was not statistically significant for the 56 Ml samples and 44 
control samples tested in this study. A similar difference was, however, shown to be 
significant (p < 0.05) in three studies of larger numbers of samples from South Wales carried 
out by Bryson (1989). Levels of IgA anti-BMFGM antibodies were not found to differ 
significantly between Ml patients and controls; a result confirmed also by the data of Bryson 
(1989).
The results in this study, together with those of Bryson (1989) can be interpreted as 
supporting the findings of Davies et al. (1974). IgM anti-BMFGM antibody levels were found 
to be elevated in serum from Ml patients, compared to age-matched controls and IgM 
antibody, being polyvalent, might be expected to dominate the haemagglutination assay 
used by Davies (Roitt.,1988).
With regard to the studies of other groups, that by Oster et al. (1974) used the same 
haemagglutination assay and supported the hypothesis, although the choice of samples has 
been, jusfifiably, criticised (Carr et al..1975: Deeth.,1983). The failure of Toivanen et al. 
(1975a) to show a significant difference in the level of anti-milk antibodies between Ml patient 
samples and controls may, to some extent, reflect their use of a fat-free milk preparation as 
antigen (Davies.,1984). This does not contain fat globules and their associated BMFGM, 
although some BMFGM will certainly have been shed into the skim milk (Briley and 
Eisenthal.,1975). They used an ELISA but the titres in the Table and text do not agree and 
the text values for IgM anti-BMFGM antibodies actually support Davies' hypothesis 
(Poston.,1975). The reasons for the results quoted by Scott et al. (1976) are less clear. 
They, like Davies, used a haemagglutination assay but their antigen preparation (National 
Dried Milk), was certainly different from the dried milk used by the Davies and Oster groups 
(Mettler.,1976) and was withdawn from the market in 1977. Gibney et al. (1980) used both
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ELISA and haemagglutination to measure anti-milk antibodies. Their ELISA detected IgG 
only and, not surprisingly, from our results, failed to show elevated titres in Ml patients. 
Furthermore, their antigen preparation (Spray Dried Milk) may well lack BMFGM. A further 
problem with the results of Gibney et al concerns their choice of donors. A large proportion 
of controls (12/37) were women, compared to that of the Ml samples (4/37). Rees (1985) 
subsequently showed, using the haemagglutination assay, that women tend to have higher 
titres of anti-milk antibodies than men. This may help to explain the failure of Gibney and his 
team to show a difference between Ml and control samples by haemagglutination assay.
5- Antigenicity of BMFGM
In view of the limited support for Davies’ hypothesis,provided by the anti-BMFGM 
antibody assays, it was decided to define more precisely the antigenic target(s) of BMFGM.
5-1 Antigenicity of BMFGM lipids.
Until relatively recently, lipid antigens received little attention from immunologists; the 
first lipid antigen to be isolated was cardiolipin (Pangborn.,1942). The foundations of modern 
glycolipid immunology were mainly laid by Yamakawa (1962), since when human antibodies 
to numerous lipid antigens have frequently been reported (eg.Yokoyama and 
Plocinick.,1965; Watanabe et al..1976: Feizi and Childs.,1978).
A crude lipid extract was made from BMFGM and used to prepare water-soluble lipids. 
The two extracts were used in the competitive ELISA for anti-BMFGM antibodies and both 
showed marked inhibition (Results, Fig. 3a). Incorporation of the extracts into liposomes 
(containing phosphatidylcholine and cholesterol) in order to present the lipids more 
effectively to the serum antibodies (Feizi and Childs.,1978) gave very similar results (Fig.
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3bc). However, assays of the above two lipid extracts showed that 9.9 % and 4.6 %  
respectively of their weight was made up of protein. From this it was suspected that their 
inhibition of the anti-BMFGM ELISA could well result from the protein contamination and the 
lipid fractions were further purified. The crude lipid extract was fractionated to give acidic 
and uncharged lipids which were protein-free and showed virtually no inhibition of 
anti-BMFGM antibodies (Fig. 4a), whether incorporated into liposomes or not (Results, Fig. 
4bc).
5-2 Antigenicity of BMFGM proteins.
As a first step in the investigation of the antigenicity of BMFGM proteins, these were 
subjected to SDS-PAGE. Such patterns have been reported many times and a number of 
protein bands have been identified and classified into three main zones (see Results, Figs 5 
and 6):
Zone A (Mr. higher than 70 KD) contains a major band at Mr. 150 KD below which is 
a minor fragment (140 KD). These two bands correspond to xanthine oxidase (XO) (Jarasch 
et al..1977. 1981; Bruder et al..1982. 1983, 1984; Johnson et al..1985). Two other 
polypeptides (Mr. 200 KD and 88 KD) are stained in this zone, but very much more faintly. 
Unlike the XO bands, which do not stain with PAS reagent, the other two bands and 
especially the 200 KD band stain stongly with PAS, indicating their glycoprotein nature 
(Bryson, personal communication).
Zone B (Mr. between 45 KD and 66 KD) contains mainly two major sets of bands at 
approximately 62 KD and 54 KD. The first comprises two bands (64 KD and 60 KD), the 
lower of which is a glycoprotein, known as butyrophilin (Mather and Keenan.,1975; Franke 
et al.,1981: Mather et al..1984: Johnson et al..1985: Greenwalt and Mather.,1985). The 
second set is also made up of two major bands (56 KD and 52 KD), as reported by Johnson
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et al. (1985) and others. All the bands of this zone stain strongly with both CBB and the 
PAS reagent (Murray et al.,1979: Johnson et al..1985) and the zone is often refered to as 
the glycoprotein zone. XO and butyrophilin account for nearly 50 % of the total protein 
detectable with CBB (Franke et al..1981: Jarasch et al..1981). Butyrophilin is firmly bound 
to BMFGM and appears to be largely restricted to the apical plasma membrane of secretory 
epithelial cells (Franke et al..1981; Heid et al..1983: Greenwalt and Mather.,1985).
Zone C (Mr. less than 35 KD) has been termed the casein zone (Basch et al..1985ab) 
and contains several bands which vary in number and intensity in different preparations. The 
polypeptide fragments in this zone do not stain with the PAS reagent (Bryson., 1989).
The SDS-PAGE patterns were transferred to nitrocellulose sheets prior to 
immunoblotting with human serum. In this latter procedure it is important to minimise 
non-specific binding of reagents to the nitrocellulose. Free binding sites on the nitrocellulose 
should, accordingly, be blocked and there is no standard method or buffer system for this 
purpose. Various blocking agents have been successfully used for different antigen-antibody 
systems. The most popular blocking agents are : BSA (Towbin et al..1979). Tween 20 
(Batteiger et al..1982: Muilerman et al..1982). a combination of BSA and Tween 20 (Wedge 
and Svenneby.,1986), haemoglobin (Gershoni and Palade.,1982) gelatine (Renart el 
al.,1979) and normal horse serum (Gordon et al..1982). Among the many blocking system 
used in this project (Results, Table 5), 2 % BSA in 0.05 % PBS-Tween 20, containing 0.1 % 
fish gelatine, was found to give clean blots with minimal background. Unlike in most other 
systems tested, human sera did not show binding to standard molecular weight markers 
(Results, Fig. 9ab).
When human sera, with different anti-BMFGM antibody titres, were immunoblotted 
against BMFGM, two bands carried most stain. These were the 200 KD polypeptide and XO
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(major band at 150 KD with a minor fragment at 140 KD). In addition to these two major 
bands, further bands at 88 KD, 60 KD, 56 KD and 52 KD showed weaker staining to different 
extents (Results, Fig.9a). When IgG preparations from the same sera were immunoblotted 
against BMFGM, clearer blots were obtained (Results, Fig. 9b) in which only the 200 KD 
band and XO (150 KD and 140 KD) were consistently stained. The intensity of staining 
generally increased with the titre of anti-BMFGM antibodies in the sera or IgG preparations 
used.
The limited staining of BMFGM proteins shown by human serum and IgG preparations 
contrasts with the immunoblots obtained with rabbit anti-BMFGM antiserum, which stained 
all the major bands of the membrane (Results, Fig. 11). The rabbit preimmune serum 
showed very weak staining against XO bands and Zone C bands but was absolutely 
negative with Zone B bands. Comparison of the immunoblotting patterns obtained with 
human and rabbit sera gives some clues as the origin of the human antibodies. The data 
argue against the generation of human anti-BMFGM antibodies following passage of whole 
membrane across the intestine, as proposed by Oster (1976, see Discussion, 13). It is, 
however, quite possible that XO (and also the 200 KD polypeptide) could be cleaved from' 
BMFGM in the gut and transported across the intestine, either intact or as peptide fragments. 
It is also possible that anti-XO antibodies could be raised against endogenous enzyme, 
although the the presence of the 200 KD protein then poses a further problem. In order to 
gain further information on the relationship of anti-BMFGM antibodies and anti-XO 
antibodies, bovine XO was prepared.
6- Bovine milk xanthine oxidase.
Bovine XO is a widely studied molybdoenzyme (Bray, 1975; Bray and 
Gutteridge.,1982; Ventom et al.. 1988), comprising two similar subunits of approximately 
150 KD. The enzyme exists in two forms. The active form contains one FAD molecule and
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two [2Fe-2S] iron-sulphur clusters per subunit, together with a molybdenum centre. The 
inactive form differs from the active form in that the molybdenum centre has lost a sulphido 
ligand which is replaced by an oxo ligand (Gutteridge et al..1978: Cramer et al..1981). 
Another form of inactive enzyme, which lacks the whole molybdenum centre, has been 
reported (Hart e ta l..197G ).
XO is abundant in bovine milk and especially enriched in BMFGM (Morton.,1954; Zittle 
et al..1956: Bruder et al..1982): a membrane derived from the apical plasma membrane of 
mammary epithelial cells during the secretion process of milk (Introduction, 5). XO 
represents 8-10 %  of the proteinaceous material of BMFGM (Swope and Brunner.,1968; 
Briley and Eisenthal.,1975), from which it has been directly isolated (Mangino and 
Brunner.,1976). The enzyme exists in soluble and membrane bound forms (Briley and 
Eisenthal.,1974,1975).
For the present study, the enzyme was purified according to the method of Nakamura 
and Yamazaki (1982) with slight modifications (Methods, 5). SDS-PAGE of the final product 
showed a major sharp band (150 KD), representing more than 95 % of total the protein 
(Results, Fig. 15), together with a minor fragment (140 KD) that was visualised with both 
CBB (Results, Fig. 14a) and Silver (Results, Fig. 14b) stains. On a native gel, the purified 
enzyme showed one single band (Results, Fig. 16) running slightly faster than urease trimer 
(272 KD). The molecular weight of XO is commonly accepted to be approximately 300 KD; 
a figure derived from gel filtration (274 ± 3 5  KD) and from centrifugation and diffusion (274 ±  
30 KD) studies (Andrews et al..1964: Nathans and Hade.,1978). Waud et al. (1975), using 
sedimentation equilibrium studies, reported a M.Wt. of 303 KD for the enzyme. A widely 
used criterion of purity of XO is the ratio between absorbance at 280 nm (protein) and at 450 
nm (FAD-iron sulfur centre). This ratio was found to be around 6.2 (Results, Table 6) which 
compares reasonably with that (5.2 ) quoted by Nakamura and Yamazaki (1982). The
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specific activity was approximately 1.6 units/mg (Results, Tables 6, 7). The gel patterns of 
the purified XO also correspond well with the patterns reported by other workers . (F o r  
example, Waud et al..1975: Nathans and Hade.,1978; Bruder et al..1984) using different 
methods of purification. Purified bovine XO showed essentially total inhibition when 
incubated with human serum prior to ELISA for anti-BMFGM antibodies (Results, Fig. 21). 
Casein and BSA, used as controls, never showed more than 30 % inhibition. This confirms 
that anti-BMFGM antibodies are largely directed towards XO and further emphasises the 
possibilities, either that bovine XO is almost alone among BMFGM proteins in interacting 
with the immune system or that the human antibodies result from endogenous XO. The 
Biozyme XO, XO-2, showed mainly the 150 KD and 140 KD bands, together with three or 
four bands of lower MWt, and caused similar inhibition to that shown by my purified enzyme. 
The Biozyme enzyme, XO-2B, on the other hand, is prepared by using pancreatin and lacks 
the 150 and 140 KD bands (Fig. 20b) as does the Sigma enzyme, XO-grade 1, (Fig. 20c). 
Neither preparation showed inhibition greater than 30 %  at concentrations of 1 mg/ml 
(Results, Fig. 22). These data suggest that the human anti-BMFGM antibodies are 
generated in response to intact XO subunits, rather than proteolytic fragments. This would 
seem to make the idea of an ingested immunogen less likely, although, of course, the 
ingested XO could be proteolysed differently from that produced commercially.
An ELISA to measure human anti-XO antibodies, using purified enzyme as antigen, 
was developed and optimized (Results, Fig.23). This antigen was generally successfully 
used in ELISAs with all the four goat anti-human immunoglobulin conjugates (anti-IgG, IgM, 
IgA and anti-polyvalent). However, two preparations of the enzyme showed high 
background absorbance with all serum samples in the ELISA when anti-IgM and 
anti-MpolyvalentM conjugates were used. SDS-PAGE patterns of the enzyme, in these cases, 
showed an extra band, at approximately 80 KD, which was absent from most preparations. 
This band stained both with CBB and PAS reagents and is accordingly likely to be a
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contaminant rather than a degradation product of the enzyme, which does not stain with PAS 
(for glycoprotein). This contaminant band could be removed by affinity chromatography on a 
folate column and the resulting XO preparation showed no background in anti-IgM and 
anti-"polyvalent" ELISAs.
The contaminant band (80 KD) could well be derived from secretory component 
receptor, which is involved in the transport of polymeric IgA and IgM into external secretions 
(Mostov et al..1984). Such receptors (Mr. ranging from 83 KD to 93 KD) have been shown 
to be present on the mammary gland membranes and to bind bovine and human IgM (Beale 
and Hopley.,1986). This could explain why the background occured only with anti-IgM and 
anti-"polyvalent" conjugates but not with anti-IgG conjugate. The lack of background with 
anti-lgA is more difficult to rationalise.
Purified XO, from various sources, was used to inhibit the ELISA for human anti-XO 
antibodies. A pattern similar to that shown for anti-BMFGM antibodies, was observed. 
BMFGM, purified XO and XO-2 (Biozyme) showed high inhibition (up to 80 % at 1 mg/ml) 
whereas XO-2B (Biozyme) and XO grade 1 (Sigma) caused inhibitions lower than 50 % 
(Results, Fig. 24). These inhibition studies serve to confirm the suspicion that human 
anti-XO antibodies are raised in response to intact (150 KD) enzyme, of bovine or 
endogenous origin.
Although the inhibition of anti-BMFGM or anti-XO antibody ELISAs by degraded XO is 
low, proteolytic fragments of XO are, nevertheless, still capable of binding human antibodies. 
Human sera, with different anti-(bovine XO) antibody titers, reacted strongly against the 150 
KD and 140 KD bands when immunoblotted against purified XO (Results, Fig. 25a) but also 
reacted with all the lower molecular weight fragments present in the two enzyme 
preparations (XO-2 and XO-2b) provided by Biozyme (Results Fig. 25b).
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Immunoblotting of rabbit anti-XO antiserum against the BMFGM SDS-PAGE pattern 
showed a positive reaction with most bands except the set of two bands around 60 KD, and 
the bands of Zone C (caseins) (Results, Fig. 27a). As expected, this pattern of staining was 
very much sparser than that shown by rabbit anti-BMFGM antiserum (Results, Figs.11 and 
27b), althought it is not clear why the complex of bands around 50 KD is stained. The rabbit 
anti-XO antiserum stained all degraded fractions in XO preparations, as was the case for 
human serum.
7- Affinity purification of human anti-bovine XO antibodies
In the hope of obtaining cleaner immunoblots and in order to classify human 
anti-(bovine XO) antibodies, these were affinity purified (Methods, 5). In immmunoblots, 
affinity-purified antibodies reacted strongly against the 200 KD and XO bands of BMFGM 
and against purified XO, essentially as found for human serum. The blots were indeed 
cleaner with the purified antibodies (Results, Fig. 30), compared to the ones obtained with 
human sera or their IgG preparations (Results, Fig. 9ab) but were not qualitatively different. 
The affinity-purified human anti-(bovine XO) antibodies were found to be of IgG and IgM 
classes but free of IgA (Results, Fig. 29). These results, obtained by using ELISA, were 
confirmed with immunodot blots (data not shown). When the five individual sera, used in the 
affinity purification, were tested in standard ELISA, three of them showed IgA anti-(bovine 
XO) antibody levels of higher than 35 % standard serum (A1), while the two others showed 
IgA anti-XO antibody levels of less than 10 % standard (A1).
The apparent loss of IgA anti-(bovine XO) antibodies, on affinity purification is hard to 
explain. It may be that the IgA antibodies are of particular low or high affinity and were lost in 
the initial washings or by retention on the column respectively. It is also conceivable, 
although possibly less likely, that IgA anti-(bovine XO) antibodies are directed towards the 
lysine amino-groups of XO that are bound to, and accordingly masked by, the 
CNBr-Sepharoe 4B.
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8- Human xanthine oxidase.
In view of the possibilities, mentioned earlier.that human anti-XO antibodies might be 
raised in response to endogenous antigen, human XO was prepared for use in further 
experiments. The most recent report of the preparation of human XO is that of Krenitsky ei 
a l. (1 9 8 6 ) ,  and this procedure was followed as far as producing a crude extract.
Krenitsky et al. (1986) described an affinity purification of human XO, using, as ligand, 
9-(p-aminoethoxyphenyl) guanine, originally used by Baker and Siebeneick (1971) to purify 
the rat liver enzyme. The ligand was prepared by Baker and Wood (1969) in a multistep 
chemical synthesis involving condensation of p-aminophenyl acetamidoethyl ether with 
2-amino-6-chloro-4 hydroxy-5 phenylazopyrimidine (Fig. 2). Clearly to attempt to reproduce 
this synthesis was a major undertaking and it was decided to try a simpler ligand, namely 
guanine. Linkage of guanine to CNBr Sepharose 4B, via the C-2 amino group, obviously 
presents a different aspect of the purine rings to the enzyme than does linkage via C-9. 
Moreover, XO oxidises hypoxanthine to xanthine and, at least in this interaction, requires 
access to C-2. Nevertheless, the inhibitor/substrate specificity of XO is broad (Baker and 
Wood.,1967; 1968; Baker and Siebeneick.,1971; Krenitsky et al.,1986) and it seemed 
worthwhile to try affinity purification using guanine, although (another potential disadvantage) 
no spacer was incorporated between the purine and the column. The enzyme preparation 
obtained by these means was some three times less active than that reported by Krenitsky at 
a l  and showed an A 2 8 0 /A 4 5 0  ratio of 6.23 compared with 5.2, quoted by Krenitsky et al 
(1986). The SDS-PAGE pattern of the enzyme prepared in this work showed bands at 70 
KD, 55 KD, 38 KD and less than 38 KD (several minor bands). This is to be compared with 
Krenitsky et al. who reported bands at 150 KD (A, 21 %); 135 (B, 7 %); 95 KD (C, 61 %); 
55 KD (D, 8 %); 38 KD (E, 3 %).
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The use of guanine as affinity ligand was clearly not ideal and an alternative 
purification was made possible by the gift of a folate affinity column from Dr.R.C.Bray of 
Sussex University. By these means, the activity was improved two fold and the A280/A450 
ratio fell to 6.0. SDS-PAGE showed bands at 90 KD,70 KD, 55 KD and 35 KD .
Krenitsky et al (1986) related their bands A-D to corresponding bands reported by 
Nagler and Vartanyan (1976) for the bovine enzyme. My fresh preparation of bovine enzyme 
only showed bands A (major) and B (minor) although, on freezing and thawing or simply on 
standing at room temperature, further bands at 80 KD, 55-60 KD and 35 KD appeared, 
together with several bands of less than 29 KD. It seems that the 55-60 KD and 35 KD 
bands might correspond to bands D and E respectively. On this basis, my human enzyme 
contained only bands C, D and E, together with 70 KD band.
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NH. OH
p-Aminophenyl acetamidoethyl ether 2-amino-€-chloro-4-hydroxy-5 phenytazopyrimkline. 
Condensation
1) reductive formytation of azo linkage
2) ring closure
^  3) hydrolysis of acetamido group.
o ( c h 2 ) n h 2
9-(p-aminoethoxyphenyl) guanine
Fig. 2 : Chemical sythesisis of 9-(p-amino ethoxyphenyl) guanine 
( Adapted from Baker and Wood, 1969).
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Clearly, proteolytic degradation is a major problem in the purification of human 
enzyme. Krenitsky et al. used liver obtained 12h post-mortem, whereas that used here was 
deep-frozen some 24 h post-mortem and stored for several weeks . Krenitsky et al found 
that the activity of purified XO decreased by 28 % after storage at -65 °C  for one month. 
There is a need for an extended programme of purification of human XO, involving the use of 
proteolysis inhibitors. In the present work, restrictions came not only from available time but 
also from the very limited supply of post-mortem liver and it became necessary to accept the 
partially-degraded enzyme as a subject for experimentation. It is worth putting this situation 
into context by pointing out that the bovine enzyme (grade 1) marketed by Sigma has no 
band on SDS-PAGE of MWt higher than 66 KD (Results, Fig. 20c).
When the SDS-PAGE patterns of human XO were transferred to nitrocellulose sheets, 
all bands could be stained with Ponceau S but only that at 55 KD was stained following 
immunoblotting with human serum (Results, Fig. 37). This result contrasts with the 
immunoblotting of bovine XO when all the SDS-PAGE bands of the degraded commercial 
enzymes were stained. It must be emphsaised, however, that in the bovine case, the 55 KD 
band was the lowest MWt band to be clearly stained.
Compared to the very high inhibition caused by purified bovine XO, purified human 
XO ■: (from both affinity chromatography columns) showed inhibitions of less than 30 %
and 25 % respectively in ELISAs measuring human anti-BMFGM and anti-bovine XO 
antibodies (Results, Figs 38a, b). Similarly low inhibitions were also shown by commercial 
bovine XO preparations which lacked the 150 KD band (Results, Figs 22 and 24). Inhibition 
caused by human enzyme is most probably caused by the 55 KD band, which showed a 
positive reaction with human sera in the immunoblots (Results, Fig. 37).
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Overall, from the immunoblots and inhibition studies, using purified bovine and human 
XO, it is still difficult to define the origin of the human anti-XO antibodies. The immunoblots 
showed more comprehensive staining with the bovine XO but the SDS-PAGE patterns were 
not strictly comparable and it is conceivable that the antigenic sites in the human XO were 
not preserved in the degraded bands. The conclusion from ELISA inhibition studies is that 
the immunogen contains the 150 KD band but whether this is bovine or human cannot be 
decided until a human preparation of the enzyme, containing largely this band, is available.
9- Generation of human monoclonal antibodies
Immmunoblotting experiments using serum or polyclonal sera, are always subject to 
the complications of non-specific binding. The likelihood of this should be less with 
monoclonal antibodies. For this reason and in order to define the precise specificities of 
human anti-BMFGM and anti-XO antibodies, attempts were made to generate monoclonal 
antibodies from human donors.
Initial attempts were based on the the production of human-mouse heterohybridomas 
by using techniques developed in this department, by Dr. K.Thompson (Thompson at 
a!.,1986). The present study focussed on fusing human peripheral blood lymphocytes with 
the mouse myeloma X-63 cell line. Human lymphocytes used in this work were all EBV 
transformed and the growth of T lymphocytes was suppresssed by the addition of PHA to the 
medium. EBV transformation has been reported to increase fusion frequency (Kozbor et 
a!.,1982; Kozbor and Roder.,1983; Thompson et al.,1986) and a series of 
EBV-immortalised cell lines from lymphocytes derived from peripheral blood, lymph node 
and bone marrow have been established (Cole et al..1984. see Introduction, Table 7). 
Stimulation of PBLs prior to fusion was reported (Roder et al..1986) to yield cells with much 
higher frequencies of hybrid formation (36 x 10-7) compared to unstimulated lymphocytes 
(10-7).
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Of the five fusions successfully carried out in this work, approximately 30 % of the 
heterohybridomas initially produced anti-BMFGM antibodies (determined by ELISA). The 
percentage dropped to 6.9 % after the first cloning stage and then to 3.8 % after the second 
cloning. After the third cloning no positives were detected.
In view of the problems encountered in trying to generate heterohybridomas, EBV 
transformation alone was tried as an immmortalisation technique, prior to cloning. 
EBV-transformed human PBLs were cloned, under limiting dilution, as early as possible 
(Roder et al..1986). By this method fifteen clones producing anti-BMFGM antibodies were 
obtained and the antibody production persisted for more than three months (Results, 9-1-2). 
The cloning of EBV transformed positive PBLs directly at low concentrations results in clones 
with a reduced growth and often cells collapse. The problem was overcome by introducing 
additional cloning at high density (100, 50 and 20 cells/well) prior to the standard cloning 
(Methods, 14-8-4).
9-1 Determination of immunoglobulin class.
Two methods were used (ELISA and dot-immunobinding) to determine the classes of 
human immunoglobulins present in the supernatants of the fifteen positive clones. The 
results agreed, except for clone 4G11, which showed a positive response with anti-IgG in the 
ELISA but was negative in the dot-immunobinding assay. (Results, Tables 20, 21; Fig. 39). 
Ten clones were producing IgG, two (1D12 and 3H7) producing IgM and the three remaining 
clones (4G11, 5H11, 5C11) apparently showed both IgG and IgM production. None of the 
clones showed IgA production.
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The three supernatants that apparently contained both IgG and IgM antibodies cast 
doubt on the efficiency of limiting dilution (Methods, 14-8-4) in generating monoclonal 
antibodies. This is not readily explainable, as comparison of the two major cloning 
procedures, limiting dilution and micromanipulation (Thompson.,1986; Jehanli, personal 
communication), showed cloning under limiting dilution (three times, 1 cell/well) to be as 
effective as the micromanipulation technique.
Supernatants of all the fifteen positive (for anti-BMFGM antibodies) clones showed a 
positive reaction (ELISA) against purified bovine XO (Results, Table 22) and stained strongly 
against the 150 KD band when subjected to immunoblotting (Results, Fig. 4 0 ) .  Against 
purified human XO none of the supernatants showed a positive reaction (Results, 9-2-2), 
suggesting that the human enzyme is not the immunogen. However, the same qualifications 
apply as were considered in Section 8 ( Discussion, p.224).
10- Anti-bovine XO levels in M I patients and controls
Two investigations (involving 57 Ml versus 57 non-cardiac controls, and 107 Ml versus 
86 non-cardiac controls) showed that levels of IgM anti-(bovine XO) antibodies were 
significantly (p < 0.001) higher in Ml samples compared to controls (Results, Figs 31, 32). 
Differences in IgA or IgG anti-(boviqe XO) antibodies were, in neither study, significant at p < 
0.05. These experiments were carried out blind with Ml samples and controls mixed on the 
same plate. The results were confirmed by a colleague (Bryson.,1989) on samples from the 
same source.
Total IgM levels were measured in 50 Ml and 50 control samples, chosen at random 
from those used in the comparison shown in Fig 32. There was no significant difference (p > 
0.05) between Ml and controls samples (Results, Table 12), nor was there any correlation (P 
> 0.05) between total IgM and IgM anti-(bovine XO) antibodies in either the Ml or control
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samples (Results, Figs 33a,b). These results show that the elevated levels of IgM 
anti-(bovine XO) antibodies in Ml patients are specific and not simply a reflection of total IgM 
levels.
Assay of IgM anti-(bovine XO) antibodies in serial serum samples from 8 patients, 
taken up to 6 months following Ml, showed no consistent patterns of change (Results, Figs 
35a,b) suggesting that higher antibody levels in Ml patients are not a consequence of the Ml 
itself. Further support for this idea comes from the fact that IgM anti-(bovine XO) levels are 
higher than controls already within 24 hours of Ml, where all the Bath samples were taken. 
Although IgM response to antigen is known to be faster than of IgG, even the faster 
secondary response commonly requires several days to build up (Fig. 3).
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Fig .3 : The biphasic immune response to antigens 
( From Kirkwood and Lewis, 1988).
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11- Immunoglobulin levels following M I
Davies and Clark. (1968) reported significantly higher levels of total IgG in the serum 
of 50 Ml patients compared with 78 controls. Serial assays on samples from 18 patients, 
taken from day one to 167 days following the infarction, showed no consistent changes with 
time, leading the authors to suggest that the increased IgG levels in Ml patients were not a 
consequence of the infarction. In contrast, Ebringer et al. (1971) found that 30 out of 45 Ml 
patients showed a biphasic response of IgG levels, following Ml. The levels fell to a 
minimum after one week and rose to above initial levels after 15 days; a pattern also found 
by Szczeklik et al. (1988). The fall in IgG was attributed by Ebringer et al. to removal of 
antibodies from the circulation by injured myocardial tissue and the subsequent rise to 
stimulation of the immune system by such tissue. The average IgG levels in Ml patients did 
not differ from those of controls. Levels in patients with myocardial ischaemia (no Ml), on the 
other hand, were significantly higher than in controls. Neither IgA nor IgM levels were found 
to vary with time following Ml. In a third study, Gray et al. (1978) examined 20 patients with 
old Ml (6 months previously) and found their serum levels of both IgG and IgM to be 
significantly higher than those of 36 controls.
Antibodies to heart tissue were detected in 12 out of 53 Ml patients by Ehrenfeld et al. 
(1961), in one out of 36 by van der Geld. (1964) and in 43 out of 45 Ml patients by Jezkova 
and Pokorny. (1969). Heine et al. (1966) used a haemagglutination assay to follow titres of 
anti-heart antibodies in the serum of Ml patients following infarction and found that levels 
rose to a maximum after 2-3 weeks, falling almost to initial values after 8 weeks. This peak 
coincides with that shown by Ebringer et al. (1971) and by Szczeklik et al. (1988) for total 
IgG levels, although the initial fall in IgG shown by the latter groups finds no parallel in the 
data of Heine et al. (1966).
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More recently, interest has been generated in the possible role of IgE in heart disease. 
Criqui et al. (1987) found that IgE levels were significantly raised in men, but not in women, 
who had suffred Ml, while Szczeklik et al. (1988) monitored IgE levels after Ml, showing a 
steady increase to day 7, followed by a decrease to initial levels after 3 weeks. This latter 
behaviour was in striking contrast to that shown by IgG (see above). Szczeklik et al. (1988) 
additionally suggested that patients with high baseline levels of IgE had a more begnine 
course of disease. This idea was, however, disputed by Criqui (1988) who pointed out that 
the data of Szczeklik et al. showed high IgE levels in Ml patients compared to controls (even 
on day 1), as had his own results.
12 Davies* hypothesis.
The results obtained in this work are consistent with the experimental findings of 
Davies et al. (1974); ie that anti-(cows’ milk) antibodies are elevated in the serum of 
patients following Ml, compared with controls. Davies’ later work (Davies et al..1982). 
confirmed by Bryson (1989), showed that his anti-(cows’ milk) antibodies are essentially 
anti-BMFGM antibodies. The latter have now been shown, in the present study, to be largely 
made up of anti-XO antibodies, levels of which are elevated in Ml patients. That, specifically, 
the IgM anti-XO antibody levels are elevated is consistent with Davies’ use of the 
haemagglutination assay, which is largely dominated by the polyvalent IgM (Roitt, 1988).
Confirmation of Davies’ findings does not, however, imply validation of his hypothesis. 
Davies assumed that the anti-(cows’ milk) antibodies, assayed by him, arose in response to 
ingested cows’ milk. The present study, while identifying anti-(cows’ milk) antibodies as 
anti-XO antibodies has not been able to positively identify the XO antigen as bovine or 
human; the main problem being the difficulties in preparing undegraded human enzyme 
(see Discussion, 8). Apart from the origin of the antibodies, their possible pathogenic role is
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also unclear. Davies (1984) suggested that deposition of immune complexes per se in the 
arterial wall might be sufficient to initiate endothelial cell damage and plaque formation; this 
thesis presents no evidence concerning this. An alternative suggestion of Davies (1984) and 
of Rees (1985) was that anti-(cows’ milk) antibodies cross-react with human platelets and 
thereby activate the latter, promoting plaque formation. Again, this thesis has no data 
relevant to such cross-reactivity, although Bryson (1989) was unable to confirm it.
In summary, the presence of raised antibodies (to cows’ milk or xanthine oxidase) in Ml 
patients has been confirmed but their origin (bovine or endogenous) and possible causative 
role in CHD remains unclear.
13 Oster’s hypothesis.
Oster (1968; 1971) developed a hypothesis of human atherosclerosis involving
"plasmalogen disease". According to this hypothesis, ingested bovine milk fat globules, 
containing xanthine oxidase, pass the intestinal barrier and enter the bloodstream. The 
xanthine oxidase is ectopically deposited in the arterial intima and myocardial cells, where it 
oxidises fatty aldehydes, released from endothelial cell membrane plasmalogens, during 
metabolic turnover. This leads to depletion of plasmalogen stock, initiating focal membrane 
damage and plaque formation.
Oster derived support for his hypothesis from a number of sources. Plasmalogens, 
normally present in arterial intima, were found to be absent from the infarcted area of cardiac 
muscle in a case of fatal myocardial infarction (Oster and Hope-Ross.,1966) and other 
studies (Buddecke and Andresen.,1959; Miller et al..1964: Oster.,1971) have shown that 
plasmalogens are depleted in atherosclerotic areas of the aorta and in otherwise healthy 
aortas in older individuals. Moreover, Ross et al. (1973) reported the presense of xanthine
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oxidase in atherosclerotic plaques and its absence from adjacent normal tissue. Further 
support was obtained from the improvement shown by atherosclerotic patients treated with 
the xanthine oxidase inhibitors, allopurinol (Oster.,1968) and folic acid (Oster.,1974). 
Epidemiological evidence linking milk consumption to heart disease was also quoted 
(Oster.,1971). In answer to the objections that a molecule of the size of xanthine oxidase 
(Mr. 300,000) could not be absorbed intact, Oster et al. (1974) cited their demonstration of 
anti-XO antibodies in the serum of CHD patients and the elevation of such antibodies 
compared to controls (Fig. 4). This same study assayed anti-(cows’ milk) antibodies by 
haemagglutination, as did Davies et al. (1974) and confirmed Davies’ findings (see 
Discussion, 2).
Oster’s hypothesis received considerable publicity in the 1970’s and was the subject of 
a report prepared for the Food and Drug Administration of the United States (Carr et 
al.,1975). This report criticised many aspects of the hypothesis, especially the liklihood of 
XO’s surviving the acid conditions of the stomach and being absorbed in enzymically active 
form. It was rightly pointed out that the presence of anti-XO antibodies in serum offers no 
proof that the corresponding immunogenic enzyme is either active or of bovine origin. The 
experiments, themselves, were also criticised in that they made use of the crude 
haemagglutination technique and an ill-defined antigen; moreover, the patients and controls 
were badly chosen and ill-matched.
The relevance of this present study to Oster’s hypothesis is largely confined to the 
question of the origin and significance of human anti-XO antibodies. Oster found levels of 
these antibodies to be elevated in the serum of CHD patients, and despite the above 
criticisms of his experiments, his basic findings have been confirmed here, in that, as in the 
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Fig- 4 : levels of anti-BXO antibodies in atherosclerotic patients 
compared to non-cardiac controls.
( From Oster £Lai, 1974 ).
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14 Origin of anti-XO antibodies
a) Ingested bovine milk XO as antigen ?
Oster (1971) proposed that bovine XO crosses the intestinal barrier bound to the 
membrane surrounding fat droplets, a significant proportion of which are absorbed intact, by 
a pinocytotic process, termed persorption. This proposed mechanism serves to answer the 
commonly-held belief that the normal adult gastrointestinal tract is impermeable to 
macromolecules. In fact, uptake and transport of macromolecules have been reviewed by 
Walker and Isselbacher (1974), who concluded that this is, indeed, a normal, if minor, 
phenomenon in normal adults (see also Walker.,1978). Paganelli et al. (1979) fed 1-2 litres 
of milk to five normal healthy adults all of whom showed a peak of immune complexes 
(containing bovine serum albumin and IgG) in their sera after 30 min. Four subjects showed 
a second peak after 4 hours, after which, complexes were rapidly cleared from the circulation 
in all cases. The general mechanisms are illustrated in Fig. 5.
The normal consequences of antigen absorption involve local production, in the 
intestine, of s-lgA which acts to exclude dietary antigens ( Walker and Isselbacher, 1977). In 
patients with selective IgA deficiency, uptake of bovine antigen increased 
(Cunningham-Rundles et al.,1978). A systemic immune response to ingested antigens may 
occasionally arise, but, most commonly, a state of tolerance develops determined principally 
by T-cell unresponsiveness (Challacombe and Tomosai.,1980; Mowat.,1987).
XO activity in normal human serum is low (Al-Khalidi and Chaglassian.,1965; 
Ramboer et al..1972: Shamma’a et al..1973). in which context it is worth noting that the 
presence, in the serum, of anti-XO antibodies is likely to lead to antigen-antibody complexes. 
Such complexes may be expected to show reduced enzymic activity (Ultmann et al.,1962;
- 2 3 3 -
this thesis, Results, Fig. 28), and to be rapidly cleared from the bloodstream. A number of 
workers have attempted experimentally to assess the liklihood that active bovine XO 
survives passage through the stomach and is absorbed into the blood serum. Thus, Zikakis 
et al. (1977) and Ho and Clifford. (1976) examined the effects of various pH buffers, human 
gastric juice and pancreatin on XO activity. Both groups of workers found that significant 
proportions of XO activity were likely to survive passage through the stomach. However, 
from their data and from molecular weight consideration, Ho and Clifford. (1976) estimated 
that, of 100 mg XO in raw fresh milk, no more than 20 ng would be absorbed functionally 
intact. Volp and Lage (1977) similarly studied the inactivation of XO by milk / buffer 
suspensions and, additionally, directly measured absorption of the enzyme through everted 
rat intestine; they also concluded that little active enzyme could reach the blood. McCarthy 
and Long (1976) sought XO activity in the blood of pigs, fed high levels of cow’s milk, without 
success and also failed to find a correlation between serum XO activity and milk 
consumption in humans. On the other hand, Clark et al. (1976) were able to measure 
significant increases in serum XO activity, 2-4 hours following administration of milk or XO to 
rats.
The above studies, in 1976 and 1977, were prompted by Oster’s claims and 
considered specifically the absorption of active enzyme. The present thesis is concerned 
with the origin of serum anti-XO antibodies which do not depend on absorption of active 
enzyme and could arise from smaller proteolysed fragments of bovine XO. It should be 
noted, however, that the work described here (Results, 6) suggests that human anti-XO 
antibodies are raised in response to intact (Mr 150,000) subunit, although it is possible that 
proteolytic fragments, other than those tested, might be responsible. Rzucidlo and Zikakis. 
(1979) found excellent correlation between anti-XO antibodies, assayed by 
haemagglutination, and dairy food intake. Taken together with the uncertainties regarding 
detection of XO itself in serum, this publication, in particular, indicates that an exogenous
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antigen for human anti-XO antibodies is entirely possible. Bruder et al. (1984) made a 
careful study of such antibodies, which they found, in contrast to the present work, to consist 
entirely of IgG types. Although their data were similarly inconclusive, they inclined towards 
the idea of self-immunization to endogenous XO.
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Fig. 5 : General mechanisms for the uptake and transport of macromolecules by the 
intestine. ( From Walker and Isselbacher, 1974).
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b) Endogenous XO as antigen ?
XO has long been known to occur in mammalian liver (Waud and Rajagopalan.,1976), 
in small intestine (Roussas.,1967; Martin et al..198Q) and in the milk fat globule membrane 
of several species (see refs in Zikakis and Wooters.,1980). Using immunolocalisation 
techniques, in bovine tissue, Jarasch et al. (1981) found XO in milk-secreting epithelial cells 
but not in epithelial cells of several other tissues. In many tissues, including liver, lung and 
intestine, XO was confined to endothelial cells, of capillaries but not of larger blood vesssels. 
In all XO-containing cells, the enzyme was distributed throughout the cytoplasm. In a 
subsequent publication (Bruder et al..1983). the same workers, found detectable, but very 
much lower levels of XO in many other cell types, including those of brain. Levels of XO in 
human milk fat globule (Jarasch et al..1977) and in other human tissues (Jarasch et al.,1986) 
were found to be very much lower than those in coresponding bovine tissue. Seeking 
explanations for the relatively high levels of XO in mammary epithelial cells and capillary 
endothelial cells, Bruder et al. (1983) suggested that, apart from its generally recognised 
role in purine nucleotide catabolism, XO might have a role in lipid transport, possibly in 
initiating exo-or endocytotic processes. A subsequent suggestion (Jarasch et al..1986) 
proposed a bactericidal defence mechanism involving generation of free-radicals by XO 
released in endothelial cell injury. A further suggested role for XO involves iron absorption in 
the small intestine and iron metabolism in the liver (Topham et al..1982ab).
15 Xanthine oxidase in the pathogenesis of ischaemia-reperfusion iniurv
In recent years, attention has been focussed on XO for reasons other than those so far 
discussed. Oxygen-derived radicals have been implicated as mediators of tissue injury in 
several disease states, including cerebral ischaemia (Granger et al.,1981). pulmonary 
disorders (Johnson et al..1981) and arthritis (Blake et al.,1989). XO is one of a number (see 
eg. Downey et al..1988) of possible sources of free-radicals in ischaemia and was first 
suggested as such by Granger et al. (1981), studying the gut. Since then, considerable 
evidence has accumulated suporting the involvement of XO in damage to the ischaemic 
heart also. According to the commonly accepted mechanism (Fig. 6), reduced oxygen 
supply creates an energy deficit and local dephosphorylation of ATP. ATP, ADP and AMP 
successively break down to nucleosides and to the purines, hypoxanthine and xanthine, 
which are finally oxidized to uric acid by XO. XO, located in capillary endothelium, is 
normally in its dehydrogenase form but, early in ischaemia, undergoes conversion to the 
oxidase form, which in reperfusion, can transfer electrons to molecular oxygen, producing 
the superoxide anion, O2 and hydrogen peroxide. Evidence for the above mechanism has 
been provided in ischaemic dog heart, in which infarct size could be shown to be limited by 
administration of allopurinol, a specific inhibitor of XO (Chambers et al..1985). Allopurinol 
was also shown to reduce the incidence of potentially lethal reperfusion-induced arrhythmias 
in the rat (Hearse et al..1986). In contrast to these results, however, allopurinol was without 
effect in ischaemic rabbit heart in which XO could not be detected (Downey et al..1987). 
Doubt about the involvement of XO in ischaemic-reperfusion damage in the human heart has 
now been raised, in that enzyme activity was found to be absent (Eddy et al..1987: Downey 
et al.,1988) or present at extremely low levels (Watts et al..1965). On the other hand it 
should be noted that Krenitsky et al. (1974) did detect XO activity in human heart and 
Jarasch et al. (1986) detected the enzyme by immunolocalization (see Downey et al..1988 
for Discussion).
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Fig. 6 : The proposed mechanism by which XO, in the heart, serves as a source 
of free oxy-radicals during ischaemia and reperfusion.
( From Downey et al. 1988 ).
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16 Conclusions and suggestions for further work
The major conclusion from this work is undoubtedly that circulating IgM anti-XO 
antibodies occur in normal humans and are significantly higher in Ml patients. Bruder et al.
(1984) have previosly reported the presence of IgG, but not IgM anti-XO antibodies, although 
no association with any disease state was found. Oster et al. (1974) and Rzucidlo and 
Zikakis (1979) also reported the occurence of human anti-XO antibodies of undefined class 
and , indeed, Oster et al. (1974) found their levels to be higher in CHD patients, compared 
to controls.
Oster and collegues used their findings in support of Oster’hypothesis (Section, 13), 
that ingested bovine XO finds its way into blood stream and hencee to arterial intima where it 
initiates atherosclerosis. This thesis is irrelevant to most of Oster’hypothesis, apart from his 
report (Oster et al..1974) of elevated anti-XO antibodies in CHD patients. Despite many 
justified criticisms (Carr et al. 1975) of this report, its findings are essentially confirmed here, 
in that Oster’haemagglutination assay was probably dominated by the multivalent IgM 
antibodies (Roitt, 1988). Concerning Oster’s idea that bovine XO reaches the bloodstream 
on the surface of intact fat globules (Section, 14a), the evidence in this thesis (Section 5.2) is 
against an immunogenic role for intact BMFGM, although absorption of XO protein cannot be 
ruled out.
While the clinical studies of Davies and colleagues only considered anti-(whole cows’ 
milk) antibodies, their findings of raised levels in Ml patients, compared with controls, can be 
explained in terms of the relationship of anti-(whole cows’ milk) antibodies with anti-BMFGM 
antibodies (Davies et al., 1980,1982; Bryson, 1989) and of the latter with anti-XO antibodies 
(this thesis, Bryson, 1989). As in the case of Oster, Davies haemagglutination assay is likely
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to have been dominated by IgM. The present thesis, accordingly, serves to explain most of 
Davies’ findings but, again, as for Oster, does not justify his interpretation of their findings.
The important questions clearly concern the origin and possible pathogenic role of IgM 
anti-XO antibodies. As discussed in Section 14, the question of origin remains open. From 
the literature and the evidence presented in this thesis, it appears quite possible that bovine 
XO might reach the bloodstream in immunogenic amounts, but probably not as part of 
BMFGM. It is also conceivable that anti-XO antibodies might arise in response to 
endogenous XO, possibly following disruption of capillary endothelial cells, although neither 
time consideration nor serial assays supported the idea of their elevation as a consequence 
of the Ml it self (Section 10). As stated in Section 8, the origin can probably best setteled by 
use of undegraded human XO in competitive ELISAs and immunoblots. In this context, it 
should be borne in mind that IgG anti-XO antibodies, present in high amounts and apparently 
unchanged in Ml patients, might arise by a different route from that of IgM anti-XO 
antibodies.
Even if IgM anti-XO antibodies do not arise as a result of the Ml, it is possible that they 
are stimulated by release of endogenous XO from capillary endothelium in earlier, possibly 
repeated sub-clinical events. In such a case, the antibodies would not necessary be 
pathogenic but might, nonetheless, be useful diagnostically. If, as suggested by Jarasch e i 
al. (1986), disruption of endothelia can result in the release of XOr  its conversion from 
dehydrogenase to oxidase form, it is conceivable that an increase in anti-XO antibodies 
might represent means of eliminating the free radical producing oxidase form of the 
enzyme. It would be interesting to check the specificities of monoclonal human anti-XO 
antibodies; specie anti-oxidase activity would have not only be informative but could also be 
of therapeutic value (see Section, 15).
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If anti-XO antibodies arise in response to ingested cows’ milk, then a pathogenic role 
must be considered. It is possible that individuals admitting relatively high levels of bovine 
XO into their blood stream might generate elevated levels of anti-XO antibodies and hence 
immune complexes. Deposition of the latter in arterial intima could initiate atherosclerotic 
plaques, either by way of complement-mediated damage, or less probably, by enzymic 
action, as proposed by Oster.
In view of all the above consideration, it is important to ascertain the origin and precise 
specificities of human anti-XO antibodies, particularly those of IgM class. For these purposes 
the monoclonal antibodies, already prepared, could provide an excellent starting point.
In the relatively short term, there is much worthwhile information to be gained from 
straightforward assay of anti-XO antibodies in selected groups of patients. Clinical 
comparisons, described in this thesis, have been confined to Ml patients and healthy 
controls. Other forms of coronary heart diseases such as angina, and arrhythmia should be 
investigated, as indeed should other diseases involving capillary disruption (eg. Stroke). It 
would also be valuable to understand the association of anti-XO antibody levels with age and 
sex in apparently healthy humans, particularly in view of Rees’ finding that such levels are 
significantly higher in pre-menopausal women than in men (Rees, 1985); an observation 
that that is apparently at adds with the lower incidence of Ml in such women. Finally, there is 
much to be gained from a study of anti-XO antibody levels in children, particularly in relation 
to their intake of cows’ milk.
Clearly, while the results described here have gone some way to explain previously 
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